



US 20240043849A1

(19) **United States**

(12) **Patent Application Publication**
Chan et al.

(10) **Pub. No.: US 2024/0043849 A1**

(43) **Pub. Date: Feb. 8, 2024**

(54) **ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES**

(71) Applicant: **President and Fellows of Harvard College, Cambridge, MA (US)**

(72) Inventors: **Ying Kai Chan, Cambridge, MA (US); George M. Church, Cambridge, MA (US)**

(73) Assignee: **President and Fellows of Harvard College, Cambridge, MA (US)**

(21) Appl. No.: **18/332,109**

(22) Filed: **Jun. 9, 2023**

Related U.S. Application Data

(63) Continuation of application No. 16/167,764, filed on Oct. 23, 2018, now abandoned, which is a continuation of application No. PCT/US2017/036525, filed on Jun. 8, 2017.

(60) Provisional application No. 62/347,302, filed on Jun. 8, 2016.

Publication Classification

(51) **Int. Cl.**
C12N 15/117 (2006.01)
A61K 45/06 (2006.01)
A61K 31/7088 (2006.01)
A61K 35/76 (2006.01)
C12N 15/86 (2006.01)
A61P 29/00 (2006.01)
C12N 7/00 (2006.01)

(52) **U.S. Cl.**
CPC *C12N 15/117* (2013.01); *A61K 45/06* (2013.01); *A61K 31/7088* (2013.01); *A61K 35/76* (2013.01); *C12N 15/86* (2013.01); *A61P 29/00* (2018.01); *C12N 7/00* (2013.01); *C12N 2310/17* (2013.01); *C12N 2330/51* (2013.01); *C12N 2750/00032* (2013.01); *C12N 2750/00041* (2013.01); *Y02A 50/30* (2018.01); *A61K 48/00* (2013.01)

(57) **ABSTRACT**

Modified viral genomes are able to reduce induction of inflammatory and immune antiviral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.

Specification includes a Sequence Listing.






Fig. 1

Fig. 2





Fig. 3A

c41: 5'-TGGCGGCGACCCACGGCCTG-3'

Fig. 3B






Fig. 4

Fig. 5





Fig. 6A

c41: 5'-TGGGGCGCACCCACGGCCTG-3'

telomere: 5'-TTTAGGCTAGGCTAGGCTAGGG-3'

Fig. 6B







Fig. 8A

"c41": 5'-TGGCGGCACCCACGGCCTG-3'

"telomere": 5'-TTTAGGGTTAGGGTTAGGGTTAGGG-3'

Fig. 8B




Fig. 9A




Fig. 9B




Fig. 9C




Fig. 10A "control": 5'-GCTAGATGTTAGCGT-3'





Fig. 10C Primary macrophages




Fig. 10D Primary monocytes






Fig. 10E n.s.





Li & Li




Fig. 12A




Fig. 12B




Fig. 12C






Fig. 13


ssAAV-eGFP:




ssAAV-eGFP-5xtelomere:



[5 copies of "telomere" with AAAAA linkers] -- [reverse complementary of 5 copies of telomere with linkers]









Fig. 16

Fig. 17A

c41: 5'-TGGGGGGCACCACGGGCTG-3'

Fig. 17B

AAV-eGFP:



AAV-eGFP-c41:




Fig. 18A

cd1:

5-TGGGCGGCGACCCACGGGCGTGG-3'

telomere:

5-TTTAGGGGTTAGGGTTAGGGTTAGGG-3'



ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES

RELATED APPLICATION DATA

[0001] This application is continuation of PCT/US2017/036525 filed Jun. 8, 2017, which claims priority to U.S. Provisional Application No. 62/347,302 filed on Jun. 8, 2016, each of which is herein incorporated by reference in its entirety for all purposes.

FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under Grant No. HG008525 awarded by National Institutes of Health. The government has certain rights in the invention.

TECHNICAL FIELD OF THE INVENTION

[0003] This invention is related to the area of viral based therapies. In particular, it relates to recombinant viruses.

BACKGROUND OF THE INVENTION

[0004] Gene therapy has immense potential to prevent, treat, and cure multiple human diseases [1]. In 2012, Glybera™ (alipogene tiparvovec) became the first viral gene therapy to be approved for use in the western world [2]. Glybera™ utilizes adeno-associated virus (AAV) as a viral vector to deliver the human lipoprotein lipase (LPL) gene to muscle cells in patients with LPL deficiency [3]. Many AAV clinical trials are currently underway or being planned in the U.S. and the EU [4-6].

[0005] AAV is a small, non-enveloped virus that packages a single-stranded linear DNA genome that is approximately 5 kb long, and has been adapted for use as a gene transfer vehicle [4]. The coding regions of AAV are flanked by inverted terminal repeats (ITRs), which act as the origins for DNA replication and serve as the primary packaging signal [7, 8]. Both positive and negative strands are packaged into virions equally well and capable of infection [9-11]. In addition, a small deletion in one of the two ITRs allows packaging of self-complementary vectors, in which the genome self-anneals after viral uncoating. This results in more efficient transduction of cells but reduces the coding capacity by half [12, 13]. While AAV is not associated with any human disease, >70% of humans are seropositive for one or most serotypes [14, 15]. Typical routes of administration for AAV vectors include intravenous, intramuscular, subretinal and intracranial injections. AAV gene therapy is most often used to deliver a wild-type gene to treat monogenic diseases, and AAV vectors have been used to transduce cells in the liver, skeletal and cardiac muscle, retina and central nervous system [16-26]. In addition, there is now growing interest in using AAV to deliver CRISPR-Cas9 gene editing or to deliver broadly neutralizing antibodies against infectious diseases such as human immunodeficiency virus (HIV) and influenza A virus [27-32].

[0006] Despite several advances in gene therapy, a key concern is the inflammatory response elicited by the viral vector [33, 34]. This is best illustrated by a highly publicized case in 1999 when Jesse Gelsinger died four days after gene therapy with adenovirus in a clinical trial due to excessive inflammation [35]. While AAV has been shown to elicit much weaker inflammation in comparison to adenoviruses

[36, 37], Glybera™ therapy still includes twelve weeks of immunosuppression, beginning three days before Glybera™ administration [38]. These immunosuppressive and anti-inflammatory drugs (cyclosporine A, mycophenolate mofetil, and methylprednisolone) compromise the patient's immune system during treatment, and all patients still developed neutralizing antibodies against AAV capsid, precluding future re-administration. Furthermore, many AAV gene therapy clinical trials do not utilize immunosuppression prophylactically and only administer corticosteroids upon signs of inflammation or tissue damage, which has been associated with variable therapeutic efficacy [22, 23]. Interestingly, in agreement with their ability to trigger inflammatory and immune responses, AAV vectors have also been developed as vaccine vehicles against infectious diseases and cancer [39-41].

[0007] Inflammation has been implicated as a critical determinant of successful AAV-mediated transgene expression. A study found that following AAV administration in mice, artificially inducing systemic inflammation such as the upregulation of tumor necrosis factor (TNF), led to a decline in transgene expression in the liver [42]. This indicates that immunological tolerance to AAV-encoded transgene can be broken given sufficient inflammatory responses. Another study characterized inflammation in the murine liver following AAV infection and found transient increases in liver enzymes in the serum, and also liver pathology consistent with portal and lobular inflammation [43]. Strikingly, the authors observed that the use of AAVrh.32.33 viruses, which induced higher liver enzymes than other tested AAV serotypes, also led to a decline in transgene expression to below detection levels, again suggesting that inflammatory and immune responses are associated with poor transgene expression.

[0008] In hemophilia B clinical trials, it has been observed that a subset of patients exhibited elevated liver enzymes, and this transient transaminitis was accompanied by declining levels of transgene-encoded factor IX [22, 23]. A tapering course of corticosteroid therapy was used on a patient with transaminitis, which subsequently normalized aminotransferase levels in the serum and rescued further decline of factor IX expression. Overall, these observations are compatible with immune-mediated destruction of AAV-transduced hepatocytes and demonstrate that inflammatory and immune responses triggered by AAV administration are a safety concern and can hamper therapeutic efficacy in humans. Thus, it would be advantageous to develop viral vectors that intrinsically evade eliciting inflammation. Furthermore, instead of systemic immunosuppression with drugs, it would be beneficial to avoid triggering specific immune responses.

[0009] It has been previously shown that the DNA genome of AAV is sensed by Toll-like receptor 9 (TLR9) during AAV's entry into the cell through the endocytic pathway [36, 44]. TLR9 is a pattern recognition receptor (PRR) found on endosomal membranes of immune cells such as B cells, monocytes, macrophages and plasmacytoid dendritic cells, and binds to unmethylated CpG motifs found in the AAV genome [45, 46]. This leads to TLR9 dimerization, which triggers a cascade of signal transduction that activates NF- κ B (also known as p52-RelA complex) and induces type I interferons (IFNs). NF- κ B in turn drives the transcriptional upregulation of multiple proinflammatory cytokines such as TNF leading to inflammation and immune cell recruitment,

while secreted IFNs induce the expression of numerous interferon-stimulated genes (ISGs) and establish an antiviral state. Importantly, genetic ablation of TLR9 in mice abolishes induction of inflammatory cytokines upon AAV treatment in the liver, and also reduces formation of antibodies and T cells against AAV [36]. Thus, TLR9 plays a critical role in stimulating an early inflammatory and innate immune response during AAV infection, which also contributes to priming adaptive immunity. Finally, two other pattern recognition receptors, TLR2 and TLR4, have been implicated in triggering responses to AAV structural proteins [47, 48].

[0010] In the TLR9 field, a commonly used tool to block TLR9 activation in cell culture is short, single-stranded DNA oligonucleotides that bind TLR9 but do not activate it [49, 50]. Several such sequences are known—some synthetic and others derived from organisms—and they often bear no sequence homology [51-59]. Structural studies have revealed how an inhibitory oligonucleotide binds TLR9 tightly but does not trigger TLR9 dimerization, which is required for TLR9 activation and downstream signaling [60]. In addition to binding TLR9 directly to antagonize its activation, other mechanisms to block TLR9 activation or TLR9-mediated inflammation have been postulated or shown for other TLR9-inhibitory oligonucleotides [reviewed in 49]. These include competing for receptor-mediated endocytosis or phagocytosis, inhibition of TLR9 trafficking or TLR9 processing into a functionally active product, inhibition of endosomal acidification or activity of key proteases in endosomes, or blocking signaling proteins downstream of TLR9. When these inhibitory oligonucleotides are supplied in trans with TLR9 ligands (such as a DNA virus, or a CpG-containing oligonucleotide) in cell culture media, they are endocytosed and can bind to TLR9, preventing its activation by stimulatory ligands. Supplementation of inhibitory oligonucleotides in trans is widely adopted in immunology experiments, but it is unknown in the field if incorporation of these sequences into a viral genome allows it to evade eliciting inflammatory and immune responses.

[0011] While AAV has been shown to elicit much weaker inflammatory responses in comparison to adenoviruses, Glybera™ alipogene tiparvovec treatment still includes twelve weeks of immunosuppression, beginning three days before Glybera™ alipogene tiparvovec administration. These immunosuppressive drugs strongly hamper T cell activation and therefore compromise the patient's immune system during treatment. It would be advantageous to engineer viral vectors that evade and elicit diminished or no inflammatory response upon administration. Furthermore, it would be beneficial if the immune suppression was not systemic, and if it was transient. Preventing inflammatory and immune responses could also improve transgene expression and may allow the re-administration of the viral vector for future purposes.

[0012] There is a continuing need in the art to improve the efficacy of viral vectors for therapy and for in vivo production of biological products.

SUMMARY OF THE INVENTION

[0013] According to one aspect of the invention a nucleic acid molecule is provided. It comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.

[0014] According to another aspect a recombinant virus is provided for delivery of a desired function to a mammalian cell. The recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.

[0015] Another embodiment is an aspect of treating a mammal. The method comprises administering a recombinant virus to a mammal in need thereof. The recombinant virus comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation.

[0016] Still another aspect is a method of making a viral genome of a recombinant virus. An inhibitory nucleic acid sequence is inserted into a viral genome. The inhibitory nucleic acid sequence binds to TLR9 but does not trigger TLR9 activation.

[0017] According to one aspect a nucleic acid molecule is provided. It comprises an inverted terminal repeat (ITR) and a nucleic acid sequence which inhibits TLR9-mediated inflammation.

[0018] Another aspect of the invention is a nucleic acid molecule. The molecule comprises a viral genome covalently linked to an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.

[0019] Yet another aspect of the invention is a recombinant virus for delivery of a desired function to a mammalian cell. The recombinant virus comprises a viral genome comprising an inhibitory nucleic acid sequence which inhibits TLR9-mediated inflammation.

[0020] Still another aspect of the invention is a method of making a viral genome of a recombinant virus. A nucleic acid sequence is inserted into a viral genome. The nucleic acid sequence inhibits TLR9-mediated inflammation.

[0021] According to another aspect of the invention a nucleic acid vector is provided. The vector comprises at least one nucleic acid sequence. The nucleic acid sequence is capable of inhibiting TLR9-mediated inflammation.

[0022] Another aspect of the invention is a method of reducing immunogenicity of a modified virus having a genome. The method comprises inserting a nucleic acid sequence into the genome. The nucleic acid sequence inhibits TLR9-mediated inflammation. The modified virus causes a reduced inflammatory response in a host as compared to a virus that does not contain the inhibitory sequence.

[0023] Still another aspect of the invention is a method of increasing expression in a host cell of a virally introduced transgene. The method comprises introducing into a host a modified virus having a genome. The genome comprises a nucleic acid sequence. The nucleic acid sequence inhibits TLR9-mediated inflammation. The modified virus results in higher transgene expression in a host cell as compared to a virus that does not contain the inhibitory sequence.

[0024] Yet another aspect of the invention is a composition comprising a viral capsid encapsidating a nucleic acid sequence that inhibits TLR9-mediated inflammation.

[0025] These and other aspects and embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with tools for better treating mammals with viral vectors and virions and for better using viral vectors and virions for producing products of transgenes in host cells, host tissues, and host animals.

[0026] Any and all of the above described aspects may be combined with any of the following features.

[0027] The viral genome may be adeno-associated virus (AAV) genome.

[0028] The viral genome may be selected from the group consisting of adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, and human parvovirus B19.

[0029] The viral genome may be single stranded.

[0030] The viral genome may be packaged in a virion.

[0031] The viral genome may comprise a gene which may be expressible in a human cell.

[0032] The viral genome may be a cytotoxic virus for lysing target tumor cells.

[0033] The inhibitory nucleic acid sequence may comprise c41 oligonucleotide sequence TGGCGCGCACC-CACGGCCTG (SEQ ID NO: 1).

[0034] The inhibitory nucleic acid sequence may comprise a plurality of copies of c41 sequence (SEQ ID NO: 1).

[0035] The inhibitory nucleic acid sequence may comprise two copies of c41 sequence (SEQ ID NO: 1) separated by a linker sequence.

[0036] The linker sequence is AAAAAA (SEQ ID NO: 8).

[0037] The inhibitory nucleic acid sequence may be selected from the group consisting of:

ODN 2088: (SEQ ID NO: 2)
TCC TGG CGG GGA AGT;

ODN 4084-F: (SEQ ID NO: 3)
CCTGGATGGGAA;

ODN INH-1: (SEQ ID NO: 4)
CCTGGATGGGAATTCCCATCCAGG;

ODN INH-18: (SEQ ID NO: 5)
CCT GGA TGG GAA CTT ACC GCT GCA;

ODN TTAGGG: (SEQ ID NO: 6)
TT AGG GTT AGG GTT AGG GTT AGG G;
and

G-ODN: (SEQ ID NO: 7)
CTC CTA TTG GGG GTT TCC TAT.

[0038] The inhibitory nucleic acid sequence may be a bacterial sequence.

[0039] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human gene.

[0040] The inhibitory nucleic acid sequence may be inserted downstream of or in a 3' untranslated region of the viral genome.

[0041] The viral genome may be covalently linked to the inhibitory nucleic acid sequence by a phosphodiester bond.

[0042] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a detectable marker.

[0043] The detectable marker may be inducible.

[0044] The inhibitory nucleic acid sequence may comprise a human telomere sequence shown in SEQ ID NO: 9.

[0045] The viral genome may be self-complementary.

[0046] The viral genome may be covalently linked to a plurality of inhibitory nucleic acid sequences.

[0047] The plurality of inhibitory nucleic acid sequences may comprise an inhibitory sequence and its reverse complement.

[0048] The inhibitory nucleic acid sequence may comprise three copies of c41 sequence (SEQ ID NO: 1), each copy separated by a linker sequence.

[0049] The inhibitory nucleic acid sequence may be selected from the group consisting of:

ODN 2114: (SEQ ID NO: 16)
TCCTGGAGGGGAAGT;

ODN 4024: (SEQ ID NO: 17)
TCCTGGATGGGAAGT;

ODN INH-4: (SEQ ID NO: 18)
TTCCCATCCAGGCCTGGATGGGAA;

ODN INH-13: (SEQ ID NO: 19)
CTTACCGCTGCACCTGGATGGGAA;

ODN Poly-G: (SEQ ID NO: 20)
GGGGGGGGGGGGGGGGGGGG;

ODN GpG: (SEQ ID NO: 21)
TGACTGTGAAGGTTAGAGATGA;

ODN IRS-869: (SEQ ID NO: 22)
TCCTGGAGGGGTTGT;

ODN IRS-954: (SEQ ID NO: 23)
TGCTCCTGGAGGGGTTGT;
and

ODN 21158: (SEQ ID NO: 24)
CCTGGCGGGG.

[0050] The inhibitory nucleic acid sequence may be ODN TTAGGG (SEQ ID NO: 6).

[0051] The inhibitory sequence may be covalently linked to a linker.

[0052] The inhibitory sequence may be upstream of the linker.

[0053] The inhibitory nucleic acid sequence may comprise a plurality of copies of ODN TTAGGG (SEQ ID NO: 6).

[0054] The plurality of copies of ODN TTAGGG (SEQ ID NO: 6) may each be separated by a linker.

[0055] The inhibitory nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of ODN TTAGGG (SEQ ID NO: 6), each copy separated by a linker.

[0056] The inhibitory nucleic acid sequence may be a human sequence.

[0057] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a non-human nucleic acid sequence.

[0058] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human gene.

[0059] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a human nucleic acid sequence.

[0060] The inhibitory nucleic acid sequence may be inserted in the 5' untranslated region of the viral genome.

[0061] The inhibitory nucleic acid sequence may be inserted upstream of a promoter of the viral genome.

[0062] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise an inducible promoter.

[0063] The inhibitory nucleic acid sequence may comprise two repeated monomers of SEQ ID NO: 1.

[0064] The inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 1.

[0065] The inhibitory nucleic acid sequence may comprise SEQ ID NO: 6 or SEQ ID NO: 9.

[0066] The inhibitory nucleic acid sequence may comprise three repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.

[0067] The inhibitory nucleic acid sequence may comprise five repeated monomers of SEQ ID NO: 6 or SEQ ID NO: 9.

[0068] The step of administering may be repeated.

[0069] The viral genome may be packaged in virions.

[0070] The step of inserting may utilize a DNA ligase.

[0071] The viral genome may be single stranded when in virions.

[0072] The viral genome of the recombinant virus may comprise a gene for delivery to and expression in a human cell.

[0073] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise a linker separating each of the nucleic acid sequences.

[0074] The viral genome, recombinant virus, vector, or nucleic acid sequence may comprise at least 2, at least 3, at least 4, or at least 5 copies of the nucleic acid sequence.

[0075] The inhibitory nucleic acid may be covalently linked to a gene.

[0076] The inhibitory nucleic acid sequence may be 95% identical to c41 oligonucleotide sequence TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1).

[0077] The inhibitory nucleic acid sequence may be 95% identical to SEQ ID NO: 9.

[0078] The inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:

ODN 2088: (SEQ ID NO: 2)
TCC TGG CGG GGA AGT;

ODN 4084-F: (SEQ ID NO: 3)
CCTGGATGGGAA;

ODN INH-1: (SEQ ID NO: 4)
CCTGGATGGGAATTCCCATCCAGG;

ODN INH-18: (SEQ ID NO: 5)
CCT GGA TGG GAA CTT ACC GCT GCA;

ODN TTAGGG: (SEQ ID NO: 6)
TT AGG GTT AGG GTT AGG GTT AGG G;
and

G-ODN: (SEQ ID NO: 7)
CTC CTA TTG GGG GTT TCC TAT.

[0079] The inhibitory nucleic acid sequence may be 95% identical to a sequence selected from the group consisting of:

ODN 2114: (SEQ ID NO: 16)
TCCTGGAGGGGAAGT;

ODN 4024: (SEQ ID NO: 17)
TCCTGGATGGGAAGT;

ODN INH-4: (SEQ ID NO: 18)
TTCCCATCCAGGCCTGGATGGGAA;

ODN INH-13: (SEQ ID NO: 19)
CTTACCGCTGCACCTGGATGGGAA;

ODN Poly-G: (SEQ ID NO: 20)
GGGGGGGGGGGGGGGGGGGG;

ODN GpG: (SEQ ID NO: 21)
TGACTGTGAAGGTTAGAGATGA;

ODN IRS-869: (SEQ ID NO: 22)
TCCTGGAGGGGTTGT;

ODN IRS-954: (SEQ ID NO: 23)
TGCTCCTGGAGGGGTTGT;
and

ODN 21158: (SEQ ID NO: 24)
CCTGGCGGGG.

[0080] The inhibitory nucleic acid sequence may comprise a plurality of copies of SEQ ID NO: 6 and/or SEQ ID NO: 9

[0081] The inhibitory nucleic acid sequence may comprise two copies of SEQ ID NO: 6 and/or SEQ ID NO: 9 separated by a linker sequence.

BRIEF DESCRIPTION OF THE DRAWINGS

[0082] FIG. 1. Schematic drawing of viral gene therapy and inflammatory and immune responses.

[0083] FIG. 2. Schematic drawing showing TLR9 sensing AAV DNA during viral entry and inflammatory and immune responses. From Rogers et al., 2011, *Frontiers in Microbiology*, “Innate Immune Responses to AAV Vectors,” vol. 2, article 194.

[0084] FIGS. 3A-3B. FIG. 3A shows nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide. FIG. 3B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LPA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted in FIG. 3B is shown in SEQ ID NO: 8.

[0085] FIG. 4 shows NF-κB activity in HEK293 TLR9 cells mock-infected or infected with AAV virus (DJ capsid, self-complementary AAV genome, encoding eGFP). **, p<0.005; n.s., not significant. This experiment used a crude viral preparation.

[0086] FIG. 5. Flow cytometry histograms showing GFP expression in HEK293 TLR9 cells mock-infected or

infected with AAV virus with or without c41. This experiment used a crude viral preparation.

[0087] FIGS. 6A-6B. FIG. 6A shows nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG)₄ (SEQ ID NO: 6) motif from mammalian telomeres. FIG. 6B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown in FIG. 6B are SEQ ID NO: 8.

[0088] FIGS. 7A-7B. FIG. 7A shows the percentage of transduced cells (GFP+) 2 days after infection of a B cell line with similar amounts of indicated AAV viruses, analyzed by flow cytometry. FIG. 7B shows TNF production in the supernatant of primary human CD14+ monocytes 18 hours after infection, as assayed by ELISA.

[0089] FIG. 8A-8B. Engineering a self-complementary AAV vector. (FIG. 8A) DNA sequences of “c41” and “telomere”. (FIG. 8B) Genome organization of an AAV vector (scAAV-eGFP) and modified vectors. LpA: polyA signal.

[0090] FIG. 9A-9C Inflammatory response to various AAV vectors in human immune cells in vitro. (FIG. 9A) Primary human macrophages were infected with AAV2 viruses (MOI: 10⁵ vg/cell) and supernatants were collected 18 h later and analyzed by ELISA for TNF levels. Five uM ODN 2006, a CpG-containing oligonucleotide, served as a positive control. (FIG. 9B, FIG. 9C) Primary human CD14+ monocytes from two different donors were infected similar to (A) and analyzed for TNF levels. Data shown are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP.

[0091] FIG. 10A-10E. Further characterization of AAV vectors. (FIG. 10A) DNA sequence of “control”. (FIG. 10B) Genome organization of modified vectors. (FIG. 10C) Primary human macrophages were infected with AAV2 viruses similar to (FIG. 9A) and analyzed by ELISA for TNF levels. (FIG. 10D) Primary human monocytes were infected similar to (FIG. 9B, FIG. 9C) and analyzed by ELISA for TNF levels. Data shown (FIG. 10C, FIG. 10D) are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP. (FIG. 10E) Adult C57BL/6 mice were infected with indicated AAV2 viruses similar to (FIG. 12A, FIG. 12B and FIG. 12C) and a piece of the liver was analyzed for indicated gene expression by qRT-PCR. Data shown are mean±s.d. of n=5 mice per condition except n=3 mice for scAAV-eGFP-3xcontrol. *P<0.05 (unpaired t-test) compared to saline condition. N.s.: not significant (P>0.05).

[0092] FIG. 11A-11B. (FIG. 11A) Primary human macrophages using a different lot of both AAV2 viruses were infected similar to (FIG. 9A) and analyzed for TNF levels. (FIG. 11B) HeLa cells were infected with AAV2 viruses at indicated MOIs and cells were harvested 48 h later and analyzed by flow cytometry for GFP expression. The percentage of GFP positive cells are shown Data shown are mean±s.d. of n=3 technical replicates. *P<0.05 (unpaired t-test) compared to scAAV-eGFP.

[0093] FIG. 12A-12C Inflammatory response to intravenous administration of various AAV vectors in adult mice in vivo. (FIG. 12A, FIG. 12B and FIG. 12C) Adult C57BL/6 mice were infected with indicated AAV2 viruses (10¹¹ vg per mouse) by tail vein injections. 2 h later, the animals were euthanized and a piece of the liver was analyzed for indicated gene expression by qRT-PCR. Saline injection was set to 1-fold expression for each gene. Data shown are mean±s.d. of n=3 mice per condition (FIG. 12A) or n=4 mice per

condition (FIG. 12B and FIG. 12C). *P<0.05 (unpaired t-test) compared to saline condition. N.s.: not significant (P>0.05).

[0094] FIG. 13. Genome organization of a single-stranded AAV vector (ssAAV-eGFP) and ssAAV-eGFP-5x telomere.

[0095] FIG. 14A-14C. Inflammatory and immune response following subretinal administration of various AAV vectors in neonatal mice in vivo. (FIG. 14A, FIG. 14B and FIG. 14C) Neonatal CD1 mice (P1) received indicated AAV8 viruses (1.8×10⁸ vg per mouse eye) by subretinal injections. At P21, the animals were euthanized and the eyecup was dissected out. The retina and the rest of the eyecup were analyzed for indicated gene expression by qRT-PCR. Saline injection was set to 1 fold expression for each gene. Each triangle represents an animal. Data shown are n=3 mice (saline) and n=5 mice (each virus) and mean values are indicated.

[0096] FIG. 15A-15C. Analysis of immune cell markers in the retina following subretinal administration of various AAV vectors in neonatal mice in vivo. (FIG. 15A, FIG. 15B and FIG. 15C) Similar to (FIG. 14A-14C), the retina was analyzed for indicated gene expression by qRT-PCR. AO (Ibal) is known to be expressed in microglia, while Cd4 and Cd8a are markers of helper and cytolytic T cells respectively. Saline injection was set to 1 fold expression for each gene. Each triangle represents an animal. Data shown are n=3 mice (saline) and n=5 mice (each virus) and mean values are indicated.

[0097] FIG. 16. GFP expression in the eye. Neonatal CD1 mice (P1) received indicated AAV8 viruses (1.8×10⁸ vg per mouse eye) by subretinal injections. At P30, the animals were euthanized and GFP expression was visualized in flat-mounted eye cups. Data shown are n=2 mice per condition.

[0098] FIGS. 17A-17B. FIG. 17A shows nucleotide sequence of c41 (SEQ ID NO: 1), a single-stranded oligonucleotide. FIG. 17B shows organization of AAV-eGFP and AAV-eGFP-c41 genomes. ITR, inverted terminal repeat; LpA, late polyadenylation signal. Transgene of interest depicted in this case is eGFP. The insertion is of c41 sequence. Spacer depicted in FIG. 17B is shown in SEQ ID NO: 8.

[0099] FIGS. 18A-18B. FIG. 18A shows nucleotide sequence of “telomere” (SEQ ID NO: 9), a single-stranded oligonucleotide containing the (TTAGGG)₄ (SEQ ID NO: 6) motif from mammalian telomeres. FIG. 18B shows organization of AAV-eGFP-telomere genome. The insertion is of “telomere” sequence. Spacers shown in FIG. 18B are SEQ ID NO: 8.

DETAILED DESCRIPTION OF THE INVENTION

[0100] The inventors have developed viral vectors and virions that harbor their own protection against host immune and inflammatory systems. These vectors and virions carry short nucleic acid sequences which inhibit the activation of toll-like receptor 9 (TLR9), a host protein which activates inflammatory and immune responses in mammalian cells.

[0101] A short nucleotide sequence for inhibition of TLR9 may be of any origin. It can be bacterial, human, synthetic, or from other sources. One particular sequence is the 20 nucleotide long “c41” [TGGCGCGCACCCACGGCCTG (SEQ ID NO: 1)] from *Pseudomonas aeruginosa*. Another particular sequence is from human telomeres and comprises

(TTAGGG)₄ (SEQ ID NO:6). Other inhibitory sequences are shown in SEQ ID NO: 2-5, 7, 9, and 16-24. Inhibitory sequences may also be used which share at least 80% homology/identity with these sequences. Inhibitory sequences may also be used which share at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and/or at least 99% homology/identity with these sequences. Multiple copies of the inhibitory sequence can be used, either in tandem arrays or separated in the viral vector by spacer or linker sequences or other portions of the viral genome. In some embodiments one, two, three, four, five, six, seven, eight, nine, ten, fifteen, or twenty copies are used. In some embodiments one or more copies of the inhibitory sequence are on the plus strand and some on the minus strand of the virus genome.

[0102] The inhibitory oligonucleotide sequences are introduced into host cells as part of the viral genome or virion, rather than as a separate agent. This renders the effect of the oligonucleotide sequences local rather than systemic. Moreover, the immune evasion is transient as it occurs during AAV or other virus entry, unlike immune suppression with drugs which can last for weeks. Additionally, it ensures that the beneficial antagonist activity is where it needs to be—with the virus or viral genome. If the virus or viral genome is not replicated in the host cell, then the effect of the oligonucleotide will be transient. If the virus or viral genome is replicated, the effect will be coextensive with the replication.

[0103] An inhibitory nucleic acid sequence may be inserted into a viral genome using any means of recombinant DNA engineering. This may involve in vitro or in vivo recombination. In vitro recombination may be accomplished using a DNA ligase or other nucleic acid joining enzyme, for example. In vivo recombination may be accomplished by co-transforming a host cell with separate donor molecules that share homology by which they will recombine using host cell machinery. Alternatively, a single donor molecule may recombine in vivo with a host cell sequence. Combinations of these approaches may also be used. Typically the insertion will involve a standard linkage of one deoxyribonucleotide to another (a phosphodiester bond). However, there may be circumstances in which non-standard linkages will be used between the inhibitory nucleic acid sequence and the rest of the viral genome. Optionally, the inhibitory nucleic acid sequence is located in an untranslated region of the viral genome.

[0104] The genome may optionally contain a therapeutic gene and/or a marker gene. Typically this gene will be a non-viral gene, or a gene that is not naturally present in the viral genome. The gene may be expressible in a mammalian host cell or animal. Expression may be under the control of a viral promoter or a promoter that is introduced with the gene. Expression may be inducible, repressible, condition-responsive, or constitutive, as examples. A therapeutic gene is one which encodes an RNA or protein product beneficial to the host. The benefit may be, for example, to improve health, protect against infection, or remedy a deficiency. The marker may enable one to track the location, the level of replication, the level of propagation, the level of transcription, or the level of translation of the virus or its products or components. Suitable markers include those which are readily detectable, such as fluorescent proteins, chromogenic proteins, etc. Optionally, a second agent may be used or added for detection of the marker protein or for development

of a detectable substance. Introduced genes may be human or non-human, heterologous (from another species) or homologous (from same species) or endogenous (from the same subject).

[0105] Any DNA viral genome can be used, whether single stranded or double stranded. Examples of suitable viruses which may be used, include without limitation, wild-type or variants of adeno-associated virus (AAV), adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, human parvovirus B19, and enterovirus. The virus may be, without limitation, cytotoxic, cytolytic, or cause latent infections. Viral vectors in which viral genomes have been modified may also be used. As an example, a genome that is modified to encode fewer viral proteins may be used. As a further example, a viral genome that is modified to encode no viral proteins may be used. Viral genomes may include, by way of non-limiting example, inverted terminal repeats and/or other non-coding genetic elements that facilitate packaging of engineered viral genomes into the capsid.

[0106] Viral genomes may be delivered to a mammalian host cell as naked DNA, in a liposome, complexed to a polymer, in a condensed or compacted state, in a gold particle, in a virion, or any other means that is suitable for the application. Typically a complete viral genome will be administered, but in some situations, it may be desirable to use a partial genome. The partial genome may be complemented by helper functions provided by the host cell or another genomic or viral entity. Partial genomes may be used, for example, if the therapeutic payload is large and some essential viral functions must be omitted to package.

[0107] Recombinant viruses may be administered to a mammal or mammalian cells according to any route which is effective for the purpose. The administration may be systemic, e.g., via the blood. It may be delivered orally, subcutaneously, topically, buccally, anally, intramuscularly, intravenously, intratumorally, intracranially, intrathecally, subretinally, etc. Any suitable carrier or vehicle may also be used for administration. It may be desirable to pre-treat the cells or mammal to render them more permeable to or receptive to the recombinant virus. A mammal "in need of" a recombinant virus may be one for whom the virus will be beneficial. It may be a mammal with a disease or deficiency. It may be one for whom a diagnosis or analysis will be made. It may be one who can benefit from the administered recombinant virus, even though it does not have a disease or deficiency.

[0108] Taken together, our results show that incorporation of c41 or human telomeric sequences into the AAV genome (a) does not lower viral packaging and infectivity, (b) prevents TLR9-mediated inflammation, (c) reduces induction of pro-inflammatory cytokines, and (d) increases transgene expression. The increased transgene expression may be due to a reduced immune response, as TLR9 activation also induces interferon expression, which triggers an antiviral state. The engineered immune-evasion property we show below is specific (against TLR9), transient (e.g., may occur during viral entry), and does not result in systemic immune suppression (only targets AAV-infected immune cells).

[0109] The inhibitory nucleic acid sequences we used, as well as others known in the art, may be incorporated into

other viruses that, like AAV, have potential utility for humans and other mammals but elicit inflammatory/immune responses that may be undesirable. For example, oncolytic viruses that preferentially infect and lyse cancer cells are used to kill or shrink tumors. These viruses are replicative (unlike AAV vectors used for gene therapy) so they can release new virions to shrink the remaining tumor. Examples include wild-type or variants of herpes simplex virus, adenovirus, and enterovirus. Some reports have shown that immunosuppression by chemotherapy can enhance oncolytic virus therapy, as the immune system normally attempts to inactivate the oncolytic virus, which would prevent it from infecting cancer cells. Therefore, it is possible that incorporating inhibitory oligonucleotides in the genomes of oncolytic viruses like herpes simplex virus may allow it to evade immune clearance and persist longer for oncolysis.

[0110] The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. The disclosure of the invention includes all embodiments explicitly recited in the claims. Additionally, all features disclosed in the dependent claims apply equally to the independent claim from which they are based as to the other independent claims. Thus such combinations of dependent claims with other independent claims are expressly contemplated and disclosed.

Example 1—Construction of Modified Viral Genome

[0111] To engineer an AAV vector that has the ability to specifically evade TLR9 activation in immune cells, we inserted two copies of c41 separated by a 5-nucleotide-long spacer (AAAAA; SEQ ID NO: 8) into the 3' untranslated region of AAV vector encoding enhanced green fluorescent protein (eGFP) (FIG. 3B). Subsequently, we produced wild-type AAV-eGFP virus and AAV-eGFP-c41 virus (harboring two c41 insertions). Infectious titers of both viruses were comparable ($\sim 10^9$ infectious units/ml, as determined by titering on HeLa cells), suggesting that addition of c41 into the viral genome did not hamper viral packaging and infectivity, an important consideration for viral vectors that have to be mass-produced for gene therapy.

Example 2—Modified Viral Genome Reduces NF-kB Activation

[0112] To measure the inflammatory response, we used HEK293 cells stably expressing TLR9 (HEK293 TLR9 cells), which senses AAV DNA genomes, and also expressing alkaline phosphatase under the transcriptional control of NF-kB. When NF-kB is activated, which indicates inflammation, alkaline phosphatase is secreted into the media and acts on a provided substrate, leading to a change in color of the media that can be measured on a plate reader. We mock-infected HEK293 TLR9 cells or infected them with either AAV-eGFP or AAV-eGFP-c41. In agreement with the literature, AAV-eGFP infection induced a small but statistically significant increase in NF-kB activity (FIG. 4). In contrast, AAV-eGFP-c41 infection was not significantly different compared to mock-infected cells, indicating that the virus was able to evade eliciting an inflammatory response.

Example 3—Modified Viral Genome Transduced More Cells and Expresses More Transgene

[0113] We analyzed the above three conditions (described in FIG. 4) for eGFP expression using flow cytometry. We found that AAV-eGFP-c41 transduced more cells than AAV-eGFP (52.7% GFP+ compared to 34.6% GFP+) (FIG. 5). In addition, GFP+ cells from AAV-eGFP-c41 infection expressed —twice as much eGFP as GFP+ cells from AAV-eGFP infection (mean fluorescence intensity [MFI] of 5335 compared to 2749).

[0114] In summary, we engineered an AAV vector to evade TLR9-mediated inflammation by incorporating an inhibitory oligonucleotide in the viral genome.

Example 4—Incorporation of c41 or Telomeric Sequences in AAV Genome Transduced More Cells and Reduced TNF Induction

[0115] We inserted three copies of “telomere,” a sequence derived from mammalian telomeres that contains the suppressive (TTAGGG)₄ motif (SEQ ID NO: 6), which has been shown to block TLR9 signaling (FIG. 6A and FIG. 6B). AAV-eGFP-telomere virus yielded similar viral titers as AAV-eGFP and AAV-eGFP-c41 when titered on HeLa cells, demonstrating that incorporation of “telomere” does not hinder viral packaging and infectivity.

[0116] When we infected a B cell line with similar amounts of AAV-eGFP or AAV-eGFP-c41 or AAV-eGFP-telomere virus, both AAV-eGFP-c41 and AAV-eGFP-telomere viruses transduced more cells than AAV-eGFP (FIG. 7A). This finding suggests too that incorporation of inhibitory sequences in the genome of AAV increases transgene expression.

[0117] Subsequently, we harvested primary human CD14+ monocytes from blood and subjected them to similar infection conditions as above. We performed ELISA on the supernatant to analyze TNF production, as TNF is a prototypical pro-inflammatory cytokine induced by NF-kB activation. AAV-eGFP infection increased TNF production compared to mock-infection, while AAV-eGFP-c41 and AAV-eGFP-telomere infections showed no or little increase in TNF production (FIGS. 7A-7B), showing that the two viruses were able to evade eliciting inflammatory responses.

Example 5—Engineering a Self-Complementary AAV Vector

[0118] Investigators often use short inhibitory oligonucleotides (typically 10-30 nucleotides in length) to antagonize TLR9 signaling in cell culture. However, it is unknown if these inhibitory oligonucleotides retain functionality in the context of a much larger viral genome (i.e., the sequence is covalently linked on both ends to much longer sequences). To test this possibility, we utilized a self-complementary (sc) AAV vector encoding enhanced green fluorescent protein (eGFP), and inserted 3 copies of “c41” or “telomere”, derived from bacteria and mammalian telomeres respectively [52, 57, 58, 61], into a plasmid harboring the vector genome (FIGS. 8A and 8B). We started with sc AAV vectors as they have been shown to be more efficient at triggering TLR9 activation and inducing more inflammation in the mouse liver than single-stranded (ss) AAV vectors. As “c41” and “telomere” are predicted to have strong secondary structure, we used an AAAAA linker between copies of the inhibitory oligonucleotide. In addition, 3xc41 and 3x telo-

mere sequences were placed after the polyA sequence and upstream of the right inverted terminal repeat (ITR) so they would be present in the DNA genome during viral entry, but would be absent from subsequent mRNA transcripts upon successful transduction (“scAAV-eGFP-3xc41” and “scAAV-eGFP-3x telomere”). Finally, to determine if the location of inhibitory oligonucleotide in the viral genome matters, we also created a vector where 3x telomere was located between the left ITR and the promoter (“scAAV-3x telomere-eGFP”).

Example 6—Inflammatory Responses in Primary Human Macrophages and Monocytes In Vitro

[0119] We packaged the various AAV vectors into AAV2 serotype and infected primary human monocyte-derived macrophages at a multiplicity of infection (MOI) of 10^5 viral genomes (vg) per cell. As expected, we found that scAAV-eGFP infection of macrophages elicited robust induction of TNF in the supernatant, a prototypical inflammatory cytokine with well-described roles in stimulating fever, apoptosis and inflammation, and is produced upon TLR9 signaling and NF- κ B activation (FIG. 9A). In contrast, both scAAV-eGFP-3xc41 and scAAV-eGFP-3x telomere markedly decreased TNF induction by >95%, indicating that incorporation of “c41” or “telomere” in these viruses could evade eliciting inflammatory responses compared to the wild-type (WT) vector. Furthermore, scAAV-3x telomere-eGFP was also able to prevent TNF induction by >95%, demonstrating that the inserted inhibitory oligonucleotides can be placed in other parts of the viral genome and retain the ability to block inflammation. Mock infection with phosphate-buffered saline (PBS) and treatment with ODN 2006, a commercially available CpG-containing oligonucleotide that is known to strongly activate TLR9/NF- κ B and inflammation, served as negative and positive controls respectively. We tested primary human CD14+ monocytes and found that again, scAAV-eGFP triggered robust TNF induction while scAAV-eGFP-3xc41 and scAAV-eGFP-3x telomere negated most of the TNF induction (FIG. 9B). scAAV-3x telomere-eGFP likewise reduced TNF induction, although inhibition was ~85%, which may be due to differences between cell types or donor tissue. The evasion of TNF induction was also reproduced in primary CD14+ monocytes obtained from another donor (FIG. 9C).

[0120] As further characterization, we inserted 3 copies of “control,” a random sequence that does not block TLR9, or 1 copy of “telomere,” into a plasmid harboring the vector genome (FIG. 10A, FIG. 10B). We picked the sequence “control” as it has been used as a negative control oligonucleotide in TLR9 experiments. We found that scAAV-eGFP-1x telomere was able to reduce TNF induction compared to scAAV-eGFP in human macrophages, but not as efficiently as scAAV-eGFP-3x telomere (FIG. 10C). This indicates that 1 copy of telomere can reduce inflammation. We also observed that scAAV-eGFP-3xcontrol elicited TNF secretion as efficiently as scAAV-eGFP in human monocytes, suggesting that insertion of sequences that inhibit TLR9 are required to block inflammation (FIG. 10D).

[0121] As AAV vectors are considered biologics and may exhibit lot-to-lot variability, we produced another batch of both scAAV-eGFP and scAAV-eGFP-3x telomere AAV2 viruses, and found that scAAV-eGFP-3x telomere was able to reduce ~75% of TNF induction compared to the WT vector (FIG. 11A). Based on the multiple viral preps and

donor monocytes and macrophages (FIGS. 9A-9C, FIGS. 10A-10E and FIGS. 11A-11B), we conclude that our engineered vectors containing 3 copies of “c41” or “telomere” reduce TNF induction by approximately 75-98% compared to the WT vector. On average, scAAV-eGFP-3x telomere reduced ~85% of TNF induction compared to scAAV-eGFP. Importantly, we did not observe differences in viral titers (assayed by qPCR for viral genomes) obtained from producing any of the above AAV2 vectors, suggesting that the engineered vectors are not defective in packaging (data not shown). Furthermore, when we infected HeLa cells, a permissive cell line widely used to titer AAV infectivity, with a range of MOIs of scAAV-eGFP and scAAV-eGFP-3x telomere, we did not observe differences in transduction (% GFP+ cells) over 4 logs of viral titers, demonstrating that the engineered vector is equally competent at transducing cells (FIG. 11B).

Example 7—Inflammatory Responses in Liver Tissues of Mice In Vivo

[0122] Intravenous delivery of AAV is often used to transduce hepatocytes for gene therapy. Previous work has shown that upon intravenous administration of AAV, Kupffer cells (resident hepatic antigen-presenting cells) in the liver of mice are capable of sensing sc AAV genomes and triggering inflammatory and innate immune responses 1-9 h later [36]. These responses include induction of proinflammatory cytokines such as TNF and IL6 and type I interferons such as IFN- β . TLR9-/- mice do not exhibit these inflammatory and innate immune responses in the liver, demonstrating a central role for TLR9 in vivo as an innate immune sensor. In addition, immune cells such as neutrophils, macrophages and natural killer (NK) cells infiltrate the liver 2 h after AAV administration. To determine if our engineered vectors can reduce inflammation in the liver in vivo, we administered PBS or equal amounts of scAAV-eGFP or scAAV-eGFP-3x telomere via tail vein injection. We selected scAAV-eGFP-3x telomere for in vivo characterization as “telomere” is derived from human sequences and might be preferable for clinical use. In agreement with previous work, scAAV-eGFP stimulated increased Tnf and Il6 expression in the liver (approximately 3 to 10 fold, compared to saline), indicating inflammation (FIG. 12A). In contrast, scAAV-eGFP-3x telomere showed little to no increase in inflammatory markers. We tested more mice in subsequent experiments and found that scAAV-eGFP stimulated statistically significant Tnf induction in the liver compared to saline, while scAAV-eGFP-3x telomere and scAAV-eGFP-3xc41 did not (FIGS. 12B and 12C), demonstrating their ability to evade eliciting inflammation in the liver. Finally, we confirmed that scAAV-eGFP-3xcontrol is not able to prevent inflammation in the liver compared to scAAV-eGFP (FIG. 10E).

Example 8—Engineering a Single-Stranded AAV Vector and Determining Inflammatory Responses in Eye Tissues of Mice In Vivo

[0123] Next, we engineered a single-stranded AAV vector, ssAAV-eGFP, by inserting 5 copies of “telomere” with AAAAA linkers, followed by another 5 copies but in anti-sense orientation, into the plasmid, giving ssAAV-eGFP-5x telomere (FIG. 13). Since both positive and negative strands of the viral genome are equally likely to be packaged into a viral particle, this ensures that each packaged viral genome

would have 5 copies of “telomere” in the correct orientation. Two AAV8 viruses were produced and purified. Again, we did not observe differences in titers between the two vectors, suggesting similar packaging efficiency (data not shown). ssAAV-eGFP was selected as it has been previously used for subretinal injections in mice and efficiently transduces photoreceptors in the eye [62].

[0124] Several studies have suggested that AAV gene therapy in the eye and brain appears to be generally safe [63]. While the eye is often assumed to be an immune-privileged site, it is known to harbor microglia, resident macrophages of the central nervous system which have been reported to express TLR9 and respond to CpG motifs [64-67]. A recent study delivering AAV vectors by subretinal injection in cynomolgus macaques reported dose-related anterior and posterior segment inflammation in the animals, and a macaque was euthanized prematurely due to severe ocular inflammation [68]. Furthermore, vitreous aspirate from the euthanized animal demonstrated the presence of neutrophils and macrophages. Another study utilizing canine models similarly observed anterior and posterior uveitis upon subretinal injection of AAV vectors, and 3 of 17 eyes developed a multifocal chorioretinitis, which was likewise associated with higher vector doses [69]. These findings strongly suggest that AAV vectors are subject to innate immune surveillance in the eye and can trigger deleterious inflammatory and immune responses.

[0125] Saline or similar amounts of ssAAV-eGFP or ss-AAV-eGFP-5x telomere were delivered via subretinal injection into neonates eyes and measured the expression of inflammatory and immune genes. The three mice that received saline injections were uniformly low for Tnf expression in the retina and were set to 1 fold expression (FIG. 14A). In contrast, of the five mice that received ssAAV-eGFP, two exhibited mild upregulation of Tnf (1.9 fold and 8.3 fold), while three animals demonstrated large induction of Tnf (62.2 fold, 534 fold, and 1003 fold), with a mean of 321 fold for the five animals. This finding indicates that while there is variability in inflammation, some animals mount a very strong inflammatory response in the retina upon ssAAV-eGFP subretinal injection. The variability may be due to differences in each injection procedure or the immune status of each animal. Strikingly, the five animals receiving ssAAV-eGFP-5x telomere had a mean Tnf induction of 5.6 fold with much less variability, suggesting that ssAAV-eGFP-5x telomere was able to avoid eliciting strong inflammation. Similar results were observed in the rest of the eyecup but at a lower magnitude, indicating inflammation was not restricted to the retina (FIG. 14B). We also measured Ifng expression in the retina, a type II interferon critical for antiviral immune responses [70], and observed a similar pattern (FIG. 14C). Prior studies have suggested that subretinal injection of AAV may trigger immune cell infiltration in the eye. Therefore, we also analyzed expression of genes that are known to be expressed specifically in different types of immune cells. We found 18.2 fold higher expression of AO (encoding Ibal, a specific marker for microglia [71, 72]) in ssAAV-eGFP injections compared to saline, suggesting microglia proliferation and/or activation in the retina (FIG. 15A). In contrast, ssAAV-eGFP-5x telomere only showed 1.9 fold induction of AO expression. In addition, we found 45.8 fold and 41.8 fold induction of Cd4 and Cd8a, markers of CD4+ helper T cells and CD8+ cytolytic T cells respectively, by ssAAV-eGFP,

while ssAAV-eGFP-5x telomere only showed 1.5 fold and 3.4 fold induction (FIGS. 15B and 15C). Again, there was considerable variability among mice treated with ssAAV-eGFP with a subset of animals showing robust induction. These results demonstrate that subretinal injection of ssAAV-eGFP administration can stimulate T cells infiltration in the retina, while ssAAV-eGFP-5x telomere strongly diminishes it. Taken together, our data indicate that while ssAAV-eGFP induces robust inflammatory and immune responses in the retina and the surrounding tissue, and significant variability is observed, ssAAV-eGFP-5x telomere is capable of mitigating a large portion of these responses.

[0126] Given the marked differences in inflammation both in vitro and in vivo, we sought to determine if there are any differences in long-term gene expression. We examined flat-mounted eye cups at P30, 29 d after subretinal injection of the mice, and found that more cells were GFP+ and GFP expression was stronger in ssAAV-eGFP-5x telomere treated eyes compared to ssAAV-eGFP, suggesting enhanced gene expression (FIG. 16). Thus, the engineered vector is able to reduce inflammatory and immune responses in the retina and also augment transgene expression.

Example 9—Material and Methods

Animals

[0127] C57BL/6 mice (male, 7-9 weeks old) were purchased from the Jackson Laboratory and CD1 mice were purchased from Charles River Laboratories.

AAV Vectors

[0128] Self-complementary (sc) or single-stranded (ss) AAV vectors were used in this study. Self-complementary vectors lack the terminal resolution sequence in one ITR. All vector genomes were flanked by AAV2 ITRs. scAAV-eGFP was purchased from Cell Biolabs (VPK-430) and has been previously described [73]. scAAV-eGFP expressed enhanced green fluorescent protein (eGFP) from the cytomegalovirus (CMV) promoter, and included an SV40 intron and SV40 polyA sequence. ssAAV-eGFP has been previously described and was originally obtained from the Harvard DF/HCC DNA Resource Core (clone ID: EvN000061595). ssAAV-eGFP contained a CMV enhancer/promoter, human (3-globin intron, eGFP, and (3-globin polyA sequence. The sequences of “c41” (5'-TGGCGCGCACCCACGGCCTG-3'; SEQ ID NO: 1) derived from *Pseudomonas aeruginosa* and “telomere” (5'-TTTAGGGTTAGGGTTAGGGTTAGGG-3'; SEQ ID NO: 9; initial T nucleotide is optional for function) derived from mammalian telomeres have been described [52, 57, 58, 61]. A widely used “telomere” oligonucleotide (manufactured by Invivogen, catalog code “tlrl-ttag”) harbored an additional T (in bold) compared to published studies and thus was included in the sequence. During the course of this study, Invivogen removed the additional T in their manufactured “telomere” oligonucleotide (catalog code “tlrl-ttag151”). In addition, “control” (5'-GCTAGATGTTAGCGT-3'; SEQ ID NO: 34) was used as a negative control sequence that does not inhibit TLR9 activation (Invivogen, catalog code “tlrl-2088c”).

[0129] To engineer scAAV-eGFP, sequences were inserted into the unique SpeI site found immediately 5' of the right ITR. To facilitate sub-cloning, a unique ClaI site was created

immediately 5' of the inserted sequences, thus allowing ClaI/SpeI sub-cloning of sequences. 3 copies of “c41,” “telomere,” or “control” were inserted, separated by AAAAA linkers, giving scAAV-eGFP-3xc41, scAAV-eGFP-3x telomere and scAAV-eGFP-3x control, respectively. Alternatively, one copy of “telomere” was inserted, with an AAAAA linker (SEQ ID NO: 8), giving scAAV-eGFP-1x telomere. We also inserted 3x telomere between the left ITR and CMV promoter using the unique AvrII site, giving scAAV-3x telomere-eGFP.

[0130] To engineer ssAAV-eGFP, KpnI-5x telomere (sense)-5x telomere(anti-sense)-NheI was inserted immediately 5' of the XbaI site adjacent to the right ITR. Again, AAAAA was used as a linker between copies of “telomere”. Both sense and anti-sense sequences of “telomere” were added as single-stranded AAV vectors have an equal chance of packaging positive or negative strands of the viral genome, thus ensuring that all packaged AAV genomes will carry 5 copies of “telomere” in the right orientation.

[0131] Self-complementary vectors were packaged into AAV2 (Vigene Biosciences) by triple transfection of HEK293 cells and purified using iodixanol gradient ultracentrifugation and then concentrated to 500 ul using Amicon Ultra-15 columns in PBS. The purified viruses were titrated by qPCR using primers derived from ITR and an AAV standard. The final yield of the viruses ranged from 0.5–3×10¹³ vg.

[0132] Single-stranded vectors were packaged into AAV8 based on previously described protocols [74, 75]. Briefly, AAV vector, rep2-cap8 packaging plasmid and adenoviral helper plasmid were transfected into HEK293T cells with polyethylenimine and supernatant was collected 72 h after transfection. AAV8 viruses were precipitated with 8.5% w/v PEG8000 and 0.4M NaCl and centrifuged at 7000 g. The pellet was resuspended in lysis buffer (150 mM NaCl and 20 mM Tris, pH 8.0) and MgCl₂ was added to a final concentration of 1 mM. The resuspended viruses were incubated with 25U/ml Benzonase (Sigma) at 37° C. for 15 min and run on an iodixanol gradient. Recovered AAV vectors were washed 3 times with PBS using Amicon 100K columns (EMD Millipore) and concentrated to 100-500 ul of PBS. Protein gels were run to determine virus titers, using serial dilutions of previous AAV standards for comparison.

Primary Human Monocytes and Monocyte-Derived Macrophages for In Vitro Studies

[0133] Human peripheral blood mononuclear cells (PBMCs) from unidentified healthy donors were purchased (ZenBio). This study was done in accordance with the ethical guidelines of Harvard Medical School. CD14⁺ monocytes were positively selected from PBMCs using anti-CD14 magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec) or purchased from Stemcell Technologies. To obtain monocyte-derived macrophages, monocytes were cultured with 50 ng/ml of recombinant human macrophage colony stimulation factor (rhM-CSF, purchased from Peprotech) for 5 to 6 d to allow differentiation into macrophages. Monocytes and macrophages were either used fresh or cryopreserved for subsequent studies.

[0134] 1×10⁵ monocytes or macrophages were seeded in 190 ul of RPMI growth media per well in 96 well round bottom plates or 96 well flat bottom plates respectively, and infected with 10 ul AAV2 viruses at indicated MOIs in PBS.

Mock infection (addition of 10 ul PBS) and ODN 2006 (final concentration of 5 uM, Invivogen), a CpG-containing oligonucleotide known to activate TLR9 and trigger inflammation, served as negative and positive controls. 18 h after infection, supernatants were collected and clarified by low speed centrifugation, followed by ELISA for human TNF (Thermo Scientific).

HeLa Cells Infection

[0135] HeLa cells are highly permissive for AAV2 vectors and are commonly used to determine the transducing titer of AAV2 vector preparations [76]. Briefly, HeLa cells were seeded overnight in 12 wells and were approximately 80% confluent at time of infection (~3×10⁵ cells). Cells were infected with serial ten-fold dilutions of viruses at indicated MOIs and incubated for 48 h before fixing with 1% paraformaldehyde in PBS and followed by flow cytometry analysis for GFP⁺ cells. PBS mock-infected cells were used to determine GFP⁺ signal.

Liver Studies In Vivo

[0136] Adult C57BL/6 mice were injected intravenously with 100 ul PBS or AAV2 viruses (10¹¹ vg per animal) by tail vein injection as previously described [36]. 2 h later, the animals were sacrificed and a portion of the right median lobe of the liver was saved in RNAlater solution (Thermo Scientific). Total RNA was extracted from 10-30 mg of mechanically disrupted liver sample by using an RNA extraction kit (OMEGA Bio-Tek). Similar amounts of RNA were reverse transcribed into cDNA with a high-capacity RNA-to-cDNA kit (Thermo Scientific) and similar amounts of cDNA were assayed with quantitative PCR (qPCR) using TaqMan Fast Advanced Master Mix (Thermo Scientific) and commercially available pre-designed primers/probes with FAM reporter dye for the indicated target genes (IDT). Expression level for each gene was calculated by normalizing against the housekeeping genes Actb or Gapdh using the MET method and expressed as fold levels compared to saline-injected mice. All qPCR reactions were run on a realplex⁴ Mastercycle (Eppendorf).

Eye Studies In Vivo

[0137] Subretinal injection into postnatal day 1 (P1) CD1 neonate eyes were performed as previously described [74, 5]. Approximately 0.2 ul AAV8 virus (1.8×10⁸ vg per eye) was introduced into the subretinal space using a pulled angled glass pipette controlled by a FemtoJet (Eppendorf). At P21, animals were sacrificed and the eyecup was dissected out. The retina and the rest of the eyecup were subjected to RNA extraction, reverse transcription, and qPCR as described in the liver studies. To visualize GFP expression by histology, eyes were excised at P30, fixed in 4% paraformaldehyde for 2 h, and washed in PBS 3 times. Eye cups were dissected out by removing the cornea, lens, iris, vitreous body and peripheral muscles. Images of flat-mounted eye cups were taken using a x10 objective on a Keyence BZ-x700 microscope. Images used for comparison between groups were taken at the same imaging settings in the same imaging session.

Statistics

[0138] Unpaired two-tailed Student's t-tests were used to compare differences between two unpaired experimental

groups in all cases. A P value of <0.05 was considered statistically significant. No pre-specified effect size was assumed and in general three to five replicates for each condition was used.

REFERENCES

- [0139] 1. Naldini L. Gene therapy returns to centre stage. *Nature*. 2015; 526(7573):351-60. doi: PubMed PMID: 26469046.
- [0140] 2. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. *Mol Ther*. 2012; 20(10):1831-2. doi: PubMed PMID: 23023051; PubMed Central PMCID: PMC3464639.
- [0141] 3. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. *Curr Opin Lipidol*. 2012; 23(4):310-20. doi: 10.1097/MOL.0b013e3283555a7e. PubMed PMID: 22691709.
- [0142] 4. Samulski R J, Muzyczka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. *Annu Rev Virol*. 2014; 1(1):427-51. doi: 10.1146/annurev-virology-031413-085355. PubMed PMID: 26958729.
- [0143] 5. Mingozzi F, High K A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. *Nat Rev Genet*. 2011; 12(5):341-55. doi: 10.1038/nrg2988. PubMed PMID: 21499295.
- [0144] 6. Kotterman M A, Schaffer D V. Engineering adeno-associated viruses for clinical gene therapy. *Nat Rev Genet*. 2014; 15(7):445-51. doi: 10.1038/nrg3742. PubMed PMID: 24840552; PubMed Central PMCID: PMC34393649.
- [0145] 7. McLaughlin S K, Collis P, Hermonat P L, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. *J Virol*. 1988; 62(6):1963-73. PubMed PMID: 2835501; PubMed Central PMCID: PMC253280.
- [0146] 8. Hauswirth W W, Berns K I. Origin and termination of adeno-associated virus DNA replication. *Virology*. 1977; 78(2):488-99. PubMed PMID: 867815.
- [0147] 9. Zhong L, Zhou X, Li Y, Qing K, Xiao X, Samulski R J, et al. Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. *Mol Ther*. 2008; 16(2):290-5. doi: 10.1038/sj.mt.6300376. PubMed PMID: 18087261.
- [0148] 10. Zhou X, Zeng X, Fan Z, Li C, McCown T, Samulski R J, et al. Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. *Mol Ther*. 2008; 16(3):494-9. doi: 10.1038/sj.mt.6300397. PubMed PMID: 18180769.
- [0149] 11. Samulski R J, Chang L S, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. *J Virol*. 1987; 61(10):3096-101. PubMed PMID: 3041032; PubMed Central PMCID: PMC255885.
- [0150] 12. McCarty D M. Self-complementary AAV vectors; advances and applications. *Mol Ther*. 2008; 16(10):1648-56. doi: 10.1038/mt.2008.171. PubMed PMID: 18682697.
- [0151] 13. McCarty D M, Monahan P E, Samulski R J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther*. 2001; 8(16):1248-54. doi: 10.1038/sj.gt.3301514. PubMed PMID: 11509958.
- [0152] 14. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. *Clin Vaccine Immunol*. 2011; 18(9):1586-8. doi: 10.1128/CI.05107-11. PubMed PMID: 21775517; PubMed Central PMCID: PMC3165215.
- [0153] 15. Calcedo R, Vandenberghe L H, Gao G, Lin J, Wilson J M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *J Infect Dis*. 2009; 199(3):381-90. doi: PubMed PMID: 19133809.
- [0154] 16. Bainbridge J W, Smith A J, Barker S S, Robbie S, Henderson R, Balagun K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med*. 2008; 358(21):2231-9. doi: 10.1056/NEJMoa0802268. PubMed PMID: 18441371.
- [0155] 17. Maguire A M, High K A, Auricchio A, Wright J F, Pierce E A, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet*. 2009; 374(9701):1597-605. doi: 10.1016/S0140-6736(09)61836-5. PubMed PMID: 19854499; PubMed Central PMCID: PMC34492302.
- [0156] 18. Maguire A M, Simonelli F, Pierce E A, Pugh E N, Jr., Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med*. 2008; 358(21):2240-8. doi: 10.1056/NEJMoa0802315. PubMed PMID: 18441370; PubMed Central PMCID: PMC342829748.
- [0157] 19. Jacobson S G, Cideciyan A V, Ratnakaram R, Heon E, Schwartz S B, Roman A J, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. *Arch Ophthalmol*. 2012; 130(1):9-24. doi: PubMed PMID: 21911650; PubMed Central PMCID: PMC3600816.
- [0158] 20. Kaplitt M G, Feigin A, Tang C, Fitzsimons H L, Mattis P, Lawlor P A, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet*. 2007; 369(9579):2097-105. doi: PubMed PMID: 17586305.
- [0159] 21. Leone P, Shera D, McPhee S W, Francis J S, Kolodny E H, Bilaniuk L T, et al. Long-term follow-up after gene therapy for canavan disease. *Sci Transl Med*. 2012; 4(165):165ra3. doi: 10.1126/scitranslmed.3003454. PubMed PMID: 23253610; PubMed Central PMCID: PMC3794457.
- [0160] 22. Manno C S, Pierce G F, Arruda V R, Glader B, Ragni M, Rasko J J, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med*. 2006; 12(3):342-7. doi: 10.1038/nm1358. PubMed PMID: 16474400.
- [0161] 23. Nathwani A C, Tuddenham E G, Rangarajan S, Rosales C, McIntosh J, Linch D C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med*. 2011; 365(25):2357-65. doi: 10.1056/NEJMoa1108046. PubMed PMID: 22149959; PubMed Central PMCID: PMC3265081.
- [0162] 24. Carpentier A C, Frisch F, Labbe S M, Gagnon R, de Wal J, Greentree S, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylolipidemia. *Gene Ther*. 2001; 8(16):1248-54. doi: 10.1038/sj.gt.3301514. PubMed PMID: 11509958.

- micron metabolism in lipoprotein lipase-deficient patients. *J Clin Endocrinol Metab.* 2012; 97(5):1635-44. doi: PubMed PMID: 22438229.
- [0163] 25. Manno C S, Chew A J, Hutchison S, Larson P J, Herzog R W, Arruda V R, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood.* 2003; 101(8):2963-72. doi: 10.1182/blood-2002-10-3296. PubMed PMID: 12515715.
- [0164] 26. Jaski B E, Jessup M L, Mancini D M, Cappola T P, Pauly D F, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. *J Card Fail.* 2009; 15(3):171-81. doi: PubMed PMID: 19327618; PubMed Central PMCID: PMC32752875.
- [0165] 27. Ran F A, Cong L, Yan W X, Scott D A, Gootenberg J S, Kriz A J, et al. In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature.* 2015; 520(7546):186-91. doi: PubMed PMID: 25830891; PubMed Central PMCID: PMC393360.
- [0166] 28. Balazs A B, Chen J, Hong C M, Rao D S, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. *Nature.* 2011; 481(7379):81-4. doi: 10.1038/nature10660. PubMed PMID: 22139420; PubMed Central PMCID: PMC3253190.
- [0167] 29. Gardner M R, Kattenhorn L M, Kondur H R, von Schaewen M, Dorfman T, Chiang J J, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. *Nature.* 2015; 519(7541):87-91. doi: 10.1038/nature14264. PubMed PMID: 25707797; PubMed Central PMCID: PMC352131.
- [0168] 30. Adam V S, Crosariol M, Kumar S, Ge M Q, Czack S E, Roy S, et al. Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. *Clin Vaccine Immunol.* 2014; 21(11):1528-33. doi: PubMed PMID: 25209558; PubMed Central PMCID: PMC34248762.
- [0169] 31. Balazs A B, Bloom J D, Hong C M, Rao D S, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. *Nat Biotechnol.* 2013; 31(7):647-52. doi: 10.1038/nbt.2618. PubMed PMID: 23728362; PubMed Central PMCID: PMC34030719.
- [0170] 32. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nat Biotechnol.* 2015; 33(1):102-6. doi: 10.1038/nbt.3055. PubMed PMID: 25326897; PubMed Central PMCID: PMC34492112.
- [0171] 33. Gene-therapy trials must proceed with caution. *Nature.* 2016; 534(7609):590. doi: PubMed PMID: 27357758.
- [0172] 34. Retracing events. *Nat Biotechnol.* 2007; 25(9):949. doi: 10.1038/nbt0907-949. PubMed PMID: 17846606.
- [0173] 35. Sibbald B. Death but one unintended consequence of gene-therapy trial. *CMAJ.* 2001; 164(11):1612. PubMed PMID: 11402803; PubMed Central PMCID: PMC381135.
- [0174] 36. Martino A T, Suzuki M, Markusic D M, Zolotukhin I, Ryals R C, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. *Blood.* 2011; 117(24):6459-68. doi: PubMed PMID: 21474674; PubMed Central PMCID: PMC3123017.
- [0175] 37. Zaiss A K, Liu Q, Bowen G P, Wong N C, Bartlett J S, Muruve D A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. *J Virol.* 2002; 76(9):4580-90. PubMed PMID: 11932423; PubMed Central PMCID: PMC3155101.
- [0176] 38. Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. *Front Immunol.* 2014; 5:82. doi: PubMed PMID: 24624131; PubMed Central PMCID: PMC3939780.
- [0177] 39. Manning W C, Paliard X, Zhou S, Pat Bland M, Lee A Y, Hong K, et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. *J Virol.* 1997; 71(10):7960-2. PubMed PMID: 9311887; PubMed Central PMCID: PMC3192154.
- [0178] 40. Liu D W, Tsao Y P, Kung J T, Ding Y A, Sytwu H K, Xiao X, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. *J Virol.* 2000; 74(6):2888-94. PubMed PMID: 10684306; PubMed Central PMCID: PMC3111780.
- [0179] 41. Xin K Q, Urabe M, Yang J, Nomiya K, Mizukami H, Hamajima K, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. *Hum Gene Ther.* 2001; 12(9):1047-61. doi: PubMed PMID: 11399227.
- [0180] 42. Breous E, Somanathan S, Bell P, Wilson J M. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. *Gastroenterology.* 2011; 141(1):348-57, 57 e1-3. doi: 10.1053/j.gastro.2011.04.002. PubMed PMID: 21640112; PubMed Central PMCID: PMC3269906.
- [0181] 43. Wang L, Wang H, Bell P, McCarter R J, He J, Calcedo R, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. *Mol Ther.* 2010; 18(1):118. doi: 10.1038/mt.2009.246. PubMed PMID: 19861950; PubMed Central PMCID: PMC32839210.
- [0182] 44. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. *J Clin Invest.* 2009; 119(8):2388-98. doi: 10.1172/JCI37607. PubMed PMID: 19587448; PubMed Central PMCID: PMC32719948.
- [0183] 45. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. *Adv Drug Deliv Rev.* 2008; 60(7):795-804. doi: 10.1016/j.addr.2007.12.004. PubMed PMID: 18262306.
- [0184] 46. Rogers G L, Martino A T, Aslanidi G V, Jayandharan G R, Srivastava A, Herzog R W. Innate Immune Responses to AAV Vectors. *Front Microbiol.* 2011; 2:194. doi: PubMed PMID: 21954398; PubMed Central PMCID: PMC3175613.
- [0185] 47. Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-me-

- diated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. *Hepatology*. 2012; 55(1):287-97. doi: PubMed PMID: 21898480.
- [0186] 48. Hensley S E, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. *Mol Ther*. 2007; 15(8):1417-22. doi: 10.1038/sj.mt.6300217. PubMed PMID: 17551505.
- [0187] 49. Lenert P S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. *Mediators Inflamm*. 2010; 2010:986596. doi: 10.1155/2010/986596. PubMed PMID: 20490286; PubMed Central PMCID: PMC2873634.
- [0188] 50. Trieu A, Roberts T L, Dunn J A, Sweet M J, Stacey K J. DNA motifs suppressing TLR9 responses. *Crit Rev Immunol*. 2006; 26(6):527-44. PubMed PMID: 17341193.
- [0189] 51. Krieg A M, Wu T, Weeratna R, Efler S M, Love-Homan L, Yang L, et al. Sequence motifs in adeno-viral DNA block immune activation by stimulatory CpG motifs. *Proc Natl Acad Sci USA*. 1998; 95(21):12631-6. PubMed PMID: 9770537; PubMed Central PMCID: PMC22882.
- [0190] 52. Gursel I, Gursel M, Yamada H, Ishii K J, Takeshita F, Klinman D M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. *J Immunol*. 2003; 171(3):1393-400. PubMed PMID: 12874230.
- [0191] 53. Stunz L L, Lenert P, Peckham D, Yi A K, Haxhinasto S, Chang M, et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. *Eur J Immunol*. 2002; 32(5):1212-22. doi: 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D. PubMed PMID: 11981808.
- [0192] 54. Lenert P, Rasmussen W, Ashman R F, Ballas Z K. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. *DNA Cell Biol*. 2003; 22(10):621-31. doi: PubMed PMID: 14611683.
- [0193] 55. Lenert P, Yasuda K, Busconi L, Nelson P, Fleenor C, Ratnabalasuriar R S, et al. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. *Arthritis Res Ther*. 2009; 11(3):R79. doi: PubMed PMID: 19476613; PubMed Central PMCID: PMC2714127.
- [0194] 56. Lenert P S. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. *Arthritis Res Ther*. 2006; 8(1):203. doi: PubMed PMID: 16542467; PubMed Central PMCID: PMC21526546.
- [0195] 57. Kaminski J J, Schattgen S A, Tzeng T C, Bode C, Klinman D M, Fitzgerald K A. Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. *J Immunol*. 2013; 191(7):3876-83. doi: PubMed PMID: 23986531; PubMed Central PMCID: PMC3878640.
- [0196] 58. Shirota H, Gursel I, Gursel M, Klinman D M. Suppressing oligodeoxynucleotides protect mice from lethal endotoxic shock. *J Immunol*. 2005; 174(8):4579-83. PubMed PMID: 15814679.
- [0197] 59. Peter M, Bode K, Lipford G B, Eberle F, Heeg K, Dalpke A H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. *Immunology*. 2008; 123(1):118-28. doi: 10.1111/j.1365-2567.2007.02718.x. PubMed PMID: 17961163; PubMed Central PMCID: PMC2433270.
- [0198] 60. Ohto U, Shibata T, Tanji H, Ishida H, Krayukhina E, Uchiyama S, et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. *Nature*. 2015; 520(7549):702-5. doi: 10.1038/nature14138. PubMed PMID: 25686612.
- [0199] 61. Li Y, Cao H, Wang N, Xiang Y, Lu Y, Zhao K, et al. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. *Vaccine*. 2011; 29(11):2193-8. doi: PubMed PMID: 21036131.
- [0200] 62. Xiong W, MacColl Garfinkel A E, Li Y, Benowitz L I, Cepko C L. NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. *J Clin Invest*. 2015; 125(4):1433-45. doi: 10.1172/JCI79735. PubMed PMID: 25798616; PubMed Central PMCID: PMC4396467.
- [0201] 63. Mingozzi F, High K A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. *Blood*. 2013; 122(1):23-36. doi: 10.1182/blood-2013-01-306647. PubMed PMID: 23596044; PubMed Central PMCID: PMC3701904.
- [0202] 64. Karlstetter M, Ebert S, Langmann T. Microglia in the healthy and degenerating retina: insights from novel mouse models. *Immunobiology*. 2010; 215(9-10):685-91. doi: PubMed PMID: 20573418.
- [0203] 65. Chinnery H R, Naranjo Golborne C, Leong C M, Chen W, Forrester J V, McMenamin P G. Retinal Microglial Activation Following Topical Application of Intracellular Toll-Like Receptor Ligands. *Invest Ophthalmol Vis Sci*. 2015; 56(12):7377-86. doi: 10.1167/iovs.15-17587. PubMed PMID: 26574796.
- [0204] 66. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikegami M, et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. *Am J Pathol*. 2009; 175(5):2121-32. doi: PubMed PMID: 19834064; PubMed Central PMCID: PMC2774075.
- [0205] 67. Chinnery H R, McLenachan S, Binz N, Sun Y, Forrester J V, Degli-Esposti M A, et al. TLR9 ligand CpG-ODN applied to the injured mouse cornea elicits retinal inflammation. *Am J Pathol*. 2012; 180(1):209-20. doi: 10.1016/j.ajpath.2011.09.041. PubMed PMID: 22085974; PubMed Central PMCID: PMC3338340.
- [0206] 68. Ye G J, Budzynski E, Sonnentag P, Nork T M, Miller P E, Sharma A K, et al. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1. 7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. *Hum Gene Ther Clin Dev*. 2016. doi: 10.1089/hum.2015.164. PubMed PMID: 26956923.
- [0207] 69. Komaromy A M, Alexander J J, Rowlan J S, Garcia M M, Chiodo V A, Kaya A, et al. Gene therapy rescues cone function in congenital achromatopsia. *Hum Mol Genet*. 2010; 19(13):2581-93. doi: 10.1093/hmg/ddq136. PubMed PMID: 20378608; PubMed Central PMCID: PMC2883338.
- [0208] 70. Schoenborn J R, Wilson C B. Regulation of interferon-gamma during innate and adaptive immune

responses. *Adv Immunol.* 2007; 96:41-101. doi: 10.1016/S0065-2776(07)96002-2. PubMed PMID: 17981204.

[0209] 71. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene *ibal* in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. *Biochem Biophys Res Commun.* 1996; 224(3):855-62. doi: PubMed PMID: 8713135.

[0210] 72. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, *Ibal*. *Brain Res Mol Brain Res.* 1998;57(1):1-9. PubMed PMID: 9630473.

[0211] 73. Gray J T, Zolotukhin S. Design and construction of functional AAV vectors. *Methods Mol Biol.* 2011; 807:25-46. doi: 10.1007/978-1-61779-370-7_2. PubMed PMID: 22034025.

[0212] 74. Matsuda T, Cepko C L. Electroporation and RNA interference in the rodent retina in vivo and in vitro. *Proc Natl Acad Sci USA.* 2004; 101(1):16-22. doi: PubMed PMID: 14603031; PubMed Central PMCID: PMCPMC314130.

[0213] 75. Wang S, Sengel C, Emerson M M, Cepko C L. A gene regulatory network controls the binary fate decision of rod and bipolar cells in the vertebrate retina. *Dev Cell.* 2014; 30(5):513-27. doi: 10.1016/j.devcel.2014.07.018. PubMed PMID: 25155555; PubMed Central PMCID: PMCPMC4304698.

[0214] 76. Martino A T, Herzog R W, Anegón I, Adjali O. Measuring immune responses to recombinant AAV gene transfer. *Methods Mol Biol.* 2011; 807:259-72. doi: 10.1007/978-1-61779-370-7_11. PubMed PMID: 22034034; PubMed Central PMCID: PMCPMC3593270.

SEQUENCE LISTING		
Sequence total quantity: 34		
SEQ ID NO: 1	moltype = DNA length = 20	
FEATURE	Location/Qualifiers	
misc_feature	1..20	
	note = Synthetic Polynucleotide	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 1		
tggcgcgcac ccacggcctg		20
SEQ ID NO: 2	moltype = DNA length = 15	
FEATURE	Location/Qualifiers	
misc_feature	1..15	
	note = Synthetic Polynucleotide	
source	1..15	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 2		
tcctggcggg gaagt		15
SEQ ID NO: 3	moltype = DNA length = 12	
FEATURE	Location/Qualifiers	
misc_feature	1..12	
	note = Synthetic Polynucleotide	
source	1..12	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 3		
cctggatggg aa		12
SEQ ID NO: 4	moltype = DNA length = 24	
FEATURE	Location/Qualifiers	
misc_feature	1..24	
	note = Synthetic Polynucleotide	
source	1..24	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 4		
cctggatggg aattcccatc cagg		24
SEQ ID NO: 5	moltype = DNA length = 24	
FEATURE	Location/Qualifiers	
misc_feature	1..24	
	note = Synthetic Polynucleotide	
source	1..24	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 5		
cctggatggg aacttaccgc tgca		24
SEQ ID NO: 6	moltype = DNA length = 24	
FEATURE	Location/Qualifiers	
misc_feature	1..24	

-continued

	note = Synthetic Polynucleotide	
source	1..24	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 6		
ttagggttag ggtaggggtt aggg		24
SEQ ID NO: 7	moltype = DNA length = 21	
FEATURE	Location/Qualifiers	
misc_feature	1..21	
	note = Synthetic Polynucleotide	
source	1..21	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 7		
ctcctattgg gggtttccta t		21
SEQ ID NO: 8	moltype = length =	
SEQUENCE: 8		
000		
SEQ ID NO: 9	moltype = DNA length = 25	
FEATURE	Location/Qualifiers	
misc_feature	1..25	
	note = Synthetic Polynucleotide	
source	1..25	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 9		
ttaggggtta gggtaggggt taggg		25
SEQ ID NO: 10	moltype = DNA length = 4369	
FEATURE	Location/Qualifiers	
misc_feature	1..4369	
	note = Synthetic Polynucleotide	
source	1..4369	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 10		
aaagcttccc ggggggatct gggccactcc ctctctgcgc gctcgcctcg tcaactgaggc		60
cgggcgacca aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag tgagcgagcg		120
agcgcgcaga gagggagtgg ccaactccat cactaggggt tcctggaggg gtggagtcgt		180
gacctaggca tatgccaaat acgcccccta ttgacgtcaa tgacggtaaa tggcccgcc		240
ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat		300
tagtcatcgc tattaccatg gtgatgcggg tttggcagta catcaatggg cgtggatagc		360
ggtttgactc acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt		420
ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa ctccgcccc		480
tgggcggtag gcgtgtacgg tgggaggtct atataagcag agctcgttta gtgaaccgtc		540
agatcgccctg gagacgccat ccggactcta aggtaaatat aaaattttta agtgtataat		600
gtgttaaact actgattcta attgtttctc tcttttagat tccaaccttt ggaactgaat		660
tccgcggggc cggtatccac cggtcgccac catggtgagc aagggcgagg agctgttcac		720
cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt		780
gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt tcatctgcac		840
caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca		900
gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc		960
cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg		1020
cgcgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga		1080
cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa		1140
cgtctatata atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcc		1200
caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca ccccatcgg		1260
cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtcgg cctgagcaa		1320
agaccccaac gagaagcgcg atcacatggt cctgctggag ttctgtgacc ccgcccggat		1380
cactctcggc atggacgagc tgtacaagta aagcgccgc taggcctcac ctgcgatctc		1440
gatgctttat ttgtgaaatt tgtgatgcta ttgctttatt tgtaaccatt ataagctgca		1500
ataaacaagt taacaacaac aattgcattc attttatgtt tcaggttcag ggggaggtgt		1560
gggaggtttt ttaaactagt ccaactccctc tctgcgcgct cgctcgcctca ctgaggccgg		1620
gcgaccaaag gtcgcccgcg gcccgggctt tgcccggcg gcctcagtga gcgagcgagc		1680
gcgcagagag ggacagatcc gggcccgcgt gcgtcgacaa ttcactggcc gtcgttttac		1740
aacgtcgtga ctgggaaaac cctggcggtta cccaacttaa tcgccttgca gcacatcccc		1800
ctttcgccag ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc		1860
gcagcctgaa tggcgaaatgg cgctgatgc ggtattttct ccttacgcat ctgtgcggta		1920
tttcacaccg catatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc		1980
agccccgaca cccgccaca cccgctgacg cgccctgacg ggcttgtctg ctcccggcat		2040
ccgcttacag acaagctgtg accgtctccg ggagctgcat gtgtcagagg ttttcaccgt		2100
catcacgaa acgcgcgaga cgaaagggcc tcgtgatagc cctattttta taggttaatg		2160
tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa		2220

-continued

ccccatatttg	tttatattttc	taaatacatt	caaatatgta	tccgctcatg	agacaataac	2280
cctgataaat	gcttcaataa	tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	2340
tcgcccttat	tccctttttt	gcggcatttt	gccttcctgt	ttttgctcac	ccagaaacgc	2400
tggtgaaagt	aaaagatgct	gaagatcagt	tgggtgcacg	agtgggttac	atcgaactgg	2460
atctcaacag	cggtaagatc	cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	2520
gcacttttaa	agttctgcta	tgtggcgcg	tattatcccc	tattgacgcc	gggcaagagc	2580
aactcggtcg	ccgcatacac	tattctcaga	atgacttggt	tgagtactca	ccagtcacag	2640
aaaagcatct	tacggatggc	atgacagtaa	gagaattatg	cagtgcctgc	ataaccatga	2700
gtgataaac	tgcggccaac	ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	2760
cttttttgca	caacatgggg	gatcatgtaa	ctcgccctga	tcgttgggaa	ccggagctga	2820
atgaagccat	accaaacgac	gagcgtgaca	ccacgatgcc	tgtagcaatg	gcaacaacgt	2880
tgcgcaaact	attaactggc	gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	2940
ggatggaggc	ggataaagt	gcaggaccac	ttctgcgctc	ggcccttcct	gctggctggg	3000
ttattgctga	taaatctgga	gccgggtgag	gtgggtctcg	cggatcatt	gcagcactgg	3060
ggccagatgg	taagccctcc	cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	3120
tggatgaacg	aaatagacag	atcgctgaga	taggtgcctc	actgattaag	cattggtaac	3180
tgtcagacca	agtttactca	tatatacttt	agattgattt	aaaacttcat	ttttaattta	3240
aaaggatcta	gggtgaagatc	ctttttgata	atctcatgac	caaaatccct	taacgtgagt	3300
tttcgttcca	ctgagcgtca	gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	3360
tttttctgcg	cgtaatctgc	tgcttgcaaa	caaaaaaacc	accgctacca	gcggtggttt	3420
gtttgccgga	tcaagagcta	ccaactcttt	ttccgaaggt	aactggcttc	agcagagcgc	3480
agataccaaa	tactgttctt	ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	3540
tagcaccgcc	tacatacctc	gctctgctaa	tctgtttacc	agtggctgct	gccagtggcg	3600
ataagtctgt	tcttaccggg	ttggactcaa	gacgatagtt	accggataag	gcgcagcggg	3660
cgggctgaac	gggggggttc	tgcacacagc	ccagcttggg	gcgaacgacc	tacaccgaac	3720
tgagatacct	acagcgtgag	ctatgagaaa	gcgccacgct	tcccgaaggg	agaaaggcgg	3780
acagggtatcc	ggtaagcggc	agggtcggaa	caggagagcg	cacgagggag	cttccagggg	3840
gaaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	3900
ttttgtgatg	ctcgtcaggg	gggcggagcc	tatggaaaaa	cgccagcaac	gcggcctttt	3960
tacgggtcct	ggccttttgc	tggccttttg	ctcacatgtt	ctttcctgcg	ttatcccctg	4020
attctgtgga	taaccgtatt	accgcctttg	agtgaagctga	taccgctcgc	cgcagccgaa	4080
cgaccgagcg	cagcagatca	gtgagcggag	aagcgggaaga	gcgcccataa	cgcaaacccg	4140
ctctccccgc	gcgttgcccg	attcattaat	gcagctggca	cgacagggtt	cccgaactga	4200
aagcgggcag	tgagcgcaac	gcaattaatg	tgagttagct	cactcattag	gcaccccagg	4260
ctttacactt	tatgcttcgc	gctcgtatgt	tgtgtggaat	tgtgagcgga	taacaatttc	4320
acacaggaaa	cagctatgac	catgattacg	ccaagctctc	gagatctag		4369
SEQ ID NO: 11						
FEATURE						
misc_feature						
source						
SEQUENCE: 11						
aaagcttccc	gggggggatct	ggggcactcc	ctctctgcgc	gctcgtctgc	tcaactgaggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcggagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaggg	gtggagtcgt	180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tgggccgcct	240
ggcattatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtag	atctacgtat	300
tagtcacgcg	tattaccatg	gtgatgcggg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggatct	ccaagtctcc	accctattga	cgtcaatggg	agtttgtttt	420
ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccga	ttgacgcaaa	480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc	540
agatcgctcg	gagacgccat	ccggactcta	aggtaaatat	aaaattttta	agtgtataat	600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tcgcgcgggc	cgggatccac	cggtcgccac	catggtgagc	aagggcgagg	agctgttcac	720
cgggggtggt	cccacctctg	tgcagctgga	cggcgacgta	aacggccaca	agttcagcgt	780
gtccggcgag	ggcgaggggc	atgccacctc	cggcaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca	900
gtgcttcagc	cgctacccc	accacatgaa	gacgacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	ctcaaggac	gacggcaact	acaagaccgc	1020
cgccgagggt	aagttcgagg	gcgacacctc	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tcctggggca	caagctggag	tacaactaca	acagccacaa	1140
cgtctatatc	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	cccccatcgg	1260
cgacggcccc	gtgctgctgc	ccgacaacca	ctacctgagc	accagtcctg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatggg	cctgctggag	ttcgtgaccg	ccgcggggat	1380
cactctcggc	atggacgagc	tgtacaagta	aagcggccgc	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatggt	tcaggttcag	ggggaggtgt	1560
gggaggtttt	ttaaatcgat	tggcgcgcac	ccacggcctg	aaaaatggcg	cgcacccacg	1620
gcctgaaaaa	tggcgcgcac	ccacggcctg	aaaaaactag	tccactccct	ctctgcgcgc	1680
tcgctcgctc	actgaggccg	ggcgacccaa	ggtcgcccga	cgcccgggct	ttgcccgggc	1740
ggcctcagtg	agcgagcgag	cgcgcagaga	gggacagatc	cggggcccga	tgcgtcgaca	1800
attcactggc	cgtcgtttta	caacgtcgtg	actgggaaaa	ccctggcggt	acccaactta	1860

-continued

atcgcccttg	agcacatccc	cctttcgcca	gtcggcgtaa	tagcgaagag	gcccgcaccg	1920
atcgcccttc	ccaacagttg	cgcagcctga	atggcgcaatg	gcgcctgatg	cggtatttttc	1980
tccttacgca	tctgtgcggt	atttcacacc	gcatatgggtg	cactctcagt	acaatctgct	2040
ctgatgccgc	atagttaagc	cagccccgac	acccgccaac	acccgctgac	gcgcccctgac	2100
gggcttgct	gctcccggca	tccgcttaca	gacaagctgt	gaccgtctcc	gggagctgca	2160
tgtgtcagag	gttttcaccg	tcatcaccca	aacgcgcgag	acgaaagggc	ctcgtgatac	2220
gcctattttt	ataggttaat	gtcatgataa	taatggtttc	ttagacgtca	ggtggcactt	2280
ttcggggaaa	tgtgcgcgga	acccctattt	gtttattttt	ctaaatacat	tcaaatatgt	2340
atccgctcat	gagacaataa	ccctgataaa	tgcttcaata	atattgaaaa	aggaagagta	2400
tgagtattca	acatttccgt	gtcgccctta	ttcccttttt	tgcggcattt	tgcccttctg	2460
tttttgctca	cccagaaacg	ctgggtgaaag	taaaagatgc	tgaagatcag	ttgggtgcac	2520
gagtgggtta	catcgaactg	gatctcaaca	gcggtaaagt	ccttgagagt	tttcgccccg	2580
aagaacgttt	tccaatgatg	agcactttta	aagtctctgt	atgtggcgcg	gtattatccc	2640
gtattgacgc	cgggcaagag	caactcggtc	gccgcataca	ctattctcag	aatgacttgg	2700
ttgagtactc	accagtcaca	gaaaagcatc	ttacggatgg	catgacagta	agagaattat	2760
gcagtgtctg	cataaccatg	agtgataaca	ctgcggccaa	cttacttctg	acaacgatcg	2820
gaggacogaa	ggagctaacc	gcttttttgc	acaacatggg	ggatcatgta	actcgccctg	2880
atcggtggga	accggagctg	aactgaagcca	taccaaacga	cgagcgtgac	accacgatgc	2940
ctgtagcaat	ggcaacaacg	ttgcgcaaac	tattaactgg	cgaactactt	actctagctt	3000
cccggcaaca	attaatagac	tggatggagg	cggataaagt	tgcaggacca	cttctgcgct	3060
cggcccttcc	ggctggctgg	tttattgctg	ataaatctgg	agccgggtgag	cgtgggtctc	3120
gcggtatcat	tgcagactg	gggccagatg	gtaaagccctc	ccgtatcgtg	gttatctaca	3180
cgacggggag	tcaggcaact	atggatgaac	gaaatagaca	gatcgctgag	ataggtgcct	3240
cactgattaa	gcatttgtaa	ctgtcagacc	aagtttactc	atatatactt	tagattgatt	3300
taaaacttca	tttttaattt	aaaaggatct	aggtgaagat	cctttttgat	aatctcatga	3360
ccaaaatccc	tttaactgag	ttttcgttcc	actgcgcgtc	agaccccgta	gaaaagatca	3420
aaggatcttc	ttgagatcct	ttttttctgc	gcgtaactctg	ctgcttgcaa	acaaaaaac	3480
caccgctacc	agcggtggtt	tgtttgccgg	atcaagagct	accaactctt	tttccgaagg	3540
taactggctt	cagcagagcg	cagataccaa	atactgttct	tctagtgtag	ccgtagttag	3600
gccaccactt	caagaactct	gtagcaccgc	ctacatacct	cgctctgcta	atcctgttac	3660
cagtggctgc	tgccagtggc	gataagtcgt	gtcttaccgg	gttgactca	agacgatagt	3720
taccggataa	ggcgagcgcg	tccggctgaa	cgggggggtc	gtgcacacag	cccagcttgg	3780
agcgaacgac	ctacaccgaa	ctgagatacc	tacagcgtga	gctatgagaa	agcgccacgc	3840
ttcccgaagg	gagaaaggcg	gacaggtatc	cggtaagcgg	cagggtcgga	acaggagagc	3900
gcacgagggg	gcttccaggg	ggaaaacgct	ggtatcttta	tagtcctgtc	gggtttcgcc	3960
acctctgact	tgagcgtcga	tttttgat	gctcgtcagg	ggggcgagc	ctatggaaaa	4020
acgccagcaa	cgcggccttt	ttacggttcc	tggccttttg	ctggcctttt	gtcacatgt	4080
tctttcctgc	gttatcccct	gattctgtgg	ataaccgtat	taccgccttt	gagtgagctg	4140
ataccgctcg	ccgcagccga	acgaccgagc	gcagcgagtc	agtgcgagc	gaagcggaag	4200
agcgcccaat	acgcaaaccg	cctctccccg	cgcgttgccc	gattcattaa	tgagctggc	4260
acgacagggt	tcccgactgg	aaagcgggca	gtgagcgcaa	cgcaattaat	gtgagttagc	4320
tcactcatta	ggcaccccag	gctttacact	ttatgcttcc	ggctcgtatg	ttgtgtggaa	4380
ttgtgagcgg	ataacaattt	cacacaggaa	acagctatga	ccatgattac	gccaagctct	4440
cgagatctag						4450
SEQ ID NO: 12						
FEATURE						
misc_feature						
source						
SEQUENCE: 12						
aaagcttccc	gggggggatct	gggcccactcc	ctctctgcgc	gtcgcgtcgc	tcaactgaggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaggg	gtggagtcgt	180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tggccgcct	240
ggcattatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtag	atctacgtat	300
tagtcacgc	tattaccatg	gtgatgcggg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggattt	ccaagtctcc	acccatttga	cgtcaatggg	agtttgtttt	420
ggcaccaaaa	tcaacgggac	tttccaaaa	ctcgcgccca	ttgacgcaaa		480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc	540
agatcgccctg	gagacgccat	ccggactcta	aggtaaatat	aaaattttta	agtgtataat	600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tccgcgggcc	cgggatccac	cggtcgccac	catggtgagc	aagggcgagg	agctgttcac	720
cggggtgggtg	cccacccctg	tcgagctgga	cggcgacgta	aacggccaca	agttcagcgt	780
gtccggcgag	ggcgagggcg	atgccaccta	cggcaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca	900
gtgcttcagc	cgctaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagaccgc	1020
cgcggagggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tcctggggca	caagctggag	tacaactaca	acagccacaa	1140
cgtctatata	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	cccccatcgg	1260
cgacggcccc	gtgctgctgc	cgcacaacca	ctacctgagc	acccagtcgg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatggt	cctgctggag	ttcgtgaccg	ccgcggggat	1380

-continued

cactctcggc	atggacgagc	tgtacaagta	aagcggccgc	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatgtt	tcagggttcag	ggggaggtgt	1560
gggaggtttt	ttaaatcgat	tttagggtta	gggttagggg	tagggaaaaa	tttagggtta	1620
gggttagggg	tagggaaaaa	tttagggtta	gggttagggg	tagggaaaaa	actagtccac	1680
tccctctctg	cgcgctcgct	cgtcactga	ggccgggcga	ccaaaggtcg	cccgacgccc	1740
gggctttgcc	cgggcggcct	cagtgagcga	gcgagcgcgc	agagagggac	agatccgggc	1800
ccgcatgcgt	cgacaattca	ctggccgctg	ttttacaacg	tcgtgactgg	gaaaaccctg	1860
gcgttaccca	acttaatcgc	cttgacgac	atcccccttt	cgccagctgg	cgtaatagcg	1920
aagaggcccg	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatggcgcc	1980
tgatgcggta	ttttctcctt	acgcctctgt	gcggtatttc	acaccgcata	tggtgcactc	2040
tcagtacaat	ctgctctgat	gccgcatagt	taagccagcc	ccgacacccg	ccaacacccg	2100
ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	2160
tctccgggag	ctgcatgtgt	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	2220
agggcctcgt	gatacgcccta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	2280
cgtaagggtg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	2340
tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	2400
gaaaaaggaa	gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	2460
cattttgcct	tcctgttttt	gctcaccag	aaacgctggg	gaaagtaaaa	gatgctgaag	2520
atcagttggg	tgacagagt	ggttacatcg	aactggatct	caacagcggg	aagatccttg	2580
agagttttcg	ccccgaagaa	cgtttttccaa	tgatgagcac	ttttaaggtt	ctgctatgtg	2640
gcgcgggtatt	atcccgtatt	gacgcggggc	aagagcaact	cggtcgcccgc	atacactatt	2700
ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcctcttacg	gatggcatga	2760
cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	taacactcgc	gccaaacttac	2820
ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	tttgcaaac	atgggggatc	2880
atgtaactcg	ccttgatcgt	tgggaaccgc	agctgaatga	agccatacca	aacgacgagc	2940
gtgacaccac	gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	actggcgaa	3000
tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	3060
gaccacttct	gcgctcggcc	cttcgggctg	gctggtttat	tgctgataaa	tctggagccg	3120
gtgagcgtgg	gtctcgcggg	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	3180
tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	3240
ctgagatagg	tgccctactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	3300
tacttttagat	tgatttaaaa	cttcattttt	aattttaaag	gatctagggtg	aagatccttt	3360
ttgataatct	catgaccaa	atcccctaac	gtgagttttc	gttccactga	gcgtcagacc	3420
ccgtagaaaa	gatcaaaagg	tcttctttgag	atcctttttt	tctgcgcgta	atctgctgct	3480
tgcaaaacaa	aaaaccacgc	ctaccagcgg	tggtttgttt	gccggatcaa	gagctaccaa	3540
ctctttttcc	gaaggttaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	3600
tgtagccgta	gtagggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	3660
tgctaatact	gttaccagt	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	3720
actcaagacg	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	gggtcgtgca	3780
cacagcccg	cttgagcgca	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	3840
gagaaagcgc	cacgcttccc	gaaggagaga	aggcggacag	gtatccggta	agcggcaggg	3900
tcggaacagg	agagcgcacg	aggagccttc	cagggggaaa	cgcctgggat	ctttatagtc	3960
ctgtcggggt	tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	4020
ggagcctatg	gaaaaacgcc	agcaacgcgg	cctttttacg	gttcctggcc	ttttgctggc	4080
cttttgctca	catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	4140
cctttgagt	agctgatacc	gctcgcgcga	gccgaacgac	cgagcgcagc	gagtcagtga	4200
gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tgcccgattc	4260
attaatgcag	ctggcacgac	aggtttcccg	actggaaagc	gggcagtga	cgcaacgcaa	4320
ttaatgtgag	ttagctcact	cattagggac	cccaggtttt	acactttatg	cttcgggctc	4380
gtatgttgtg	tggaattgtg	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	4440
attacgcaaa	gctctcgaga	tctag				4465
SEQ ID NO: 13 moltype = DNA length = 4465						
FEATURE Location/Qualifiers						
misc_feature 1..4465						
note = Synthetic Polynucleotide						
source 1..4465						
mol_type = other DNA						
organism = synthetic construct						
SEQUENCE: 13						
aaagcttccc	gggggggatct	ggggcactcc	ctctctgcgc	gctcgtcgcg	tcaactgaggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccg	gcggcctcag	tgagcgagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaggg	gtggagtcgt	180
gacctaggtt	tagggttagg	gttagggtta	gggaaaaatt	tagggttagg	gttagggtta	240
gggaaaaatt	tagggttagg	gttagggtta	gggaaaaacc	taggcatatg	ccaagtacgc	300
cccctattga	cgtcaatgac	ggtaaatggc	ccgcctggca	ttatgccag	tacatgacct	360
tatgggactt	tcctacttgg	cagtacatct	acgtattagt	catcgctatt	accatgggtga	420
tgcggttttg	gcagtacatc	aatgggcgtg	gatagcgggt	tgactcacgg	ggatttccaa	480
gtctccaccc	cattgacgtc	aatgggagtt	tgttttggca	ccaaaatcaa	cgggactttc	540
caaaatgtcg	taacaactcc	gccccattga	cgcaaatggg	cggtaggcgt	gtacgggtggg	600
aggtctatat	aagcagagct	cgttttagtga	accgtcagat	cgcttgagga	cgccatccgg	660
actctaaggt	aaatataaaa	tttttaagt	tataatgtgt	taaactactg	attctaattg	720
tttctctctt	ttagattcca	acctttggaa	ctgaattccg	cgggcccggg	atccaccggg	780
cgccaccatg	gtgagcaagg	gcgaggagct	gttcaccggg	gtggtgccca	tcctggtcga	840
gctggacggc	gacgtaaacg	gccacaagtt	cagcgtgtcc	ggcgagggcg	agggcgatgc	900

-continued

cacctacggc	aagctgaccc	tgaagttcat	ctgcaccacc	ggcaagctgc	ccgtgccctg	960
gcccaccctc	gtgaccaccc	tgacctacgg	cgtgcagtgc	ttcagccgct	accccgacca	1020
catgaagcag	cacgacttct	tcaagtccgc	catgcccga	ggctacgtcc	aggagcgcac	1080
catcttcttc	aaggacgacg	gcaactacaa	gacccgcgcc	gaggtgaagt	tcgagggcga	1140
caccttggtg	aaccgcatcg	agctgaaggg	catcgacttc	aaggaggacg	gcaacatcct	1200
ggggcacaa	ctggagtaca	actacaacag	ccacaacgtc	tatatcatgg	ccgacaagca	1260
gaagaacggc	atcaaggtga	acttcaagat	ccgccacaac	atcgaggacg	gcagcgtgca	1320
gctcgccgac	cactaccagc	agaacacccc	catcggcgac	ggccccgtgc	tgctgcccga	1380
caaccactac	ctgagcaccc	agtcgcccct	gagcaaaagac	cccaacgaga	agcgcgatca	1440
catggtcctg	ctggagtctg	tgaccgcccgc	cgggatcact	ctcggcatgg	acgagctgta	1500
caagtaaagc	ggccgctagg	cctcacctgc	gatctcgatg	ctttatttgt	gaaatttgtg	1560
atgctattgc	tttatttgta	accattataa	gctgcaataa	acaagttaac	aacaacaatt	1620
gcattcatct	tatgtttcag	gttcaggggg	aggtgtggga	ggttttttta	actagtccac	1680
tcctctctct	cgcgctcgct	cgtcactga	ggcggggcga	ccaaaggtcg	cccgcgccc	1740
gggctttgcc	cgggcggcct	cagtgagcga	gcgagcgcg	agagagggac	agatccgggc	1800
ccgcatgcgt	cgacaattca	ctggccgctc	ttttacaacg	tcgtgactgg	gaaaaccctg	1860
gcgttaccca	acttaatcgc	cttgacgac	atcccccttt	cgccagctgg	cgtaatagcg	1920
aagaggcccc	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatggcgcc	1980
tgatgcggta	ttttctcctt	acgcctctgt	gcggtatttc	acaccgcata	tggtgcactc	2040
tcagtacaat	ctgctctgat	gcgcgatagt	taagccagcc	ccgacacccg	ccaacacccg	2100
ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	2160
tctccgggag	ctgcatgtgt	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	2220
agggcctcgt	gatacgccca	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	2280
cgtcagggtg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	2340
tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	2400
gaaaaaggaa	gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	2460
cattttgcct	tcctgttttt	gctcacccag	aaacgctggg	gaaagtataa	gatgctgaag	2520
atcagttggg	tgacagagt	ggttacatcg	aactggatct	caacagcggg	aagatccttg	2580
agagttttcg	ccccgaagaa	cgtttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	2640
gcgcgggtatt	atcccgtatt	gacgcggggc	aagagcaact	cggtcgcccgc	atacactatt	2700
ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcattcttac	gatggcatga	2760
cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	taacactcgc	gccaaacttac	2820
ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	tttgacacac	atgggggatc	2880
atgtaactcg	ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	2940
gtgacaccac	gaatgcctga	caacgttgcg	caaactatta	actggcgaa	actggcgaa	3000
tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	3060
gaccacttct	gcgctcggcc	cttcgggctg	gctgggttat	tgctgataaa	tctggagccg	3120
gtgagcgtgg	gtctcgcggg	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	3180
tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	3240
ctgagatagg	tgccctactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	3300
tacttttagat	tgatttaaaa	cttcattttt	aatttaaaa	gatctagggtg	aagatccttt	3360
ttgataaatc	catgacaaa	atcccctaac	gtgagttttc	gttccactga	gcgtcagacc	3420
ccgtagaaaa	gatcaaaagg	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	3480
tgcaaacaaa	aaaaccacgc	ctaccagcgg	tggtttgttt	gccggatcaa	gagctaccaa	3540
ctctttttcc	gaaggttaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	3600
tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	3660
tgctaatact	gttaccagt	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	3720
actcaagacg	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	gggtcgtgca	3780
cacagcccag	cttgagcgga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	3840
gagaaagcgc	cacgcttccc	gaaggagaga	aggcggacag	gtatccggta	agcggcaggg	3900
tcggaacagg	agagcgcacg	agggagcttc	cagggggaaa	cgctgggtat	ctttatagtc	3960
ctgtcggggt	tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	4020
ggagccctat	gaaaaacgcc	agcaacgcgg	ccttttttac	gttcctggcc	ttttgctggc	4080
cttttgctca	catgttcttt	cctgcgttat	ccctgatctc	tgtggataac	cgtattaccg	4140
cctttgagtg	agctgatacc	gctcgcgcga	gccgaacgac	cgagcgcagc	gagtcagtga	4200
gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tgcccgattc	4260
attaatgcag	ctggcacgac	aggtttcccg	actggaaaag	gggcagtgag	cgcaacgcaa	4320
ttaatgtgag	ttagctcact	cattagggac	ccaggctttt	acactttatg	cttcgggctc	4380
gtatgttgtg	tggaattgtg	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	4440
attacgcaa	gctctcgaga	tctag				4465

SEQ ID NO: 14 moltype = DNA length = 6940
FEATURE Location/Qualifiers
misc_feature 1..6940
 note = Synthetic Polynucleotide
source 1..6940
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 14						
cagcagctgc	gcgctcgctc	gctcactgag	gccgcccggg	caaagcccgg	gcgtcggggc	60
acctttggtc	gcccggcctc	agtgagcgag	cgagcgcgca	gagagggagt	ggccaactcc	120
atcactaggg	gttccttgta	gttaatgatt	aacccgccat	gctacttatc	tacgtagcca	180
tgctctagcg	gcctcggcct	ctgcataaat	aaaaaaaaatt	agtcagccat	gagcttggcc	240
cattgcatac	gttgatatcca	tatcataata	tgtacattta	tattgggtcca	tgtccaacat	300
taccgccatg	ttgacattga	ttattgacta	gttattaata	gtaatcaatt	acgggggtcat	360
tagttcatag	cccatatatg	gagttccgcg	ttacataact	tacggtaaat	ggcccgcctg	420

-continued

gctgaccgcc	caacgacccc	cgcccattga	cgccaataat	gacgtatgtt	cccatagtaa	480
cgccaatagg	gactttccat	tgacgtcaat	gggtggagta	tttacggtaa	actgcccact	540
tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta	600
aatggcccg	ctggcattat	gcccagtaca	tgaccttatg	ggactttcct	acttggcagt	660
acatctacgt	attagtcac	gctattacca	tggtgatgcg	gttttggcag	tacatcaatg	720
ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	ccacccatt	gacgtcaatg	780
ggagtttggt	ttggcaccaa	aatcaacggg	actttccaaa	atgtcgtaac	aactccgccc	840
cattgacgca	aatgggcggt	aggcgtgtac	ggtgggaggt	ctatataagc	agagctcggt	900
tagtgaaccg	tcagatcgcc	tgagagacgc	atccacgctg	ttttgacctc	catagaagac	960
accgggaccg	atccagcctc	ccctcgaagc	tgatcctgag	aacttcaggg	tgagtctatg	1020
ggacccttga	tgttttcttt	ccccctcttt	tctatggtta	agttcatgtc	ataggaaggg	1080
gagaagtaac	agggtacaca	tattgaccaa	atcagggtaa	ttttgcattt	gtaattttta	1140
aaaatgcttt	cttcttttaa	tatacttttt	tgtttatctt	atcttctaata	ctttccctaa	1200
tctctttctt	tcagggcaat	aatgatacaa	tgtatcatgc	ctctttgcac	cattctaaag	1260
aataacagtg	ataatttctg	ggtaaggca	atagcaatat	ttctgcata	aaatatttct	1320
gcatataaat	tgtaactgat	gtaagaggtt	tcatattgct	aatagcagct	acaatccagc	1380
taccattctg	cttttatatt	atgggtggga	taaggctgga	ttattctgag	tccaagctag	1440
gcccttttgc	taatcatgtt	catacctctt	atcttcctcc	cacagctcct	gggcaacgtg	1500
ctgggtctgtg	tgctggccca	tcactttggc	aaagaattcc	gcgggcccg	gatccaccgg	1560
tcgccaccat	ggtgagcaag	ggcgaggagc	tggtcaccgg	ggtgggtgcc	atcctgggtc	1620
agctggacgg	cgacgtaaac	ggccacaagt	tcagcgtgtc	cggcgagggc	gagggcgatg	1680
ccacctacgg	caagctgacc	ctgaagttca	tctgcaccac	cggcaagctg	cccgtgccct	1740
ggccccacct	cgtgaccacc	ctgacctacg	gcgtgcagtg	cttcagccgc	taccccgacc	1800
acatgaagca	gcacgacttc	ttcaagtccg	ccatgcccga	aggctacgtc	caggagcgca	1860
ccatcttctt	caaggacgac	ggcaactaca	agaccgcgc	cgaggtgaag	ttcgagggcg	1920
acaccctggg	gaaccgcac	gagctgaagg	gcctcgactt	caaggaggac	ggcaacatcc	1980
tggggcacaa	gctggagtac	aactacaaca	gccacaacgt	ctatatcatg	gccgacaagc	2040
agaagaacgg	catcaagggtg	aacttcaaga	tccgccacaa	catcgaggac	ggcagcgtgc	2100
agctcgccga	ccactaccag	cagaacaccc	ccatcgccga	cggcccgctg	ctgctgccc	2160
acaaccacta	cctgagcacc	cagtcgcgcc	tgagcaaaga	ccccaacgag	aagcgcgatc	2220
acatggctct	gctggagtgc	gtgaccgcgc	ccgggatcac	tctcggcattg	gacgagctgt	2280
acaagtaaa	cggccgctct	agaggatcca	agcttatcga	taccgtcgac	ctcgagggcc	2340
cagatctaat	tcacccacc	agtgcaggct	gcctatcaga	aagtgggtgg	tggtgtggct	2400
aatgccctgg	cccacaagta	tcactaagct	cgctttcttg	ctgtccaatt	tctattaaag	2460
gttcccttgg	tccttaagtc	caactactaa	actgggggat	attatgaagg	gccttgagca	2520
tctggattct	gcctaataaa	aaacatttat	tttcattgca	atgatgtatt	taaattattt	2580
ctgaatatatt	tactaaaaag	ggaatgtggg	aggtcagtg	atttaaaaca	taaagaaatg	2640
aagagctagt	tcaaaccctg	ggaaaataca	ctatatctta	aactccatga	agaaggtga	2700
ggctgcaaac	agctaatagc	cattggcaac	agccctgat	gcctatgcct	tattcatccc	2760
tcagaaaagg	attcaagtag	aggcttgatt	tgagggttaa	agttttgcta	tgctgtattt	2820
tacattactt	attgttttag	ctgtcctcat	gaatgtcttt	tcactacca	tttgcttatc	2880
ctgcatctct	cagccttgac	tcactcagt	tctcttgctt	agagatacca	cttttcccct	2940
gaagtgttcc	ttccatggtt	taaggcgaga	tggtttctcc	tcgcctggcc	actcagcctt	3000
agttgtctct	gttgcttat	agaggctctac	ttgaaagagg	aaaaacagg	ggcatgggtt	3060
gactgtcctg	tgagcccttc	ttccctgcct	ccccactca	cagtgaccgc	gaatccctcg	3120
acatctagag	catggctacg	tagataagta	gcattggcgg	ttaatcatta	actacaagga	3180
accctagtg	atggagttgg	ccactccctc	tctgcgcgct	cgctcgctca	ctgaggccgg	3240
gcgaccaaag	gtcgcccgac	gcccgggctt	tgcccgggcg	gcctcagtga	gcgagcgagc	3300
gcgccagctg	gcgtaatagc	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca	3360
gcctgaatgg	cgaatggaat	tccagacgat	tgagcgtcaa	aatgtaggta	tttccatgag	3420
cgtttttctt	gttgcaatgg	ctggcggtaa	tattgttctg	gatattacca	gcaaggccga	3480
tagtttgagt	tcttctactc	aggcaagtga	tgttattact	aatcaaagaa	gtattgagac	3540
aacgggtaat	ttgcgtgatg	gacagactct	tttactcggt	ggcctcactg	attataaaaa	3600
cacttctcag	gattctggcg	taccgttctt	gtctaaaatc	cctttaatcg	gcctcctggt	3660
tagctcccg	tctgattcta	acgaggaaag	cacgttatat	gtgctcgtca	aagcaaccat	3720
agtacgcgc	ctgtagcggc	gcattaaagc	cggcggtgtg	ggtggttacg	cgcagcgtga	3780
ccgctacact	tgccagcgcc	ctagcgcccg	ctccttctgc	tttcttccct	tcctttctcg	3840
ccacgttcgc	cggcttttcc	cgtcaagctc	taaatcgggg	gctcccttta	gggttccgat	3900
ttagtgttt	acggcacctc	gacccccaaa	aacttgatta	gggtgatggt	tcacgtagt	3960
ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	ttcttttaata	4020
gtggactctt	gttccaaact	ggaacaacac	tcaaccctat	ctcgggtctat	tcttttgatt	4080
tataaagggt	tttgccgatt	tcggcctatt	ggttaaaaaa	tgagctgatt	taacaaaaat	4140
ttaacgcgaa	ttttaacaaa	atattaacgt	ttacaattta	aatatttgct	tatacaatct	4200
tctgttttt	ggggcttttc	tgattatcaa	ccggggtaca	tatgattgac	atgctagtgt	4260
tacgattacc	gttcatcgat	tctcttggtt	gctccagact	ctcaggcaat	gacctgatag	4320
cctttgtaga	gacctctcaa	aaatagctac	cctctccggc	atgaatttat	cagctagaac	4380
ggttgaatat	catattgatg	gtgatttgac	tgtctccggc	ctttctcacc	cgtttgaatc	4440
ttacctaca	cattactcag	gcattgcatt	taaaatatat	gaggggtcta	aaaattttta	4500
tccttgcggt	gaaataaagg	cttctcccg	aaaagtatta	caggggtcata	atgtttttgg	4560
tacaaccgat	ttagctttat	gctctgaggc	tttattgctt	aatttttgcta	attctttgcc	4620
ttgcctgtat	gatttattgg	atggttgaat	tctgtatgcg	gtattttctc	cttacgcac	4680
tgtgcgggat	ttcacaccgc	atatggtgca	ctctcagta	aatctgctct	gatgccgcac	4740
agttaagcca	gccccgacac	ccgccaacac	ccgtgacgc	gcccgtgacg	gcttgctctg	4800
tcgccgcatc	cgtttacaga	caagctgtga	ccgtctccgg	gagctgcatg	tgtcagaggt	4860
tttcaccgct	atcaccgaaa	cgcgcgagac	gaaagggcct	cgtgatacgc	ctattttttat	4920
aggttaatgt	catgataata	atggtttctt	agacgtcagg	tggcactttt	cggggaaatg	4980

-continued

tgcgcggaac	ccctatttgt	ttatttttct	aaatacatto	aaatatgtat	ccgctcatga	5040
gacaataacc	ctgataaatg	cttcaataat	attgaaaaag	gaagagtatg	agtattcaac	5100
atttccgtgt	cgcccttatt	cccttttttg	cggcattttg	ccttcctgtt	tttgctcacc	5160
cagaaacgct	ggtgaaagta	aaagatgctg	aagatcagtt	gggtgcacga	gtgggttaca	5220
tcgaaactga	tctcaacagc	ggtaagatcc	ttgagagttt	tgcgcccgaa	gaacgttttc	5280
caatgatgag	cactttttaa	gttctgctat	gtggcgcggt	attatcccgt	attgacgccg	5340
ggcaagagca	actcggtcgc	cgcatacact	attctcagaa	tgacttggtt	gagtactcac	5400
cagtcacaga	aaagcatctt	acggatggca	tgacagtaag	agaattatgc	agtgctgcca	5460
taaccatgag	tgataaacact	gcggccaact	tacttctgac	aacgatcgga	ggaccgaagg	5520
agctaaccgc	ttttttgcac	aacatggggg	atcatgtaac	tgccttgat	cgttgggaaac	5580
cggagctgaa	tgaagccata	ccaaacgacg	agcgtgacac	cacgatgcct	gtagcaatgg	5640
caacaacggt	gcgcaaaact	ttaactggcg	aactacttac	tctagcttcc	cggcaacaat	5700
taatagactg	gatggaggcg	gataaagttg	caggaccact	tctgcgctcg	gcccttccgg	5760
ctggctgggt	tattgctgat	aaatctggag	ccggtgagcg	tggtctcgcg	ggatcatttg	5820
cagcactggg	gccagatggt	aagccctccc	gtatcgtagt	tatctacacg	acggggagtc	5880
aggcaactat	ggatgaacga	aatagacaga	tcgtgagat	aggtgcctca	ctgattaagc	5940
attggtaact	gtcagaccaa	gtttactcat	atatacttta	gattgattta	aaacttcatt	6000
tttaatttaa	aaggatctag	gtgaagatcc	tttttgataa	tctcatgacc	aaaatccctt	6060
aacgtgagtt	ttcgttccac	tgagcgtcag	accccgtaga	aaagatcaaa	ggatcttctt	6120
gagatccttt	ttttctgcgc	gtaatctgct	gcttgcaaac	aaaaaaacca	ccgctaccag	6180
cggtggtttg	tttgccggat	caagagctac	caactctttt	tccgaaggta	actggcttca	6240
gcagagcgca	gataccaaat	actgtccttc	tagtgtagcc	gtagttaggc	caccacttca	6300
agaactctgt	agcaccgcct	acatacctcg	ctctgctaat	cctgttacca	gtggctgctg	6360
ccagtggcga	taagtcgtgt	cttaccgggt	tggactcaag	acgatagtta	ccggataagg	6420
cgcagcggtc	gggctgaacg	gggggttcgt	gcacacagcc	cagcttgagg	cgaacgacct	6480
acaccgaact	gagataccta	cagcgtgagc	tatgagaaag	cgccacgctt	cccgaaggga	6540
gaaaggcgga	caggtatccg	gtaagcggca	gggtcggaac	aggagagcgc	acgagggagc	6600
ttccaggggg	aaacgcctgg	tatctttata	gtcctgtcgg	gtttcgccac	ctctgacttg	6660
agcgtcgatt	tttgtgatgc	tcgtcagggg	ggcggagcct	atggaaaaac	gccagcaacg	6720
cggccttttt	acggttcctg	gccttttgct	ggccttttgc	tcacatgttc	tttctgcgt	6780
tatccccctg	ttctgtggat	aaccgtatta	ccgcctttga	gtgagctgat	accgctcgcc	6840
gcagccgaac	gaccgagcgc	agcaggtcag	tgagcgagga	agcggaagag	cgcccaatac	6900
gcaaaccgcc	tctccccgcg	cgttggccga	ttcattaatg			6940
SEQ ID NO: 15						
FEATURE						
misc_feature						
source						
SEQUENCE: 15						
cagcagctgc	gcgctcgctc	gctcactgag	gccgccccgg	caaagcccgg	gcgtcggggc	60
acctttgggt	gcccggcctc	agtgagcgag	cgagcgcgca	gagagggagt	ggccaactcc	120
atcactaggg	gttccttgta	gttaatgatt	aacccgccat	gctacttatc	tacgtagcca	180
tgctctagcg	gcctcggcct	ctgcataaat	aaaaaaaaatt	agtcagccat	gagcttggcc	240
cattgcatac	gttgatcca	tatcataata	tgtacattta	tattggctca	tgtccaacat	300
taccgcoatg	ttgacattga	ttattgacta	gttattaata	gtaatcaatt	acgggggtcat	360
tagttcatag	cccatatatg	gagttccgcg	ttacataaact	tacggtaaatt	ggcccgcctg	420
gctgaccgcc	caacgacccc	cgccttattga	cgtcaataat	gacgtatggt	cccatagtaa	480
cgccaatagg	gactttccat	tgacgtcaat	gggtggagta	tttacggtaa	actgcccact	540
tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta	600
aatggccccg	ctggcattat	gcccagtaca	tgaccttatg	ggactttcct	acttggcagt	660
acatctacgt	attagtcatc	gctattacca	tggtgatgcg	gttttggcag	tacatcaatg	720
ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	ccaccccat	gacgtcaatg	780
ggagtttggt	ttggcaccaa	aatcaacggg	actttccaaa	atgtcgtaac	aactccgccc	840
cattgacgca	aatgggcggg	aggcgtgtac	ggtgggagg	ctatataagc	agagctcggt	900
tagtgaaccg	tcagatcgcc	tggagacgcc	atccacgctg	ttttgacctc	catagaagac	960
accgggaccg	atccagcctc	ccctcgaagc	tgatcctgag	aacttcaggg	tgagtctatg	1020
ggacccttga	tgttttcttt	cccttctctt	tctatggtta	agttcatgtc	ataggaagg	1080
gagaagtaac	agggtacaca	tattgaccaa	atcagggtaa	ttttgcattt	gtaattttta	1140
aaaatgcttt	cttcttttaa	tatacttttt	tgtttatctt	atttctaata	ctttccctaa	1200
tctctttctt	tcagggcaat	aatgatacaa	tgtatcatgc	ctctttgcac	cattctaaag	1260
aataaacagt	ataatttctg	ggttaaggca	atagcaatat	ttctgcatat	aaatatttct	1320
gcatataaat	tgtaactgat	gtaagagggt	tcatattgct	aatagcagct	acaatccagc	1380
taccattctg	cttttatttt	atggttggga	taaggctgga	ttattctgag	tccaagctag	1440
gcccttttgc	taatcatgtt	catacctctt	atcttctctc	cacagctcct	gggcaacgtg	1500
ctggtctgtg	tgctggccca	tcactttggc	aaagaattcc	gcggggcccg	gatccaccgg	1560
tcgccaccat	ggtgagcaag	ggcgaggagc	tgttcaccgg	ggtggtgcc	atcctggtcg	1620
agctggacgg	cgacgtaaac	ggccacaagt	tcagcgtgtc	cggcgagggc	gagggcgatg	1680
ccacctacgg	caagctgacc	ctgaagttca	tctgcaccac	cggcaagctg	cccgtgccct	1740
ggccccacct	cgtgaccacc	ctgacctacg	gcgtgcagtg	cttcagccgc	taccccgacc	1800
acatgaagca	gcacgacttc	ttcaagtccg	ccatgcccca	aggctacgtc	caggagcgca	1860
ccatcttctt	caaggacgac	ggcaactaca	agaccgcgc	cgaggtgaag	ttcgagggcg	1920
acaccctggt	gaaccgcatc	gagctgaagg	gcatcgactt	caaggaggac	ggcaacatcc	1980
tggggcacaa	gctggagtac	aactacaaca	gccacaacgt	ctatatcatg	gccgacaagc	2040

-continued

agaagaacgg	catcaagggtg	aacttcaaga	tccgccacaa	catcgaggac	ggcagcgtgc	2100
agctcgccga	ccactaccag	cagaacaccc	ccatcgccga	cggcccccgtg	ctgctgccc	2160
acaaccacta	cctgagcacc	cagtccgccc	tgagcaaaga	ccccaacgag	aagcgcgatc	2220
acatggctct	gctggagttc	gtgaccgccc	ccgggatcac	tctcggcattg	gacgagctgt	2280
acaagtaaag	cggccgctct	agaggatcca	agcttatcga	taccgtcgac	ctcgagggcc	2340
cagatctaata	tcaccccacc	agtgcaggct	gcctatcaga	aagtgggtggc	tgggtgtggct	2400
aatgccctgg	cccacaagta	tcactaagct	cgctttcttg	ctgtccaatt	tctattaaag	2460
gttcctttgt	tccctaagtc	caactactaa	actgggggat	attatgaagg	gccttgagca	2520
tctggattct	gcctaataaa	aaacatttat	tttcattgca	atgatgtatt	taaattattt	2580
ctgaatatatt	tactaaaaag	ggaatgtggg	aggtcagtgc	atttaaaaca	taaagaaatg	2640
aagagctagt	tcaaaccctg	ggaaaataca	ctatatctta	aactccatga	agaaggtga	2700
ggctgcaaac	agctaatagca	cattggcaac	agccctgat	gcctatgcct	tattcatccc	2760
tcagaaaagg	attcaagtag	aggcttgatt	tggagggttaa	agttttgcta	tgtgttattt	2820
tacattactt	attgttttag	ctgtcctcat	gaatgtcttt	tcactacca	tttgcctatc	2880
ctgcatctct	cagccttgac	tcactcagt	tctcttgctt	agagatacca	cctttcccct	2940
gaagtgttcc	ttccatgttt	tacggcgaga	tggtttctcc	tcgcctggcc	actcagcctt	3000
agttgtctct	gttgtcttat	agaggtctac	ttgaagaagg	aaaaacaggg	ggcatggttt	3060
gactgtcctg	tgagcccttc	ttccctgcct	ccccactca	cagtgaccgc	gaatccctcg	3120
acaggtagct	ttagggttag	ggtaggggtt	agggaaaaat	ttagggttag	ggtaggggtt	3180
agggaaaaat	ttagggttag	ggtaggggtt	agggaaaaat	ttagggttag	ggtaggggtt	3240
agggaaaaat	ttagggttag	ggtaggggtt	agggaaaaac	cctaacccta	accctaacc	3300
taaatTTTTT	ccctaaccct	aaccctaacc	ctaaatTTTT	tccctaacc	taaccctaac	3360
cctaaatTTTT	ttccctaacc	ctaacccta	ccctaaatTT	ttccctaacc	cctaacccta	3420
accctaattt	ttttgctagc	tctagagcat	ggctacgtag	ataagtagca	tggcgggtta	3480
atcattaact	acaaggaacc	cctagtgatg	gagttggcca	ctccctctct	gcgcgctcgc	3540
tcgctcactg	aggccgggcg	accgaaggcc	gccgacgcc	cgggctttgc	ccggcgccgc	3600
tcagtgcgag	agcgagcgcg	ccagctggcg	taatagcgaa	gaggcccgca	ccgatcgccc	3660
ttcccaacag	ttgcgcagcc	tgaatggcga	atggaattcc	agacgattga	gcgtcaaaat	3720
gtaggtagtt	ccatgagcgt	ttttcctggt	gcaatggctg	gcggtaatat	tgttctggat	3780
attaccagca	aggccgatag	tttgagttct	tctactcagg	caagtgatgt	tattactaat	3840
caaagaagta	ttgcgacaac	ggttaattttg	cgtgatggac	agactctttt	actcgggtggc	3900
ctcactgatt	ataaaaaac	ttctcaggat	tctggcgtag	cgttcctgtc	taaaatccct	3960
ttaatcgccc	tccgttttag	ctcccgctct	gattctaacg	aggaaagcac	gttatacgtg	4020
ctcgtcaaag	caaccatagt	acgcgcctct	tagcggcgca	ttaagcgcg	cgggtgtggt	4080
ggttacgcgc	agcgtgaccg	ctacacttgc	cagcgcccta	gcgcccgtct	ccttcgcttt	4140
cttcccttcc	tttctcgcca	cgttcgcggg	ctttcccgct	caagctctaa	atcgggggct	4200
ccctttaggg	ttccgattta	gtgctttacg	gcacctcgac	ccccaaaaac	ttgattaggg	4260
tgatggttca	cgtagtgggc	catcgccctg	atagacgggt	tttcgcccct	tgacgttgga	4320
gtccacgttc	tttaatatgt	gactcttggt	ccaaactgga	acaacactca	accctatctc	4380
ggtctattct	tttgatttat	aagggaatttt	gccgatttccg	gcctattggt	taaaaaatga	4440
gctgatttaa	caaaaattta	acgcgaattt	taacaaaata	ttaacgttta	caattttaa	4500
atttgcttat	acaatcttcc	tgtttttggg	gcttttctga	ttatcaaccg	gggtacatat	4560
gattgacatg	ctagttttac	gattaccggt	catcgattct	cctgtttgct	ccagactctc	4620
aggcaatgac	ctgatagcct	ttgtagagac	ctctcaaaaa	tagctaccct	ctccggcatg	4680
aattttatcag	ctagaacggg	tgaatatcat	attgatgggt	atttgactgt	ctccggcctt	4740
tctcaccgt	ttgaatcttt	acctacacat	tactcaggca	ttgcatttaa	aatatatgag	4800
ggttctaaaa	atttttatcc	ttgcgttgaa	ataaaggctt	ctcccgcaaa	agtattacag	4860
ggtcataatg	tttttggtac	aaccgattta	gctttatgct	ctgaggcttt	attgcttaat	4920
tttgctaatt	ccttgccctg	cctgtatgat	ttattggatg	ttggaattcc	tgatgcggta	4980
ttttctcctt	acgcactctg	gcggatattc	acaccgcata	tgggtgcactc	tcagtacaat	5040
ctgctctgat	gccgcatagt	taagccagcc	ccgacacccg	ccaacacccg	ctgacgcgcc	5100
ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	tctccgggag	5160
ctgcatagtg	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	agggcctcgt	5220
gatacgccct	tttttatagg	ttaatgtcat	gataaataatg	gtttcttaga	cgtcaggtgg	5280
cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	ttttctaaa	tacattcaaa	5340
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	5400
gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcct	5460
tctgtttttt	gctcaccag	aaacgctggg	gaaagtaaaa	gatgctgaag	atcagttggg	5520
tgacagagt	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	5580
ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcgggtatt	5640
atcccgattt	gacgcggggc	aagagcaact	cgttcgcgcg	atacactatt	ctcagaatga	5700
cttggttgag	tactcaccag	tcacagaaaa	gcattcttacg	gatggcatga	cagtaagaga	5760
attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	ttctgacaac	5820
gatcgaggga	ccgaaggagc	taaccgcttt	tttgcaaac	atgggggatc	atgtaactcg	5880
ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	5940
gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	actggcgaa	tacttactct	6000
agcttcccg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	gaccacttct	6060
gcgctcgcc	cttccggctg	gctgggttat	tgctgataaa	tctggagccg	gtgagcgtgg	6120
gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctccccta	tcgtagttat	6180
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	6240
tgctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	6300
tgatttaaaa	cttcattttt	aattttaaag	gatctagggtg	aagatccttt	ttgataatct	6360
catgacaaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	6420
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	6480
aaaaccaccg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	ctctttttcc	6540
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	6600

-continued

```

gttagggccac cacttcaaga actctgtagc accgcctaca tacctcgtc tgctaatacct 6660
gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttg actcaagacg 6720
atagttaccg gataaggcgc agcggtcggg ctgaacgggg gggttcgtgca cacagcccag 6780
cttgagagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 6840
cacgcttccc gaaggagaaa aggcggacag gtatccggta agcggcaggg tcggaacagg 6900
agagcgcacg agggagcttc cagggggaaa cgcctggat ctttatagtc ctgtcgggtt 6960
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 7020
gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca 7080
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg 7140
agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga gcgaggaagc 7200
ggaagagcgc ccaatacgca aaccgcctct ccccgcgctg tggccgattc attaatag 7257

```

```

SEQ ID NO: 16      moltype = DNA  length = 15
FEATURE           Location/Qualifiers
misc_feature       1..15
                   note = Synthetic Polynucleotide
source            1..15
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 16
tcctggaggg gaagt                                     15

```

```

SEQ ID NO: 17      moltype = DNA  length = 15
FEATURE           Location/Qualifiers
misc_feature       1..15
                   note = Synthetic Polynucleotide
source            1..15
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 17
tcctggatgg gaagt                                     15

```

```

SEQ ID NO: 18      moltype = DNA  length = 24
FEATURE           Location/Qualifiers
misc_feature       1..24
                   note = Synthetic Polynucleotide
source            1..24
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 18
ttcccatcca ggctggatg ggaa                             24

```

```

SEQ ID NO: 19      moltype = DNA  length = 24
FEATURE           Location/Qualifiers
misc_feature       1..24
                   note = Synthetic Polynucleotide
source            1..24
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 19
cttaccgctg cacctggatg ggaa                             24

```

```

SEQ ID NO: 20      moltype = DNA  length = 20
FEATURE           Location/Qualifiers
misc_feature       1..20
                   note = Synthetic Polynucleotide
source            1..20
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 20
gggggggggg gggggggggg                                20

```

```

SEQ ID NO: 21      moltype = DNA  length = 22
FEATURE           Location/Qualifiers
misc_feature       1..22
                   note = Synthetic Polynucleotide
source            1..22
                   mol_type = other DNA
                   organism = synthetic construct

```

```

SEQUENCE: 21
tgactgtgaa ggtagagat ga                                22

```

```

SEQ ID NO: 22      moltype = DNA  length = 15
FEATURE           Location/Qualifiers
misc_feature       1..15
                   note = Synthetic Polynucleotide

```

-continued

source	1..15	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 22		
tcttgagggt gttgt		15
SEQ ID NO: 23	moltype = DNA length = 18	
FEATURE	Location/Qualifiers	
misc_feature	1..18	
	note = Synthetic Polynucleotide	
source	1..18	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 23		
tgctcctgga ggggttgt		18
SEQ ID NO: 24	moltype = DNA length = 10	
FEATURE	Location/Qualifiers	
misc_feature	1..10	
	note = Synthetic Polynucleotide	
source	1..10	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 24		
cctggcgagg		10
SEQ ID NO: 25	moltype = DNA length = 4369	
FEATURE	Location/Qualifiers	
misc_feature	1..4369	
	note = Synthetic Polynucleotide	
source	1..4369	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 25		
aaagcttccc ggggggatct gggccactcc ctctctgcgc gctcgctcgc tcaactgaggg		60
cgggcgacca aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag tgagcgagcg		120
agcgcgcgaga gagggagtgg ccaactccat cactaggggt tcttgagggt gtggagtcgt		180
gacctaggca tatgccagt acgcccccta ttgacgtcaa tgacggtaaa tggccgcct		240
ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat		300
tagtcatcgc tattaccatg gtgatgcggg tttggcagta catcaatggg cgtggatagc		360
ggtttgactc acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt		420
ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa ctccgcccc ttagcgcaaa		480
tgggcggtag gcgtgtacgg tgggaggtct atataagcag agctcgttta gtgaaccgtc		540
agatcgccctg gagacgcat cgggactcta aggtaaatat aaaattttta agtgtataat		600
gtgttaaaact actgattcta attgtttctc tcttttagat tccaaccttt ggaactgaat		660
tccgcgggcc cgggatccac cggctcgccac catggtaggc aaggcgaggg agctgttcac		720
cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt		780
gtccggcgag ggcgagggcg atgccacct cggcaagctg accctgaagt tcatctgcac		840
caccggcaag ctgcccgtgc cctggccccac cctcgtgacc accctgacct acggcgtgca		900
gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc		960
cgaaggetac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagaccgg		1020
cgccgaggtg aagttcgagg gcgacacct ggtgaaccgc atcgagctga agggcatcga		1080
cttcaaggag gacggcaaca tccctggggca caagctggag tacaactaca acagccaca		1140
cgtctatata atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca		1200
caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca ccccatcgg		1260
cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtcgg cctgagcaa		1320
agaccccaac gagaagcgcg atcacatggg cctgctggag ttctgtgacc ccgcccggat		1380
cactctcggc atggacgagc tgtacaagta aagcggccgc taggcctcac ctgcgatctc		1440
gatgctttat ttgtgaaatt tgtgatgcta ttgctttatt tgtaaccatt ataagctgca		1500
ataaacaagt taacaacaac aattgcattc attttatggt tcaggttcag ggggaggtgt		1560
gggaggtttt ttaaaactag tctccctcgc tctgcgcgct cgctcgctca ctgagggcgg		1620
gcgaccaaag gtcgcccgcg gcccgggctt tgcccggcg gcctcagtga gcgagcgagc		1680
gcgcgagag gacagatcc gggcccgcat gcgtcgacaa ttcactggcc gtcgttttac		1740
aacgtcgtga ctgggaaaac cctggcggtta cccaacttaa tcgccttgca gcacatcccc		1800
ctttcgccag ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc		1860
gcagcctgaa tggcgaaatgg cgcctgatgc ggtattttct ccttacgcat ctgtgcggta		1920
tttcacaccg catatggtgc actctcagta caatctgctc tgatgcgca tagttaagcc		1980
agccccgaca cccgccaaca cccgctgacg cgccctgacg ggcttgtctg ctcccggcat		2040
ccgcttacag acaagctgtg accgtctccg ggagctgcat gtgtcagagg ttttcaccgt		2100
catcaccgaa acgcgcgaga cgaaagggcc tcgtgatacg cctattttta taggttaatg		2160
tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa		2220
cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac		2280
cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg		2340
tcgcccctat tccctttttt gcggcatttt gccttcctgt ttttgetcac ccagaaacgc		2400
tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaaactgg		2460
atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga		2520

-continued

gcactttttaa	agttctgcta	tgtggcgcg	tattatcccg	tattgacgcc	gggcaagagc	2580
aactcggtcg	ccgcatacac	tattctcaga	atgacttgg	tgagtactca	ccagtcacag	2640
aaaagcatct	tacggatggc	atgacagtaa	gagaattatg	cagtgtctgc	ataacatga	2700
gtgataaac	tgcggccaac	ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	2760
cttttttgca	caacatgggg	gatcatgtaa	ctcgccctga	tcgttgggaa	ccggagctga	2820
atgaagccat	accaaacgac	gagcgtgaca	ccacgatgcc	tgtagcaatg	gcaacaacgt	2880
tgcgcaaaact	attaactggc	gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	2940
ggatggaggc	ggataaaagt	gcaggaccac	ttctgcgctc	ggcccttccg	gctggctgg	3000
ttattgctga	taaatctgga	gccgggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	3060
ggccagatgg	taagccctcc	cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	3120
tggtgaacg	aaatagacag	atcgctgaga	taggtgcctc	actgattaag	catttggtaac	3180
tgtcagacca	agtttactca	tatatacttt	agattgattt	aaaacttcat	ttttaattta	3240
aaaggatcta	ggtgaagatc	ctttttgata	atctcatgac	caaaatccct	taacgtgagt	3300
tttcggtcca	ctgagcgtca	gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	3360
tttttctgcg	cgtaatctgc	tgcttgcaaa	caaaaaaacc	accgctacca	gcggtgggtt	3420
gtttgcggga	tcaagagcta	ccaactcttt	ttccgaagg	aactggcttc	agcagagcgc	3480
agataccaaa	tactgttctt	ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	3540
tagcacccgc	tacatacctc	gctctgctaa	tctgttacc	agtggctgct	gccagtggcg	3600
ataagtcgtg	tcttaccggg	ttggactcaa	gacgatagtt	accggataag	gcgcagcgg	3660
cgggctgaac	gggggggttc	tgcacacagc	ccagcttgg	gcgaacgacc	tacaccgaac	3720
tgagatacct	acagcgtgag	ctatgagaaa	gcgccacgct	ttccgaagg	agaaaggcgg	3780
acagggtatcc	ggtaagcggc	agggtcggaa	caggagagcg	cacgagggag	cttccagggg	3840
gaaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	3900
ttttgtgatg	ctcgtcaggg	ggggcgagcc	tatggaaaaa	cgccagcaac	gcggcctttt	3960
tacggttcct	ggccttttgc	tggccttttg	ctcacatgtt	ctttcctgcg	ttatcccctg	4020
attctgtgga	taaccgtatt	accgcctttg	agtgcgtgga	taccgctcgc	cgcagccgaa	4080
cgaccgagcg	cagcgagtca	gtgagcgagg	aagcggaaga	gcgcccaata	cgcaaaccgc	4140
ctctccccgc	gcgttgggcg	attcattaat	gcagctggca	cgacagggtt	cccgaactga	4200
aagcgggcag	tgagcgcaac	gcaattaatg	tgagttagct	cactcattag	gcaccccgag	4260
ctttacactt	tatgcttccg	gctcgtatgt	tgtgtggaat	tgtgagcgga	taacaatttc	4320
acacaggaaa	cagctatgac	catgattacg	ccaagctctc	gagatctag		4369
SEQ ID NO: 26						
FEATURE						
misc_feature						
source						
SEQUENCE: 26						
aaagcttccc	gggggggatct	ggggccactcc	ctctctgcgc	gctcgtcgc	tactgaggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg	120
agcgcgaga	gagggagtgg	ccaactccat	cataggggg	tcctggagg	gtggagtcgt	180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tgggccgcct	240
ggcattatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtac	atctacgtat	300
tagtcacgc	tattaccatg	gtgatgcgg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggattt	ccaagtctcc	accccattga	cgtcaatggg	agtttgtttt	420
ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccc	ttgacgcaaa	480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc	540
agatcgccctg	gagacgccat	ccggactcta	aggtaaatat	aaaattttta	agtgtataat	600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tccgcggggc	cgggatccac	cggctcgccac	catgggtgag	aagggcgagg	agctgttcac	720
cgggggtggg	cccatcctgg	tcgagctgga	cggcgacgta	aacggccaca	agttcagcgt	780
gtccggcgag	ggcgagggcg	atgccacct	cggcaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca	900
gtgcttcagc	cgctaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagaccgg	1020
cgcggagggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tcctggggca	caagctggag	tacaactaca	acagccacaa	1140
cgtctatatc	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	ccccatcgg	1260
cgcgggcccc	gtgctgctgc	ccgacaacca	ctacctgagc	accagtcgg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatgg	cctgctggag	ttcgtgaccg	ccgcgggat	1380
cactctcggc	atggacgagc	tgtacaagta	aagcgccgc	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaacatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatgtt	tcaggttcag	ggggaggtgt	1560
gggagggttt	ttaaatcgat	tggcgcgcac	ccacggcctg	aaaaatggcg	cgcacccacg	1620
gcctgaaaaa	tggcgcgcac	ccacggcctg	aaaaaactag	tccactccct	ctctgcgcgc	1680
tcgctcgcgc	actgaggccg	ggcgacaaaa	ggtcgcccga	cgcccgggct	ttgcccgggc	1740
ggcctcagtg	agcgagcgag	cgcgcagaga	gggacagatc	cgggcccgc	tgcgctcgaca	1800
attcactggc	cgctgtttta	caacgtcgtg	actgggaaaa	ccctggcggt	acccaactta	1860
atcgcccttg	agcacatccc	cctttcgcca	gctggcgtaa	tagegaagag	gcccgcaccg	1920
atcgcccttc	ccaacagttg	cgcagcctga	atggcgaaatg	gcgcctgatg	cggtattttc	1980
tccttaecga	tctgtgcgg	atttcacacc	gcataatgg	cactctcagt	acaatctgct	2040
ctgatgccgc	atagttaagc	cagccccgac	acccgccaac	acccgctgac	gcgccttgac	2100
gggcttgtct	gctcccggca	tccgcttaca	gacaagctgt	gaccgtctcc	gggagctgca	2160

-continued

tgtgtcagag	gttttcaccg	tcatcaccga	aacgcgcgag	acgaaagggc	ctcgtgatac	2220
gcctatTTTT	ataggttaat	gtcatgataa	taatggtttc	ttagacgtca	ggtggcactt	2280
ttcggggaaa	tgtgcgcgga	accctatTTT	gtttatTTTT	ctaaatacat	tcaaatatgt	2340
atccgctcat	gagacaataa	ccttgataaa	tgcttcaata	atattgaaaa	aggaagagta	2400
tgagtattca	acatttccgt	gtcgccctta	ttccctTTTT	tgcggcattt	tgccttcctg	2460
tttttgcTca	cccagaaacg	ctggtgaaag	taaaagatgc	tgaagatcag	ttgggtgcac	2520
gagtgggtta	catcgaaactg	gatctcaaca	gcggtaaagt	ccttgagagt	tttcgccccg	2580
aagaacgttt	tccaatgatg	agcactTTTa	aagttctgct	atgtggcgcg	gtattatccc	2640
gtattgacgc	cgggcaagag	caactcggtc	gccgcataca	ctattctcag	aatgacttgg	2700
ttgagtactc	accagtcaca	gaaaagcatc	ttacggatgg	catgacagta	agagaattat	2760
gcagtgtctg	cataaccatg	agtgataaca	ctgcggccaa	cttacttctg	acaacgatcg	2820
gaggaccgaa	ggagctaaac	gcttttttgc	acaacatggg	ggatcatgta	actcgccttg	2880
atcgttggga	accggagctg	aatgaagcca	taccaaacga	cgagcgtgac	accacgatgc	2940
ctgtagcaat	ggcaacaacg	ttgcgcaaac	tattaactgg	cgaactactt	actctagctt	3000
cccggcaaca	attaatagac	tggatggagg	cggataaagt	tgcaggacca	cttctgcgct	3060
cggcccttcc	ggctggctgg	tttattgctg	ataaatctgg	agccggtgag	cgtgggtctc	3120
gcggtatcat	tgcagcactg	gggccagatg	gtaaagccctc	ccgtatcgta	gttatctaca	3180
cgaacggggag	tcaggcaact	atggatgaac	gaaatagaca	gatcgtgag	ataggtgcct	3240
cactgattaa	gcattggtaa	ctgtcagacc	aagtttactc	atatatactt	tagattgatt	3300
taaaacttca	tttttaattt	aaaaggatct	aggtgaagat	cctttttgat	aatctcatga	3360
ccaaaatccc	ttaacgtgag	ttttcgttcc	actgagcgtc	agaccccgtg	gaaaagatca	3420
aaggatcttc	ttgagatcct	ttttttctgc	gcgtaatctg	ctgcttgcaa	acaaaaaaac	3480
caccgctacc	agcggtggtt	tgtttgccgg	atcaagagct	accaactctt	tttccgaagg	3540
taactggctt	cagcagagcg	cagataccaa	atactgttct	tctagtgtag	ccgtagttag	3600
gccaccactt	caagaactct	gtagcaccgc	ctacatacct	cgctctgcta	atcctgttac	3660
cagtggctgc	tgccagtggc	gataagtcgt	gtcttaccgg	gttggaactca	agacgatagt	3720
taccggataa	ggcgagcgcg	tcgggctgaa	cgggggggtt	gtgcacacag	cccagcttgg	3780
agcgaacgac	ctacaccgaa	ctgagatacc	tacagcgtga	gctatgagaa	agcgccacgc	3840
ttcccgaagg	gagaaaggcg	gacaggtatc	cggtaagcgg	cagggtcgga	acaggagagc	3900
gcacgagggg	gcttccaggg	ggaaacgcct	ggtatcttta	tagtcctgtc	gggtttcgcc	3960
acctctgact	tgagcgtcga	tttttgtgat	gctcgtcagg	ggggcgagc	ctatggaaaa	4020
acgccagcaa	cgcggccttt	ttacggttcc	tggccttttg	ctggcctttt	gtccacatgt	4080
tctttcctgc	gttatccctt	gattctgttg	ataaccgtat	taccgccttt	gagtgagctg	4140
ataccgctcg	cgcgagccga	acgaccgagc	gcagcgagtc	agtgagcgag	gaagcggaag	4200
agcgcccaat	acgcaaaccg	cctctccccg	cgcgttgggc	gattcattaa	tgcagctggc	4260
acgacagggt	tcccgactgg	aaagcgggca	gtgagcgcaa	cgcaattaat	gtgagttagc	4320
tcactcatta	ggcaccccag	gctttacact	ttatgcttcc	ggctcgtatg	ttgtgtggaa	4380
ttgtgagcgg	ataacaattt	cacacaggaa	acagctatga	ccatgattac	gccaagctct	4440
cgagatctag						4450

SEQ ID NO: 27 moltype = DNA length = 4425
FEATURE Location/Qualifiers
misc_feature 1..4425
 note = Synthetic Polynucleotide
source 1..4425
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 27						
aaagcttccc	gggggggatct	ggggccactcc	ctctctgcgc	gctcgtctgc	tcaactgaggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaagg	gtggagtcgt	180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tggcccgcc	240
ggcatttatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtag	atctacgtat	300
tagtcatcgc	tattaccatg	gtgatgcggg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggattt	ccaagtctcc	accccattga	cgtcaatggg	agtttgTTTT	420
ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccc	ttgacgcaaa	480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc	540
agatcgccctg	gagacgccat	cgggactcta	aggtaaatat	aaaattttta	agtgtataat	600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tccgcggggc	cgggatccac	cggtcgccac	catggtgagc	aagggcgagg	agctgttcac	720
cggggtgggtg	cccatcctgg	tcgagctgga	cggcgacgta	aacggccaca	agttcagcgt	780
gtccggcgag	ggcgagggcg	atgccacctg	cggcaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgctg	cctggccccac	cctcgtgacc	accctgacct	acggcgtgca	900
gtgcttcagc	cgctaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagaccgg	1020
cgcgaggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tcctggggga	caagctggag	tacaactaca	acagccacaa	1140
cgtctatatc	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	cccccatcgg	1260
cgacggcccc	gtgctgctgc	ccgacaacca	ctacctgagc	accagtcctg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatggg	cctgctggag	ttcgtgaccg	ccgccgggat	1380
cactctcggc	atggacgagc	tgtacaagta	aagcggccgc	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatgtt	tcaggtttcag	ggggaggtgt	1560
gggaggtttt	ttaaategat	tggcgcgcac	ccacggcctg	aaaaatggcg	cgcacccacg	1620
gcctgaaaaa	actagtcac	tccctctctg	cgcgctcgct	cgctcactga	ggccgggcga	1680

-continued

ccaaagggtcg	cccgacgccc	gggctttgcc	cgggcggcct	cagtgagcga	gcgagcgcg	1740
agagaggggac	agatccgggc	ccgcatgcgt	cgacaattca	ctggccgctcg	ttttacaacg	1800
tcgtgactgg	gaaaaccctg	gcgttaccca	acttaatcgc	cttgacgacac	atcccccttt	1860
cgccagctgg	cgtaatagcg	aagaggcccg	caccgatcgc	ccttcccaac	agttgcgcag	1920
cctgaatggc	gaatggcgcc	tgatgcggta	ttttctcctt	acgcactctgt	gcgggtatttc	1980
acaccgcata	tggtgcactc	tcagtacaat	ctgctctgat	gccgcatagt	taagccagcc	2040
ccgacacccg	ccaacacccg	ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcacccgc	2100
ttacagaaaa	gctgtgaccg	tctccgggag	ctgcatgtgt	cagaggtttt	caccgtcatc	2160
accgaaacgc	gcgagacgaa	agggcctcgt	gatacgccta	tttttatagg	ttaatgtcat	2220
gataataatg	gtttcttaga	cgtcaggtgg	cacttttcgg	ggaaatgtgc	gcggaacccc	2280
tatttgttta	tttttctaaa	tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	2340
ataaatgctt	caataatatt	gaaaaaggaa	gagtatgagt	attcaacatt	tccgtgtcgc	2400
ccttattccc	ttttttgcgg	cattttgcct	tctgtttttt	gctcaccacg	aaacgctggg	2460
gaaagtaaaa	gatgctgaag	atcagttggg	tgacagagtg	ggttacatcg	aactggatct	2520
caacagcggg	aagatccttg	agagttttcg	ccccgaagaa	cgttttccaa	tgatgagcac	2580
ttttaaggtt	ctgctatgtg	gcgcgggtatt	atcccgtatt	gacgcggggc	aagagcaact	2640
cggtcgccgc	atacactatt	ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	2700
gcatcttacg	gatggcatga	cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	2760
taacactgcg	gccaacttac	ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	2820
tttgacaaac	atgggggatc	atgtaactcg	ccttgatcgt	tggaaccggg	agctgaatga	2880
agccatacca	aacgacgagc	gtgacaccac	gatgcctgta	gcaatggcaa	caacgttgcg	2940
caaactatta	actggcgaac	tacttactct	agcttcccgg	caacaattaa	tagactggat	3000
ggaggcggat	aaagttagcag	gaccacttct	gcgctcgggc	cttcgggctg	gctgggttat	3060
tgctgataaa	tctggagccg	gtgagcgtgg	gtctcgcggt	atcattgcag	cactggggcc	3120
agatggtaag	ccctcccgtg	tcgtagtatt	ctacacgacg	gggagtcagg	caactatgga	3180
tgaaacgaaat	agacagatcg	ctgagatagg	tgctcactg	attaagcatt	ggtaactgtc	3240
agaccaagtt	tactcatata	tacttttagat	tgatttaaaa	cttcattttt	aatttaaaaag	3300
gatctagggtg	aagatccttt	ttgataatct	catgacccaa	atcccttaac	gtgagttttc	3360
gttccactga	gcgtcagacc	ccgtagaaaa	gatcaaagga	tcttcttgag	atcctttttt	3420
tctgcgcgta	atctgctgct	tgcaaacaaa	aaaaccaccg	ctaccagcgg	tggtttgttt	3480
gccggatcaa	gagctaccaa	ctctttttcc	gaaggtaact	ggcttcagca	gagcgcagat	3540
accaaatact	gttcttctag	tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	3600
accgcctaca	tacctcgctc	tgctaatcct	gttaccagtg	gctgctgcca	gtggcgataa	3660
gtcgtgtcct	accgggttgg	actcaagacg	atagtaccg	gataaggcgc	agcggtcggg	3720
ctgaacgggg	ggttcgtgca	cacagcccag	cctggagcga	acgacctaca	ccgaactgag	3780
atacctacag	cgtgagctat	gagaaagcgc	cacgcttccc	gaagggagaa	aggcggacag	3840
gtatccggta	agcggcaggg	tcggaacagg	agagcgcacg	agggagcttc	cagggggaaa	3900
cgctcggtat	ctttatagtc	ctgtcggggt	tcgccacctc	tgacttgagc	gtcgattttt	3960
gtgatgctcg	tcaggggggc	ggagcctatg	gaaaaacgcc	agcaacgcgg	cctttttacg	4020
gttcctggcc	ttttgtggc	cttttgctca	catgttcttt	cctgcgttat	ccccgatctc	4080
tgtggataac	cgtattaccg	cctttgagtg	agctgatacc	gctcgccgca	gccgaacgac	4140
cgagcgcagc	gagtcagtga	gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	4200
ccccgcgcgt	tggtccgattc	attaatgcag	ctggcagcag	aggtttcccg	actggaaagc	4260
gggcagtgag	cgcaacgcaa	ttaatgtgag	ttagctcact	cattaggcac	cccaggcttt	4320
acactttatg	cttcgggctc	gtatgttgtg	tggaattgtg	agcggataac	aatttcacac	4380
aggaaacagc	tatgaccatg	attacgccaa	gctctcgaga	tctag		4425
SEQ ID NO: 28						
FEATURE						
misc_feature						
source						
moltype = DNA length = 4465						
Location/Qualifiers						
1..4465						
note = Synthetic Polynucleotide						
1..4465						
mol_type = other DNA						
organism = synthetic construct						
SEQUENCE: 28						
aaagcttccc	gggggggatct	ggggccactcc	ctctctgcgc	gctcgctcgc	tactgagggc	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaggg	gtggagtcgt	180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tgggccgcct	240
ggcattatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtac	atctacgtat	300
tagtcacgcg	tattaccatg	gtgatgcggg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggatttt	ccaagtctcc	acccatttga	cgtcaatggg	agtttgtttt	420
ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccc	ttgacgaaa	480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc	540
agatcgccctg	gagacgccat	ccggactcta	aggtaaatat	aaaattttta	agtgtataat	600
gtgttaaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tccgcggggc	cgggatccac	cggtcgccac	catggtgagc	aagggcgagg	agctgttcac	720
cggggtgggtg	cccatacctg	tcgagctgga	cggcgacgta	aacggccaca	agttcagcgt	780
gtccggcgag	ggcgagggcg	atgccaccta	cggaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgtgc	cctggccccc	cctcgtgacc	accctgacct	acggcggtgca	900
gtgcttcagc	cgtaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagaccgc	1020
cgccgaggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tccctggggc	caagctggag	tacaactaca	acagccacaa	1140
cgtctatatc	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgacgctcgc	cgaccactac	cagcagaaca	cccccatcgg	1260

-continued

cgacggcccc	gtgctgctgc	ccgacaacca	ctacctgagc	accaggtccg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatggg	cctgctggag	ttcgtgaccg	ccgccgggat	1380
cactctcggc	atggacgagc	tgtacaagta	aagcgcccg	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaacatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatggt	tcagggttcag	ggggaggtgt	1560
gggaggtttt	ttaaatcgat	tttaggggta	gggttagggg	tagggaaaaa	tttaggggta	1620
gggttagggg	tagggaaaaa	tttaggggta	gggttagggg	tagggaaaaa	actagtccac	1680
tccctctctg	cgcgctcgct	cgtccactga	ggccggcgga	ccaaagggtc	cccgacgccc	1740
gggctttgcc	cggcgcgcc	cagtgagcga	gcgagcgcg	agagagggac	agatccgggc	1800
ccgcatgcgt	cgacaattca	ctggccgctg	ttttacaacg	tcgtgactgg	gaaaaccctg	1860
gcgttaccca	acttaatcgc	cttgacgac	atcccccttt	cgcagctgg	cgtaatagcg	1920
aagaggcccc	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatggcgcc	1980
tgatgcggta	ttttctcctt	acgcctctgt	gcgtatttcc	acaccgata	tgggtgactc	2040
tcagtacaat	ctgctctgat	gccgcatagt	taagccagcc	ccgacaccgg	ccaacaccgg	2100
ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	2160
tctccgggag	ctgcatgtgt	cagagggttt	caccgtcatc	accgaaacgc	gcgagacgaa	2220
agggcctcgt	gatacgccca	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	2280
cgtcagggtg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	2340
tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	2400
gaaaaaggaa	gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	2460
cattttgcct	tcctgttttt	gctcaccacg	aaacgctggg	gaaagtataa	gatgctgaag	2520
atcagttggg	tgcacgagtg	gggtacatcg	aactggatct	caacagcggt	aagatccttg	2580
agagttttcg	ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaggtt	ctgctatgtg	2640
gcgcggtatt	atcccgat	gacgcggggc	aagagcaact	cggtcgccc	atacactatt	2700
ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcattctacg	gatggcatga	2760
cagtaagaga	attatgcagt	gctgccataa	ccatgagtg	taacactgcg	gccaacttac	2820
ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	tttgacaaac	atgggggatc	2880
atgtaactcg	ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	2940
gtgacaccac	gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	actggcgaac	3000
tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggt	aaagttgcag	3060
gaccacttct	gcgctcgggc	cttccggctg	gctgggttat	tgctgataaa	tctggagccg	3120
gtgagcgtgg	gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgt	3180
tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	3240
ctgagatagg	tgccctactg	attaagcatt	ggttaactgtc	agaccaagtt	tactcatata	3300
tacttttagat	tgatttaaaa	cttcattttt	aattttaaag	gatctagggt	aagatccttt	3360
ttgataatct	catgaccaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	3420
ccgtagaaaa	gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	3480
tgcaaacaaa	aaaaccaccg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	3540
ctctttttcc	gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	3600
tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	3660
tgctaactct	gttaccagt	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	3720
actcaagacg	atagttaccg	gataaaggcg	agcggtcggg	ctgaacgggg	ggttcgtgca	3780
cacagcccag	cttgagcgga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	3840
gagaaagcgc	cacgcttccc	gaagggagaa	aggcggacag	gtatccggt	agcggcaggg	3900
tcggaacagg	agagcgcacg	agggagcttc	cagggggaaa	cgcctggtat	ctttatagtc	3960
ctgtcggggt	tcgccacctc	tgaacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	4020
ggagcctatg	gaaaaacgcc	agcaacgcgg	cctttttacg	gttcctggcc	ttttgctggc	4080
cttttgctca	catgttcttt	cctgcgttat	ccctgatctc	tgtggataac	cgtattaccg	4140
cctttgagt	agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	4200
gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgct	tgcccgattc	4260
attaatgcag	ctggcacgac	agggtttccc	actggaaagc	gggcagtgg	cgcaacgcaa	4320
ttaatgtgag	ttagctcact	cattagggac	cccaggcttt	acactttatg	cttccggctc	4380
gtatgtgtgt	tgggaattgt	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	4440
attacgcaaa	gctctcgaga	tctag				4465
SEQ ID NO: 29						
FEATURE						
misc_feature						
source						
SEQUENCE: 29						
aaagcttccc	gggggggatct	gggcccactcc	ctctctgcgc	gctcgtctgc	tcaactgaggg	60
cgggcgacca	aaggctcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgcgagc	120
agcgcgcaga	gagggagtg	ccaactccat	cactaggggt	tcttgagggg	gtggagtcgt	180
gacctaggca	tatgccaa	acgcccccta	ttgacgtcaa	tgacggtaaa	tgcccgccct	240
ggcattatgc	ccagtagatg	accttatggg	actttcctac	ttggcagtag	atctacgtat	300
tagtcacgc	tattaccatg	gtgatgcggg	tttggcagta	catcaatggg	cgtggatagc	360
ggtttgactc	acggggat	ccaagtctcc	acccatttga	cgtcaatggg	agtttgtttt	420
ggcaccacaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccc	ttgacgcaaa	480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgct	540
agatcgccctg	gagacgccat	ccggactcta	aggtaaata	aaaattttta	agtgtataat	600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat	660
tccgcggggc	cgggatccac	cggtcgccac	catgggtgag	aagggcgagg	agctgttcac	720
cggggtggtg	cccattcctg	tcgagctgga	cggcgacgta	aacggccaca	agttcagcgt	780

-continued

gtccggcgag	ggcgagggcg	atgccaccta	cggcaagctg	accctgaagt	tcatctgcac	840
caccggcaag	ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca	900
gtgcttcagc	cgctaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc	960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagacccg	1020
cgcggaggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga	1080
cttcaaggag	gacggcaaca	tcctggggca	caagctggag	tacaactaca	acagccacaa	1140
cgtctatata	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca	1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	ccccatcgg	1260
cgcggccccc	gtgctgctgc	ccgacaacca	ctacctgagc	accagtcgg	ccctgagcaa	1320
agaccccaac	gagaagcgcg	atcacatggg	cctgctggag	ttcgtgaccg	ccgcggggat	1380
cactctcggc	atggacgagc	tgtacaagta	aagcggccgc	taggcctcac	ctgcgatctc	1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaacatt	ataagctgca	1500
ataaacaagt	taacaacaac	aattgcattc	attttatggt	tcagggttcag	ggggaggtgt	1560
gggaggtttt	ttaaactgat	tttagggtta	gggttagggg	tagggaaaaa	actagtccac	1620
tcctctctct	cgcgctcgct	cgtcactga	ggccggggcg	ccaaaggtcg	cccgacgccc	1680
gggctttgcc	cgggcggcct	cagtgagcga	gcgagcgcgc	agagagggac	agatccgggc	1740
ccgcatgcgt	cgacaattca	ctggccgtcg	ttttacaacg	tcgtgactgg	gaaaaccctg	1800
gcgttaccca	acttaatcgc	cttgacgac	atcccccttt	cgcagctgg	cgtaatagcg	1860
aagaggcccg	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatggcgcc	1920
tgatgcggta	ttttctcctt	acgcctctgt	gcggtatttc	acaccgcata	tgggtgactc	1980
tcagtacaat	ctgctctgat	gccgcatagt	taagccagcc	ccgacacccg	ccaacacccg	2040
ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	2100
tctccgggag	ctgcatgtgt	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	2160
agggcctcgt	gatacgccca	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	2220
cgtcaggtgg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	2280
tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	2340
gaaaaaggaa	gagtatgagt	attcaacatt	tcctgtgcgc	ccttattccc	ttttttgcgg	2400
cattttgcct	tcctgttttt	gctcaccag	aaacgctggg	gaaagtataa	gatgctgaag	2460
atcagttggg	tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	2520
agagttttcg	ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagt	ctgctatgtg	2580
gcgcgggtatt	atcccgtatt	gacgcggggc	aagagcaact	cggtcgccc	atacactatt	2640
ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcactttacg	gatggcatga	2700
cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	2760
ttctgacaac	gatcggagga	ccgaaggagc	taaccgcctt	tttgcacaa	atgggggagc	2820
atgtaactcg	ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	2880
gtgacaccac	gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	actggcgaa	2940
tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	3000
gaccacttct	gcgctcgccc	cttccggctg	gctgggttat	tgctgataaa	tctggagccg	3060
gtgagcgtgg	gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	3120
tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	3180
ctgagatagg	tgccctactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	3240
tacttttagat	tgatttaaaa	cttcattttt	aattttaaag	gatctaggtg	aagatccttt	3300
ttgataatct	catgaccaa	atcccctaac	gtgagttttc	gttccactga	gcgtcagacc	3360
ccgtagaaaa	gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	3420
tgcaaacaaa	aaaaccacgg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	3480
ctctttttcc	gaaggttaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	3540
tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	3600
tgctaatact	gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	3660
actcaagacg	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	3720
cacagcccg	cttgagcgga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	3780
gagaaagcgc	cacgcttccc	gaaggagaga	aggcggacag	gtatccggta	agcggcaggg	3840
tcggaacagg	agagcgcacg	agggagcttc	cagggggaaa	cgcctgggat	ctttatagtc	3900
ctgtcggggt	tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	3960
ggagcctatg	gaaaaacgcc	agcaacgcgg	cctttttacg	gttcctggcc	ttttgctggc	4020
cttttgctca	catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	4080
cctttgagtg	agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	4140
gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tggccgattc	4200
attaatgcag	ctggcacgac	aggtttcccg	actggaaaagc	gggcagtgag	cgcaacgcaa	4260
ttaatgtgag	ttagctcact	cattagggc	cccagggctt	acactttatg	cttccggctc	4320
gtatgttgtg	tggaaattgtg	agcggataac	aatttcacac	aggaaaacagc	tatgaccatg	4380
attacgccaa	gctctcgaga	tctag				4405

SEQ ID NO: 30 moltype = DNA length = 4465
FEATURE Location/Qualifiers
misc_feature 1..4465
 note = Synthetic Polynucleotide
source 1..4465
 mol_type = other DNA
 organism = synthetic construct

aaagcttccc	ggggggatct	gggcccactcc	ctctctgcgc	gctcgcctcgc	tcaactgagge	60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg	120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tcctggaggg	gtggagtcgt	180
gacctaggtt	tagggttagg	gttagggtta	gggaaaaatt	tagggttagg	gttagggtta	240
gggaaaaatt	tagggttagg	gttagggtta	gggaaaaacc	taggcatatg	ccaagtacgc	300
cccctattga	cgtcaatgac	ggtaaatggc	ccgcctggca	ttatgcccg	tacatgacct	360

-continued

tatgggaactt	tectacttgg	cagtacatct	acgtattagt	catcgctatt	accatggtga	420
tgcggttttg	gcagtacatc	aatgggcgtg	gatagcgggt	tgactcacgg	ggatttccaa	480
gtctccaccc	cattgacgtc	aatgggagtt	tgttttggca	ccaaaatcaa	cgggactttc	540
caaaatgtcg	taacaactcc	gccccattga	cgcaaatggg	cggtaggcgt	gtacggtggg	600
aggtctatat	aagcagagct	cgttttagtga	accgtcagat	cgcttgagga	cgccatccgg	660
actctaaggt	aaatataaaa	tttttaagtg	tataatgtgt	taaactactg	attctaattg	720
tttctctctt	ttagattcca	acctttggaa	ctgaattccg	cggggccggg	atccaccggt	780
cgccaccatg	gtgagcaagg	gcgaggagct	gtcccccggg	gtggtgcca	tcctggtcga	840
gctggacggc	gacgtaaacc	gccacaagtt	cagcgtgtcc	ggcgaggggc	agggcgatgc	900
cacctacggc	aagctgaccc	tgaagttcat	ctgcaccacc	ggcaagctgc	ccgtgccctg	960
gcccaccctc	gtgaccaccc	tgacctacgg	cgtgcagtgc	ttcagccgct	accccgacca	1020
catgaagcag	cacgacttct	tcaagtccgc	catgcccga	ggctacgtcc	aggagcgcac	1080
catcttcttc	aaggacgacg	gcaactacaa	gaccgcgcgc	gaggtgaagt	tcgagggcga	1140
caccctgggtg	aaccgcatcg	agctgaaggg	catcgacttc	aaggaggacg	gcaacatcct	1200
ggggcacaa	ctggagtaca	actacaacag	ccacaacgtc	tatatcatgg	ccgacaagca	1260
gaagaacggc	atcaagtgga	acttcaagat	ccgccacaac	atcgaggacg	gcagcgtgca	1320
gctcgccgac	cactaccagc	agaacacccc	catcggcgac	ggccccgtgc	tgctgcccga	1380
caaccactac	ctgagcacc	agtccgcct	gagcaaaag	cccaacgaga	agcgcgatca	1440
catggtcctg	ctggagtctg	tgaccgccc	cgggatcact	ctcggcatgg	acgagctgta	1500
caagtaaagc	ggccgctagg	cctcacctgc	gatctcgatg	ctttatttgt	gaaatttgtg	1560
atgctattgc	tttatttgta	accattataa	gctgcaataa	acaagttaac	aacaacaatt	1620
gcattcatctt	tatgtttcag	gttcaggggg	aggtgtggga	ggttttttta	actagtccac	1680
tcctctctctg	cgcgctcgct	cgtcactga	ggccggggcga	ccaaaggtcg	cccgcgcgcc	1740
gggctttgcc	cgggcggcct	cagtgagcga	gcgagcgccg	agagaggggc	agatccgggc	1800
ccgcatgcgt	cgacaattca	ctggccgctc	ttttacaacg	tcgtgactgg	gaaaaccctg	1860
cggttaccca	acttaatcgc	cttgccagc	atcccccttt	cgccagctgg	cgtaatagcg	1920
aagaggcccg	caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatggcgcc	1980
tgatgcggta	ttttctcctt	acgcctctgt	gcggtatttc	acaccgcata	tggtgcactc	2040
tcagtacaat	ctgctctgat	gccgcatagt	taagccagcc	ccgacacccg	ccaacacccg	2100
ctgacgcgcc	ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	2160
tctccgggag	ctgcatgtgt	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	2220
agggcctcgt	gatagccta	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	2280
cgtcagggtg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	2340
tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	2400
gaaaaaggaa	gagtatgagt	attcaacatt	tcogtgcgc	ccttattccc	ttttttgcgg	2460
cattttgcct	tcctgttttt	gctcacccag	aaacgctggg	gaaagtataa	gatgctgaag	2520
atcagttggg	tgacagagt	ggttacatcg	aactggatct	caacagcggg	aagatccttg	2580
agagttttcg	ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	2640
gcgcgggtatt	atcccgctatt	gacgcggggc	aagagcaact	cggtcgccc	atacactatt	2700
ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcattcttac	gatggcatga	2760
cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	taacactcgc	gccaaacttac	2820
ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	tttgacaaac	atgggggatc	2880
atgtaactcg	ccttgatcgt	tggaaccgg	agctgaatga	agccatacca	aacgacgagc	2940
gtgacaccac	gaatgcctga	gcaatggcaa	caacgttgcg	caaaactatta	actggcgaa	3000
tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	3060
gaccacttct	gcgctcggcc	cttcgggctg	gctggtttat	tgctgataaa	tctggagccg	3120
gtgagcgtgg	gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	3180
tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	3240
ctgagatagg	tgctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	3300
tacttttagat	tgatttaaaa	cttcattttt	aatttaaaa	gatctagggtg	aagatccttt	3360
ttgataaatc	catgacaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	3420
ccgtagaaaa	gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	3480
tgcaaaacaaa	aaaaccacg	ctaccagcgg	tggtttgttt	gccggatcaa	gagctaccaa	3540
ctctttttcc	gaaggtaaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	3600
tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	3660
tgctaactct	gttaccagt	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	3720
actcaagacg	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	3780
cacagcccag	cttgagcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	3840
gagaaagcgc	cacgcttccc	gaaggagaga	aggcggacag	gtatccggta	agcggcaggg	3900
tcggaacagg	agagcgcacg	aggagccttc	cagggggaaa	cgctgggtat	ctttatagtc	3960
ctgtcgggtt	tcgcccacct	tgacttgagc	gtgatgtctg	tcaggggggc		4020
ggagccctatg	gaaaaacgcc	agcaacgcgg	ccttttttacg	gttcctggcc	ttttgctggc	4080
cttttgctca	catgttcttt	cctgcgttat	ccctgatctc	tgtggataac	cgtattaccg	4140
cctttgagt	agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	4200
gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tgcccgattc	4260
attaatgcag	ctggcacgac	aggtttcccg	actggaaagc	gggcagtgag	cgcaacgcaa	4320
ttaatgtgag	ttagctcact	cattaggcac	cccaggcttt	acactttatg	cttcgggctc	4380
gtatgttgtg	tggaattgtg	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	4440
attacgccaa	gctctcgaga	tctag				4465

SEQ ID NO: 31

FEATURE

misc_feature

source

moltype = DNA length = 4435

Location/Qualifiers

1..4435

note = Synthetic Polynucleotide

1..4435

mol_type = other DNA

-continued

organism = synthetic construct					
SEQUENCE: 31					
aaagcttccc	gggggggatct	ggggccactcc	ctctctgctgc	gctcgctcgc	tactgaggc 60
cgggcgacca	aaggtcgccc	gacgcccggg	ctttgcccgg	gcggcctcag	tgagcgagcg 120
agcgcgcaga	gagggagtgg	ccaactccat	cactaggggt	tccctggagg	gtggagtcgt 180
gacctaggca	tatgccaaat	acgcccccta	ttgacgtcaa	tgacggtaaa	tgccccgcct 240
ggcattatgc	ccagtacatg	accttatggg	actttcctac	ttggcagtac	atctacgtat 300
tagtcacgcg	tattaccatg	gtgatgcggt	tttggcagta	catcaatggg	cgtggatagc 360
ggtttgactc	acggggattt	ccaagtctcc	accccatgga	cgtcaatggg	agtttgtttt 420
ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaacaa	ctccgcccc	ttgacgcaaa 480
tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	agctcgttta	gtgaaccgtc 540
agatcgccctg	gagacgccat	cgggactcta	aggtaaatat	aaaattttta	agtgtataat 600
gtgttaaact	actgattcta	attgtttctc	tcttttagat	tccaaccttt	ggaactgaat 660
tccgcggggc	cgggatccac	cggtcgcccac	catgggtgagc	aagggcgagg	agctgttcac 720
cggggtggtg	cccacctggg	tgcagctgga	cggcgacgta	aacggccaca	agttcagcgt 780
gtccggcgag	ggcgagggcg	atgccaccta	cggcaagctg	accctgaagt	tcatctgcac 840
caccggcaag	ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca 900
gtgcttcagc	cgctaccccg	accacatgaa	gcagcacgac	ttcttcaagt	ccgccatgcc 960
cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac	gacggcaact	acaagaccgg 1020
cgcgaggtg	aagttcgagg	gcgacaccct	ggtgaaccgc	atcgagctga	agggcatcga 1080
cttcaaggag	gacggcaaca	tccctggggc	caagctggag	tacaactaca	acagccacaa 1140
cgtctatatc	atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca 1200
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca	cccccatcgg 1260
cgacggcccc	gtgctgctgc	ccgacaacca	ctacctgagc	acccagtccg	ccctgagcaa 1320
agaccccaac	gagaagcgcg	atcacatggt	cctgctggag	ttcgtgaccg	ccgcggggat 1380
cactctcggc	atggacgagc	tgtacaagta	aagcggccgc	taggcctcac	ctgcatctc 1440
gatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca 1500
ataaacaagt	taacaacaac	aattgcattc	attttatgtt	tcaggttcag	ggggaggtgt 1560
gggaggtttt	ttaaatcgat	gctagatgtt	agcgtaaaaa	gctagatgtt	agcgtaaaaa 1620
gctagatgtt	agcgtaaaaa	actagtccac	tccctctctg	cgcgctcgtc	cgtcactga 1680
ggccggggcga	ccaaaggtcg	cccgcgccc	gggctttgcc	cgggcggcct	cagtgagcga 1740
gcgagcgcg	agagagggac	agatccgggc	ccgcatgcgt	cgacaattca	ctggccgtcg 1800
ttttacaacg	tctgactggg	gaaaaccctg	gcgttaccga	acttaatcgc	cttgcagcac 1860
atcccccttt	cgccagctgg	cgtaatagcg	aagaggcccg	caccgatcgc	ccttcccaac 1920
agttgcgcag	cctgaatggc	gaatggcgcc	tgtgctggta	ttttctcctt	acgcatctgt 1980
gcggtatatt	acaccgcata	tgggtgcactc	tcagtacaat	ctgctctgat	gccgcatagt 2040
taagccagcc	ccgacacccg	ccaacacccg	ctgacgcgcc	ctgacgggct	tgtctgctcc 2100
cggcatccgc	ttacagacaa	gctgtgaccg	tctccgggag	ctgcatgtgt	cagaggtttt 2160
caccgtcatc	accgaaacgc	gcgagacgaa	agggcctcgt	gatacgccta	tttttatagg 2220
ttaatgtcat	gataataatg	gtttcttaga	cgtcagggtg	cacttttcgg	ggaaatgtgc 2280
gcggaaacccc	tatttgttta	tttttctaaa	tacattcaaa	tatgtatccg	ctcatgagac 2340
aataacccctg	ataaatgctt	caataatatt	gaaaaaggaa	gagtatgagt	attcaacatt 2400
tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcc	tccgtgtttt	gctcaccag 2460
aaacgcgtgg	gaaagtaaaa	gatgctgaag	atcagttggg	tgacagagtg	ggttacatcg 2520
aactggatct	caacagcggt	aagatccttg	agagttttcg	ccccgaagaa	cgttttccaa 2580
tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcggtatt	atcccgtatt	gacgcggggc 2640
aagagcaact	cggtcgccc	atacactatt	ctcagaatga	cttggttgag	tactcaccag 2700
tcacagaaaa	gcattcttac	gatggcatga	cagtaagaga	attatgcagt	gctgccataa 2760
ccatgagtga	taacactgcg	gccaacttac	ttctgacaac	gatcggagga	ccgaaggagc 2820
taaccgcttt	tttgacaaac	atgggggatc	atgtaactcg	ccttgatcgt	tggaaccggg 2880
agctgaatga	agccatacca	aacgacgagc	gtgacaccac	gatgcctgta	gcaatggcaa 2940
caacgttgcg	caaactatta	actggcgaac	tacttactct	agcttcccgg	caacaattaa 3000
tagactggat	ggaggcggt	aaagtgcag	gaccactctc	gcgctcgggc	cttcgggctg 3060
gctggtttat	tgtgataaaa	tctggagccg	gtgagcgtgg	gtctcgcggt	atcattgcag 3120
cactggggcc	agatggtaag	ccctcccgtg	tcgtagtatt	ctacacgacg	gggagtcagg 3180
caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	tgccctactg	attaagcatt 3240
ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	tgatttaaaa	cttcattttt 3300
aatttaaaag	gatctagggtg	aagatccttt	ttgataatct	catgacccaa	atcccttaac 3360
gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	gatcaaagga	tcttcttgag 3420
atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	aaaaccaccg	ctaccagcgg 3480
tggtttggtt	gccggatcaa	gagctaccaa	ctctttttcc	gaaggtaact	ggcttcagca 3540
gagcgcagat	accaaatact	gttcttctag	tgtagccgta	gttaggccac	cacttcaaga 3600
actctgtagc	accgcctaca	tacctcgctc	tgctaactct	gttaccagtg	gctgctgcca 3660
gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	atagttaccg	gataaggcgc 3720
agcgttcggg	ctgaacgggg	ggttcgtgca	cacagcccag	cttgagcgca	acgacctaca 3780
ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	cacgcttccc	gaaggagaaa 3840
aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	agagcgcacg	aggagcttc 3900
cagggggaaa	cgcctggtat	ctttatagtc	ctgtcgggtt	tcgccacctc	tgacttgagc 3960
gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	gaaaaacgcc	agcaacgcgg 4020
ccttttttac	gttcctggcc	ttttgctggc	cttttgctca	catgttcttt	cctgcgttat 4080
ccctgatttc	tgtggataac	cgtattaccg	cctttgagtg	agctgatacc	gctcgccgca 4140
gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	ggaagagcgc	ccaatacgca 4200
aaccgcctct	ccccgcgcgt	tggccgattc	attaatgcag	ctggcacgac	aggtttccc 4260
actggaaagc	gggcagttag	cgcaacgcaa	ttaatgtgag	ttagctcact	cattaggcac 4320
cccaggtttt	acactttatg	cttcgggctc	gtatgttgtg	tggaattgtg	agcggataac 4380
aatttcacac	aggaaacagc	tatgaccatg	attacgccaa	gctctcgaga	tctag 4435

-continued

SEQ ID NO: 32	moltype = DNA length = 6940				
FEATURE	Location/Qualifiers				
misc_feature	1..6940				
	note = Synthetic Polynucleotide				
source	1..6940				
	mol_type = other DNA				
	organism = synthetic construct				
SEQUENCE: 32					
cagcagctgc	gcgctcgctc	gctcactgag	gccgcccggg	caaagcccg	gcgtcgggcg 60
accttttggtc	gcccggcctc	agtgagcgag	cgagcgcgca	gagagggagt	ggccaactcc 120
atcactaggg	gttccttgta	gttaatgatt	aaccgcgcat	gctacttatc	tacgtagcca 180
tgctctagcg	gcctcggcct	ctgcataaat	aaaaaaaaatt	agtcagccat	gagcttggcc 240
cattgcatac	gttgtatcca	tatcataata	tgtacattta	tattggctca	tgtccaacat 300
taccgccatg	ttgacattga	ttattgacta	gttattaata	gtaatcaatt	acgggggtcat 360
tagttcatag	cccatatatg	gagttccgcg	ttacataact	tacggtaaat	ggcccgcctg 420
gctgaccgcc	caacgacccc	cgcccattga	cgtcaataat	gacgtatgtt	cccatagtaa 480
cgccaatagg	gactttccat	tgacgtcaat	gggtggagta	tttacggtaa	actgcccact 540
tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta 600
aatggcccg	ctggcattat	gcccagtaca	tgaccttatg	ggactttcct	acttggcagt 660
acatctacgt	attagtcatc	gctattacca	tggtgatgcg	gttttggcag	tacatcaatg 720
ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	ccaccccat	gacgtcaatg 780
ggagtttggt	ttggcaccaa	aatcaacggg	actttccaaa	atgtcgtaac	aactccgccc 840
cattgacgca	aatgggcggt	aggcgtgtac	gggtgggagg	ctatataagc	agagctcggt 900
tagtgaaccg	tcagatcgcc	tggagacgcc	atccacgctg	ttttgacctc	catagaagac 960
accgggaccg	atccagcctc	ccctcgaaag	tgatcctgag	aacttcaggg	tgagtctatg 1020
ggacccttga	tgttttcttt	ccccctcttt	tctatgggta	agttcatgtc	ataggaaggg 1080
gagaagtaac	agggtacaca	tattgaccaa	atcagggtaa	ttttgcattt	gtaattttta 1140
aaaaatgcttt	cttcttttaa	tatacttttt	tgtttatctt	atttctaata	ctttccctaa 1200
tctctttctt	tcagggcaat	aatgatacaa	tgtatcatgc	ctctttgcac	cattctaaag 1260
aataacagtg	ataatttctg	ggttaaggca	atagcaatat	ttctgcatat	aaatatttct 1320
gcatataaat	tgtaactgat	gtaagagggt	tcatattgct	aatagcagct	acaatccagc 1380
taccattctg	cttttatttt	atggttggga	taaggctgga	ttattctgag	tccaagctag 1440
gcccttttgc	taatcatgtt	catacctctt	atcttctctc	cacagctcct	gggcaacgtg 1500
ctgggtctgtg	tgctggccca	tcactttggc	aaagaattcc	gcgggcccgg	gatccaccgg 1560
tcgccaccat	ggtgagcaag	ggcgaggagc	tggtcaccgg	gggtggtgcc	atcctggtcg 1620
agctggacgg	cgacgtaaac	ggccacaagt	tcagcgtgtc	cggcgagggc	gagggcgatg 1680
ccacctacgg	caagctgacc	ctgaagttca	tctgcaccac	cggcaagctg	cccgtgccct 1740
ggcccaccct	cgtgaccacc	ctgacctacg	gcgtgcagtg	cttcagccgc	taccccgacc 1800
acatgaagca	gcacgacttc	ttcaagtccg	ccatgcccga	aggctacgtc	caggagcgca 1860
ccatcttctt	caaggacgac	ggcaactaca	agaccgcgcg	cgaggtgaag	ttcgagggcg 1920
acaccctggt	gaaccgcatc	gagctgaagg	gcatcgactt	caaggaggac	ggcaacatcc 1980
tggggcacaa	gctggagtac	aactacaaca	gccacaacgt	ctatatcatg	gccgacaagc 2040
agaagaacgg	catcaaggtg	aacttcaaga	tccgccacaa	catcgaggac	ggcagcgtgc 2100
agctcgccga	ccactaccag	cagaacaccc	ccatcgccga	cggccccgtg	ctgctgcccg 2160
acaaccacta	cctgagcacc	cagtcgcgcc	tgagcaaaga	ccccaacgag	aagcgcgatc 2220
acatggctct	gctggagttc	gtgaccgccc	ccgggatcac	tctcggcgat	gacgagctgt 2280
acaagtaaa	cggccgctct	agaggatcca	agcttatcga	taccgtcgac	ctcgagggcc 2340
cagatcta	tcacccacc	agtgcaggct	gcctatcaga	aagtgggtgg	tggtgtggct 2400
aatgccttgg	cccacaagta	tcactaagct	cgttttcttg	ctgtccaatt	tctattaaag 2460
gttcctttgt	tcctaagtc	caactactaa	actgggggat	attatgaagg	gccttgagca 2520
tctctgattct	gcctaataaa	aaacatttat	tttcattgca	atgatgtatt	taaattattt 2580
ctgaatat	tactaaaaag	ggaatgtggg	aggtcagtg	atttaaaaca	taaagaaatg 2640
aagagctagt	tcaaaccctg	ggaaaataca	ctatatctta	aactccatga	aagaagggtga 2700
ggctgcaaac	agctaatgca	cattggcaac	agccccgat	gcctatgcct	tattcatccc 2760
tcagaaaagg	attcaagtag	aggcttgatt	tggagggtta	agttttgcta	tgctgtattt 2820
tacattactt	attgttttag	ctgtcctcat	gaatgtcttt	tcactacca	tttgcttatc 2880
ctgcatctct	cagccttgac	tcactcagt	tctcttgctt	agagatacca	cctttcccct 2940
gaagtgttcc	ttccatgttt	tacggcgaga	tggtttctcc	tcgcctggcc	actcagcctt 3000
agttgtctct	gttgctttat	agaggtctac	ttgaagaagg	aaaaacaggg	ggcatggttt 3060
gactgtcctg	tgagcccttc	ttccctgcct	ccccactca	cagtgacctg	gaatccctcg 3120
acatctagag	catggctacg	tagataagta	gcatggcggg	ttaatcatta	actacaagga 3180
acccctagtg	atggagtggg	ccactccctc	tctgcgcgct	cgctcgctca	ctgaggccgg 3240
gcgaccaaag	gtcgcccgac	gcccgggctt	tgcccgggcg	gcctcagtga	gcgagcgagc 3300
gcgccagctg	gcgtaatagc	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca 3360
gcctgaatgg	cgaatggaat	tccagacgat	tgagcgtcaa	aatgtaggta	tttccatgag 3420
cgtttttcct	gttgcaatgg	ctggcggtta	tattgttctg	gatattacca	gcaaggccga 3480
tagtttgagt	tcttctactc	aggcaagtga	tgttattact	aatcaaagaa	gtattgcgac 3540
aacggtta	ttgcgtgatg	gacagactct	tttactcggg	ggcctcactg	attataaaaa 3600
cacttctcag	gattctggcg	taccgttcct	gtctaaaatc	cgtttaaatcg	gcctcctggt 3660
tacttcccgc	tctgattcta	acgaggaaa	cacgttatata	gtgctcgtca	aagcaaccat 3720
agtacgcgcc	ctgtagcggc	gcattaagcg	cggcggggtg	gggtggttac	cgcagcgtga 3780
ccgctacact	tgccagcgcc	ctagcgcccc	ctcctttcgc	tttcttccct	tcctttctcg 3840
ccacgttcgc	cggctttccc	cgtcaagctc	taaatcgggg	gctcccttta	gggttccgat 3900
ttagtgcttt	acggcacctc	gacccccaaa	aacttgatta	gggtgatggg	tcacgtagtg 3960
ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	ttctttaata 4020

-continued

gtggactott	gttccaaact	ggaacaacac	tcaaccctat	ctcgggtctat	tcttttgatt	4080
tataagggat	tttgccgatt	tcggcctatt	ggttaaaaaa	tgagctgatt	taacaaaaat	4140
ttaacgcgaa	ttttaacaaa	atattaacgt	ttacaattta	aatatttgct	tatacaatct	4200
tctgtttttt	ggggcttttc	tgattatcaa	ccgggggtaca	tatgattgac	atgctagttt	4260
tacgattacc	gttcacgat	tctcttggtt	gctccagact	ctcaggcaat	gacctgatag	4320
cctttgtaga	gacctctcaa	aaatagctac	cctctccggc	atgaatttat	cagctagaac	4380
ggttgaatat	catattgatg	gtgatttgac	tgtctccggc	ctttctcacc	cgtttgaatc	4440
tttacctaca	cattactcag	gcattgcatt	taaaatatat	gagggttcta	aaaattttta	4500
tcttgcggtt	gaaataaagg	cttctccgcg	aaaagtatta	cagggtcata	atgttttttg	4560
tacaaccgat	ttagctttat	gctctgaggc	tttattgctt	aattttgcta	attctttgcc	4620
ttgctgtat	gatttattgg	atgttggaat	tcctgatgcg	gtattttctc	cttacgcac	4680
tgtgcggtat	ttcacaccgc	atatggtgca	ctctcagtac	aatctgctct	gatgccgcac	4740
agttaagcca	gccccgacac	ccgccaacac	ccgtcgacgc	gccctgacgg	gcttgctctgc	4800
tcccggcac	cgcttacaga	caagctgtga	ccgtctccgg	gagctgcatg	tgctcagagg	4860
tttcaccgct	atcaccgaaa	cgcgcgagac	gaaagggcct	cgtgatacgc	ctatttttat	4920
aggttaatgt	catgataata	atggtttctt	agacgtcagg	tggcactttt	cggggaaatg	4980
tcgcgcggaac	ccctatttgt	ttatttttct	aaatacattc	aaatatgtat	ccgctcatga	5040
gacaataacc	ctgataaatg	cttcaataat	attgaaaaag	gaagagtatg	agtattcaac	5100
atttcctgtg	cgcccttatt	cccttttttg	cggcattttg	ccttctctgt	tttgctcacc	5160
cagaaacgct	ggtgaaagta	aaagatgctg	aagatcagtt	gggtgcacga	gtgggttaca	5220
tcgaactgga	tctcaacagc	ggtaagatcc	ttgagagttt	tcgccccgaa	gaacgttttc	5280
caatgatgag	cactttttaa	gttctgctat	gtggcgcggt	attatcccgt	attgacgccg	5340
ggcaagagca	actcggtcgc	cgcatacact	attctcagaa	tgacttggtt	gagtactcac	5400
cagtcacaga	aaagcatctt	acggatggca	tgacagtaag	agaattatgc	agtgctgcc	5460
taaccatgag	tgataaacct	gcggccaact	tacttctgac	aacgatcgga	ggaccgaagg	5520
agctaaccgc	ttttttgcac	aacatggggg	atcatgtaac	tcgccttgat	cgttggggaa	5580
cggagctgaa	tgaagccata	ccaaacgacg	agcgtgacac	cacgatgcct	gtagcaatgg	5640
caacaacggt	gcgcaaaact	ttaactggcg	aactacttac	tctagcttcc	cggcaacaat	5700
taatagactg	gatggaggcg	gataaagttg	caggaccact	tctgcgctcg	gcccttcctg	5760
ctggctgggt	tattgctgat	aaatctggag	ccggtgagcg	tgggtctcgc	gggtatcattg	5820
cagcactggg	gccagatggt	aagccctccc	gtatcgtagt	tatctacacg	acggggagtc	5880
aggcaactat	ggatgaacga	aatagacaga	tcgtcgagat	aggtgcctca	ctgattaagc	5940
attggttaact	gtcagaccaa	gtttactcat	atatacttta	gattgattta	aaacttcatt	6000
tttaatttaa	aaggatctag	gtgaagatcc	tttttgataa	tctcatgacc	aaaatccctt	6060
aacgtgagtt	ttcgttccac	tgagcgtcag	accccgtaga	aaagatcaaa	ggatcttctt	6120
gagatccttt	ttttctgcgc	gtaatctgct	gcttgcaaac	aaaaaaacca	ccgctaccag	6180
cggtggtttg	tttgccggat	caagagctac	caactctttt	tccgaaggta	actggcttca	6240
gcagagcgca	gataccaaat	actgtccttc	tagtgtagcc	gtagttaggc	caccacttca	6300
agaactctgt	agcaccgcct	acatacctcg	ctctgcta	cctgttacca	gtggctgctg	6360
ccagtggcga	taagtcgtgt	cttaccgggt	tggactcaag	acgatagtta	ccggataagg	6420
cgcagcggtc	gggctgaacg	gggggttcgt	gcacacagcc	cagcttgagg	cgaacgacct	6480
acaccgaact	gagataccta	cagcgtgagc	tatgagaaag	cgccacgctt	cccgaaggga	6540
gaaaggcgga	caggatcccg	gtaagcggca	gggtcggaac	aggagagcgc	acgagggagc	6600
ttccaggggg	aaacgcctgg	tatctttata	gtcctgtcgg	gtttcgccac	ctctgacttg	6660
agcgtcgatt	tttgtgatgc	tcgtcagggg	ggcggagcct	atggaaaaac	gccagcaacg	6720
cggccttttt	acggttcctg	gccttttctg	ggccttttgc	tcacatgttc	tttctgctgc	6780
tatccccctga	ttctgtggat	aaccgtatta	ccgcctttga	gtgagctgat	accgctcgcc	6840
gcagccgaac	gaccgagcgc	agcgagtcag	tgagcgagga	agcggaagag	cgcccaatac	6900
gcaaacccgc	tctccccgcg	cgttggccga	ttcattaatg			6940
SEQ ID NO: 33						
FEATURE						
misc_feature						
source						
SEQUENCE: 33						
cagcagctgc	gcgctcgctc	gctcactgag	gccgcccggg	caaagcccgg	gcgtcggggc	60
acctttgggt	gcccggcctc	agtgagcgag	cgagggcgca	gagaggaggt	ggccaactcc	120
atcactaggg	gttccttgta	gttaatgatt	aaccgcgcat	gctacttatc	tacgtagcca	180
tgtcttagcg	gcctcggcct	ctgcataaat	aaaaaaaatt	agtcagccat	gagcttggcc	240
cattgcatac	gttgatatca	tatcataata	tgtacattta	tattgggtca	tgtccaacat	300
taccgccatg	ttgacattga	ttattgacta	gttattaata	gtaatcaatt	acgggggtcat	360
tagttcatag	cccatatatg	gagttccgcg	ttacataact	tacggtaa	ggcccgcctg	420
gctgaccgcc	caacgacccc	cgccatttga	cgtcaataat	gacgtatgtt	cccatagtaa	480
cgccaatagg	gactttccat	tgacgtcaat	gggtggagta	tttacggtaa	actgccact	540
tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta	600
aatggccgcg	ctggcattat	gcccagtaca	tgaccttatg	ggactttcct	acttggcagt	660
acatctacgt	attagtcac	gctattacca	tgggtgatgcg	gttttggcag	tacatcaatg	720
ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	ccaccccat	gacgtcaatg	780
ggagtttggt	ttggcacc	aatcaacggg	actttccaaa	atgtcgtaac	aactccgccc	840
cattgacgca	aatgggcggg	aggcgtgtac	gggtggagggt	ctatataagc	agagctcggt	900
tagtgaaccg	tcagatcgcc	tggagacgcc	atccacgctg	ttttgacctc	catagaagac	960
accgggaccg	atccagcctc	ccctcgaagc	tgatcctgag	aacttcaggg	tgagtctatg	1020
ggacccttga	tgttttcttt	cccttctttt	tctatggtta	agttcatgtc	ataggaaggg	1080

-continued

gagaagtaac	aggggtacaca	tattgaccaa	atcagggttaa	ttttgcattt	gtaatttttaa	1140
aaaatgcttt	cttcttttta	tatacttttt	tgtttatctt	atttctaata	ctttccctaa	1200
tctctttctt	tcagggcaat	aatgatacaa	tgtatcatgc	ctctttgcac	cattctaaag	1260
aataacagtg	ataatttctg	ggttaaggca	atagcaatat	ttctgcatat	aaatatttct	1320
gcatataaat	tgtaactgat	gtaagagggt	tcataattgt	aatagcagct	acaatccagc	1380
taccattctg	cttttatttt	atggttggga	taaggctgga	ttattctgag	tccaagctag	1440
gcccttttgc	taatcatgtt	catacctctt	atcttctctc	cacagctcct	gggcaacgtg	1500
ctggtctgtg	tgctggccca	tcactttggc	aaagaattcc	gcgggcccgg	gatccaccgg	1560
tcgccaccat	ggtagagcaag	ggcgaggagc	tgttcaccgg	ggtaggtgcc	atcctggtcg	1620
agctggacgg	cgacgtaaac	ggccacaagt	tcagcgtgtc	cggcgagggc	gagggcgatg	1680
ccacctacgg	caagctgacc	ctgaagttca	tctgcaccac	cggcaagctg	cccgtgccct	1740
ggcccaccct	cgtgaccacc	ctgacctacg	gcgtgcagtg	cttcagccgc	taccccgacc	1800
acatgaagca	gcacgacttc	ttcaagtccg	ccatgcccga	aggctacgtc	caggagcgca	1860
ccatcttctt	caaggacgac	ggcaactaca	agacccgcgc	cgaggtgaag	ttcgagggcg	1920
acaccctggt	gaaccgcatc	gagctgaagg	gcatcgactt	caaggaggac	ggcaacatcc	1980
tggggcacia	gctggagtac	aactacaaca	gccacaacgt	ctatatcatg	gccgacaagc	2040
agaagaacgg	catcaagggt	aacttcaaga	tccgccacaa	catcgaggac	ggcagcgtgc	2100
agctcgccga	ccactaccag	cagaacaccc	ccatcgccga	cggccccgtg	ctgctgcccg	2160
acaaccacta	cctgagcacc	cagtcgcgcc	tgagcaaaga	ccccaacgag	aagcgcgatc	2220
acatggctct	gctggagttc	gtgaccgcgc	ccgggatcac	tctcggcag	gacgagctgt	2280
acaagtaaag	cggccgctct	agaggatcca	agcttatcga	taccgtcgac	ctcgagggcc	2340
cagatctaat	tcacccacc	agtgcaggct	gcctatcaga	aagtgggtgg	tggtgtggct	2400
aatgccctgg	cccacaagta	tcactaagct	cgctttcttg	ctgtccaatt	tctattaaag	2460
gttcctttgt	tcctaagtc	caactactaa	actgggggat	attatgaagg	gccttgagca	2520
tctggattct	gcctaataaa	aaacatttat	tttcattgca	atgatgtatt	taaattattt	2580
ctgaataatt	tactaaaaag	ggaatgtggg	aggtcagtg	atttaaaaca	taaagaaatg	2640
aagagctagt	tcaaaccttg	ggaaaataca	ctatatctta	aactccatga	aagaagggtga	2700
ggctgcaaac	agctaatagc	cattggcaac	agccctgat	gcctatgcct	tattcatccc	2760
tcagaaaagg	attcaagtag	aggcttgatt	tggagggtta	agttttgcta	tgtgtatttt	2820
tacattactt	attgttttag	ctgtcctcat	gaatgtcttt	tcactacca	tttgcttacc	2880
ctgcatctct	cagccttgac	tcactcagct	tctcttgctt	agagatacca	cctttccctt	2940
gaagtgttcc	ttccatgttt	tacggcgaga	tggtttctcc	tcgcctggcc	actcagcctt	3000
agttgtctct	gttgctttat	agagggtctac	ttgaagaagg	aaaaacaggg	ggcatggttt	3060
gactgtcctg	tgagcccttc	ttccctgcct	ccccactca	cagtgaccgg	gaatccctcg	3120
acaggtaacct	ttagggttag	ggtaggggtt	agggaaaaat	ttagggttag	ggtaggggtt	3180
agggaaaaat	ttagggttag	ggtaggggtt	agggaaaaat	ttagggttag	ggtaggggtt	3240
agggaaaaat	ttagggttag	ggtaggggtt	agggaaaaac	cctaacccta	accctaacc	3300
taaatttttt	ccctaaccct	aaccctaacc	ctaaattttt	tcctaacc	taaccctaac	3360
cctaaatttt	ttccctaacc	ctaacccta	ccctaaattt	ttccctaacc	cctaacccta	3420
accctaattt	ttttgctagc	tctagagcat	ggctacgtag	ataagtagca	tggcggttta	3480
atcattaact	acaaggaacc	cctagtgtat	gagttggcca	ctccctctct	gcgcgctcgc	3540
tcgctcactg	aggccggggc	accaaaggct	gcccgcgcgc	cgggctttgc	ccgggcgggc	3600
tcagtgcagc	agcgcgcgc	ccagctggcg	taatagcgaa	gagggccgca	ccgatcgccc	3660
ttcccaacag	ttgcgcagcc	tgaatggcga	atggaattcc	agacgattga	gcgtcaaaat	3720
gtagggtatt	ccatgagcgt	ttttcctgtt	gcaatggctg	gcggtaatat	tgttctggat	3780
attaccagca	aggccgatag	tttgagttct	tctactcagg	caagtgtatg	tattactaat	3840
caaagaagta	ttgcgacaac	ggttaatttg	cgtgatggac	agactctttt	actcgggtggc	3900
ctcactgatt	ataaaaaac	ttctcaggat	tctggcgtag	cgttcctgtc	taaaatccct	3960
ttaatcgccc	tcctgtttag	ctcccgtctt	gattctaacg	aggaaagcac	gttatacgtg	4020
ctcgtaaaag	caaccatagt	acgcgccttg	tagcggcgca	ttaagcgcgg	cgggtgtggt	4080
ggttacgcgc	agcgtgaccg	ctacacttgc	cagcgcccta	gcgcgcctc	ctttcgcttt	4140
cttcccttcc	tttctcgcca	cgttcgcgcg	cttcccccgt	caagctctaa	atcggggggt	4200
ccctttaggg	ttccgattta	gtgctttacg	gcactctgac	ccccaaaaac	ttgattaggg	4260
tgatggttca	cgtagtgggc	catcgccctg	atagacgggt	tttcgcctt	tgcggttga	4320
gtccacgttc	tttaatagt	gactcttggt	ccaaactgga	acaacactca	accctatctc	4380
ggctctattct	tttgatttat	aagggttttt	gccgatttct	gcctattggt	taaaaaatga	4440
gctgatttaa	caaaaattta	acgcgaattt	taacaaaata	ttaacgttta	caattttaat	4500
atttgcttat	acaatcttcc	tgtttttggg	gcttttctga	ttatcaaccg	gggtacatat	4560
gattgacatg	ctagttttac	gattaccgtt	catcgattct	cttgtttgc	ccagactctc	4620
aggcaatgac	ctgatagcct	ttgtagagac	ctctcaaaaa	tagctaccct	ctccggcatg	4680
aatttatcag	ctagaacgg	tgaatatcat	attgatgggt	atttgactgt	ctccggcctt	4740
tctcaccctg	ttgaatcttt	acctacacat	tactcaggca	ttgcatttaa	aatatatgag	4800
ggttctaaaa	atttttatcc	ttgcgttgaa	ataaaggctt	ctcccgcaaa	agtattacag	4860
ggtcataatg	tttttggtac	aaccgattta	gctttatgct	ctgaggcttt	attgcttaat	4920
tttgctaatt	ctttgccttg	cctgtatgat	ttattggatg	ttggaattcc	tgatgcggta	4980
ttttctcctt	acgcctctgt	gcggtatctt	acaccgcata	tggtgcactc	tcagtacaat	5040
ctgctctgat	gccgcatagt	taagccagcc	ccgacaccgc	ccaacaccgc	ctgacgcgc	5100
ctgacgggct	tgtctgctcc	cggcatccgc	ttacagacaa	gctgtgaccg	tctccgggag	5160
ctgcatgtgt	cagaggtttt	caccgtcatc	accgaaacgc	gcgagacgaa	agggcctcgt	5220
gatacgccta	tttttatagg	ttaatgtcat	gataaataat	gtttcttaga	cgtcaggtgg	5280
cacttttctg	ggaaatgtgc	gcggaacccc	tatttgttta	tttttctaaa	tacattcaaa	5340
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	5400
gagtatgagt	attcaacatt	tccgtgtcgc	ccttatctcc	ttttttgcgg	cattttgcct	5460
tctgtttttt	gctcaccag	aaacgctgg	gaaagtaaaa	gatgctgaag	atcagttggg	5520
tgcacgagt	ggttacatcg	aactggatct	caacagcgg	aagatccttg	agagttttcg	5580
ccccgaagaa	cgttttccaa	tgatgagcac	ttttaaagtt	ctgctatgtg	gcgcgggtatt	5640

-continued

atcccggtatt	gacgcccggc	aagagcaact	cggtcgcgcg	atacactatt	ctcagaatga	5700
cttggttgag	tactcaccag	tcacagaaaa	gcatcttacg	gatggcatga	cagtaagaga	5760
attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	ttctgacaac	5820
gacgaggaga	ccgaaggagc	taaccgcttt	tttgacacaac	atgggggatc	atgtaactcg	5880
ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	5940
gatgcctgta	gcaatggcaa	caacgtttcg	caactatta	actggcgaa	tacttactct	6000
agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	gaccacttct	6060
gcgctcggcc	cttcgggctg	gctgggttat	tgctgataaa	tctggagccg	gtgagcgtgg	6120
gtctcgcggg	atcattgcag	cactggggcc	agatggtaag	ccctcccgt	tcgtagttat	6180
ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	6240
tgctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	6300
tgatttaaaa	cttcattttt	aatttaaaag	gatctagggtg	aagatccttt	ttgataatct	6360
catgacaaaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	6420
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	6480
aaaaccaccg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	ctcttttttc	6540
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	6600
gttagggcac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatacct	6660
gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	6720
atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	6780
cttgagagca	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	6840
cacgcttccc	gaaggagaga	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	6900
agagcgacag	agggagcttc	cagggggaaa	cgctcggtat	ctttatagtc	ctgtcgggtt	6960
tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	7020
gaaaaacgcc	agcaacgcgg	ccttttttacg	gttcctggcc	ttttgctggc	cttttgctca	7080
catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	cctttgagtg	7140
agctgatacc	gctcgcgca	gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	7200
ggaagagcgc	ccaatacgca	aaccgcctct	cccgcgcgct	tggcgatttc	attaatg	7257
SEQ ID NO: 34	moltype = DNA length = 15					
FEATURE	Location/Qualifiers					
misc_feature	1..15					
	note = Synthetic Polynucleotide					
source	1..15					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 34						
gctagatggtt agcgt						15

1. A nucleic acid molecule comprising:
a viral genome covalently linked to an inhibitory nucleic acid sequence which binds to TLR9 but does not trigger TLR9 activation; or
an inverted terminal repeat and a nucleic acid sequence that inhibits TLR9-mediated inflammation.
2. A recombinant virus for delivery of a desired function to a mammalian cell, comprising:
the nucleic acid molecule of claim 1.
- 3.-44. (canceled)
45. A method of treating a mammal, comprising:
administering the recombinant virus of claim 2 to a mammal in need thereof.
- 46.-58. (canceled)
59. A method of making a viral genome of a recombinant virus, comprising:
inserting an inhibitory nucleic acid sequence into a viral genome, wherein the inhibitory nucleic acid sequence binds to TLR9 but does not trigger TLR9 activation; or
inserting a nucleic acid sequence into a viral genome, wherein the nucleic acid sequence inhibits TLR9-mediated inflammation.
- 60.-80. (canceled)
81. A method of increasing expression in a host cell of a virally introduced transgene, the method comprising introducing into a host the recombinant virus of claim 2, whereby the modified virus results in higher transgene expression in a host cell as compared to a virus that does not contain the nucleic acid sequence.

82. A composition comprising a viral capsid encapsidating the nucleic acid molecule of claim 1.
- 83.-90. (canceled)
91. A method of reducing an inflammatory response in a subject in need thereof, the method comprising:
administering to the subject a recombinant adeno-associated virus (AAV) comprising a viral genome, wherein the viral genome comprises a therapeutic transgene and a nucleic acid molecule comprising three tandem repeat monomers of SEQ ID NO: 6 or SEQ ID NO: 9, thereby reducing an inflammatory response in the subject, relative to a control.
92. The method of claim 91, wherein the AAV is a self-complementary AAV (scAAV).
93. The method of claim 91, wherein the AAV is an AAV2 or AAV8.
94. The method of claim 91, wherein the viral genome further comprises a 5' untranslated region, and wherein the nucleic acid molecule is in the 5' untranslated region.
95. The method of claim 91, wherein the viral genome further comprises a 3' untranslated region, and wherein the nucleic acid molecule is in the 3' untranslated region.
96. The method of claim 91, wherein the therapeutic gene is a human gene.
97. The method of claim 91, wherein the recombinant scAAV is administered systemically the subject.
98. The method of claim 91, wherein the recombinant scAAV is administered subretinally to the subject.

99. The method of claim **91**, wherein the recombinant AAV is administered in an amount effective to prevent TLR-mediated inflammation in the subject.

100. The method of claim **91**, wherein the recombinant AAV is administered in an amount effective to reduce induction of pro-inflammatory cytokines in the subject, relative to a control.

101. The method of claim **91**, wherein the recombinant AAV is administered in an amount effective to increase expression of the therapeutic transgene in the subject, relative to a control.

* * * * *